<SEC-DOCUMENT>0001144204-16-134447.txt : 20161115
<SEC-HEADER>0001144204-16-134447.hdr.sgml : 20161115
<ACCEPTANCE-DATETIME>20161114180236
ACCESSION NUMBER:		0001144204-16-134447
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		5
FILED AS OF DATE:		20161115
DATE AS OF CHANGE:		20161114

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Synthetic Biologics, Inc.
		CENTRAL INDEX KEY:			0000894158
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				133808303
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-206266
		FILM NUMBER:		161996950

	BUSINESS ADDRESS:	
		STREET 1:		617 DETROIT STREET, SUITE 100
		CITY:			ANN ARBOR
		STATE:			MI
		ZIP:			48104
		BUSINESS PHONE:		(734) 332-7800

	MAIL ADDRESS:	
		STREET 1:		155 GIBBS STREET
		STREET 2:		SUITE 412
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADEONA PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20081027

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PIPEX PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20061214

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SHEFFIELD PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19970730
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>v451836_424b5.htm
<DESCRIPTION>424B5
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Filed Pursuant to Rule 424(b)(5)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Registration No. 333-206266</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #EB0029">The information in this
preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has
been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying
prospectus are not an offer to sell these securities and we are not soliciting an offer to buy these securities in any state or
other jurisdiction where the offer or sale is not permitted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #EB0029"><B>SUBJECT TO COMPLETION,
DATED NOVEMBER 14, 2016 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>preliminary Prospectus
Supplement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>(To Prospectus dated August 18, 2015)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_001.jpg" ALT="http:||content.edgar-online.com|edgar_conv_img|2016|08|05|0001144204-16-116730_TPG43.JPG" STYLE="height: 67px; width: 224px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Shares of Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Warrants to Purchase &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Shares of Common Stock </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are offering &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
shares of our common stock and warrants to purchase up to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
shares of our common stock (and the shares of common stock issuable from time to time upon exercise of each of the warrants), pursuant
to this prospectus supplement and the accompanying prospectus. The common stock and warrants will be sold in combination, with
two warrants, each to purchase one share of common stock, for each one share of common stock sold. The purchase price for each
share of common stock and accompanying warrants is $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each warrant will be exercisable
beginning on or after its date of issuance. One of the warrants (the Series A warrants) will have an exercise price of $1.43
per share and be exercisable until the four year anniversary of the issuance date. The other warrants (the Series B warrants) will have an exercise price of $1.72 per
share and be exercisable until  December 31,
2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our common stock is listed on the NYSE
MKT under the symbol &ldquo;SYN.&rdquo; On November 11, 2016, the closing price of our common stock was $1.58 per share. There is
no established public trading market for the warrants and we do not expect a market to develop. In addition, we do not intend to
apply for listing of the warrants on any securities exchange or recognized trading system. The warrants will be issued in book-entry
form pursuant to a warrant agreement between us and Corporate Stock Transfer, Inc., as warrant agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Our business and an investment in our
securities involves a high degree of risk.&nbsp; Before making an investment decision, please read the information under &ldquo;Risk
Factors&rdquo; beginning on page S-6 of this prospectus supplement and under similar headings in the documents incorporated by
reference into this prospectus supplement. </B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="width: 95%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; padding-right: 1.8pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Per Share and Accompanying Warrants</B></FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; padding-right: 1.8pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total</B></FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 66%; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Public offering price</B></FONT></TD>
    <TD STYLE="width: 1%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 1%; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 13%; padding-right: 0.8pt; text-align: right">&nbsp;</TD>
    <TD STYLE="width: 1%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 1%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 1%; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 15%; padding-right: 0.8pt; text-align: right">&nbsp;</TD>
    <TD STYLE="width: 1%; padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Underwriting
    discounts and commissions <SUP>(1)</SUP></B></FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-right: 0.8pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0"><B>Proceeds, before expenses, to us </B></P></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B>&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin: 1pt 431.8pt 1pt 0in"><DIV STYLE="font-size: 1pt; border-top: black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1%; padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 2%; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>(1)</SUP></FONT></TD>
    <TD STYLE="width: 97%; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">See &ldquo;Underwriting&rdquo; beginning on page S-14 of this prospectus supplement for a description of compensation payable to the underwriter.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">One of our directors has
indicated an interest in purchasing up to $300,000 of shares of our common stock and warrants to purchase shares of our
common stock in this offering. An indication of interest is not binding and the director may purchase some, none or all of the
securities for which he has indicated an interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The underwriter expects to deliver
the shares of common stock and accompanying warrants against payment on or about November &nbsp;&nbsp;&nbsp;&nbsp;, 2016. We
have granted the underwriter an option for a period of 30 days to purchase up to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional shares of our common stock and warrants to purchase up to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; additional shares of our common stock. If
the underwriter exercises the option in full, the total underwriting discounts and commissions payable by us will be
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and the total proceeds to us, before expenses, will be
$&nbsp;&nbsp; .</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Cantor Fitzgerald &amp; Co. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The date of this prospectus supplement is
November&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2016</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; padding-right: 1.8pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page</B></FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 87%; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PROSPECTUS SUPPLEMENT</B></FONT></TD>
    <TD STYLE="width: 1%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 1%; padding-right: 0.8pt; text-align: right">&nbsp;</TD>
    <TD STYLE="width: 10%; padding-right: 0.8pt; text-align: right">&nbsp;</TD>
    <TD STYLE="width: 1%; padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt"><A HREF="#a_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABOUT THIS PROSPECTUS SUPPLEMENT</FONT></A></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-right: 0.8pt"><A HREF="#a_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INDUSTRY AND MARKET DATA</FONT></A></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt"><A HREF="#a_003"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROSPECTUS SUPPLEMENT SUMMARY</FONT></A></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-right: 0.8pt"><A HREF="#a_004"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THE OFFERING</FONT></A></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-5</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt"><A HREF="#a_005"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RISK FACTORS</FONT></A></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-6</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-right: 0.8pt"><A HREF="#a_006"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</FONT></A></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-8</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt"><A HREF="#a_007"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">USE OF PROCEEDS</FONT></A></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-9</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-right: 0.8pt"><A HREF="#a_008"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DIVIDEND POLICY</FONT></A></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-10</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt"><A HREF="#a_009"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DILUTION</FONT></A></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right">S-11</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-right: 0.8pt"><P STYLE="margin: 0pt 0"><A HREF="#a_100">DESCRIPTION OF THE SECURITIES WE ARE OFFERING</A></P>


</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right">S-12</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt"><A HREF="#a_010"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">UNDERWRITING</FONT></A></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-14</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-right: 0.8pt"><A HREF="#a_011"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LEGAL MATTERS</FONT></A></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-18</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt"><A HREF="#a_012"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXPERTS</FONT></A></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-18</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-right: 0.8pt"><A HREF="#a_013"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHERE YOU CAN FIND MORE INFORMATION</FONT></A></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-18</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt"><A HREF="#a_014"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE</FONT></A></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-18</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PROSPECTUS</B></FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt"><A HREF="#a_015"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABOUT THIS PROSPECTUS</FONT></A></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-right: 0.8pt"><A HREF="#a_016"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROSPECTUS SUMMARY</FONT></A></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right">2</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt"><A HREF="#a_017"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RISK FACTORS</FONT></A></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-right: 0.8pt"><A HREF="#a_018"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</FONT></A></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt"><A HREF="#a_019"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">USE OF PROCEEDS</FONT></A></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-right: 0.8pt"><A HREF="#a_020"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DIVIDEND POLICY</FONT></A></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt"><A HREF="#a_021"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DESCRIPTION OF CAPITAL STOCK</FONT></A></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-right: 0.8pt"><A HREF="#a_022"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DESCRIPTION OF WARRANTS</FONT></A></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt"><A HREF="#a_023"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DESCRIPTION OF UNITS</FONT></A></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-right: 0.8pt"><A HREF="#a_024"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PLAN OF DISTRIBUTION</FONT></A></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt"><A HREF="#a_025"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LEGAL MATTERS</FONT></A></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-right: 0.8pt"><A HREF="#a_026"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXPERTS</FONT></A></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt"><A HREF="#a_027"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHERE YOU CAN FIND MORE INFORMATION</FONT></A></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-right: 0.8pt"><A HREF="#a_028"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE</FONT></A></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.1in; text-indent: -0.1in"><A HREF="#a_029"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DISCLOSURE OF THE SECURITIES AND EXCHANGE COMMISSION POSITION ON INDEMNIFICATION FOR SECURITIES ACT LIABILITIES</FONT></A></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_001"></A><B>ABOUT THIS PROSPECTUS SUPPLEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This document is part of the registration
statement that we filed with the Securities and Exchange Commission (the &ldquo;SEC&rdquo;) using a &ldquo;shelf&rdquo; registration
process and consists of two parts. The first part is this prospectus supplement, including the documents incorporated by reference,
which describes the specific terms of this offering. The second part, the accompanying prospectus dated August 18, 2015, including
the documents incorporated by reference therein, provides more general information, some of which may not apply to this offering.
Generally, when we refer only to the &ldquo;prospectus,&rdquo; we are referring to both parts of this document combined. This prospectus
supplement may add to, update or change information in the accompanying prospectus and the documents incorporated by reference
into this prospectus supplement or the accompanying prospectus.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If information in this prospectus supplement
is inconsistent with the accompanying prospectus or with any document incorporated by reference that was filed with the SEC before
the date of this prospectus supplement, you should rely on the information in this prospectus supplement. Any statement so modified
will be deemed to constitute a part of this prospectus supplement only as so modified, and any statement so superseded will be
deemed not to constitute a part of this prospectus supplement. This prospectus supplement, the accompanying prospectus and the
documents incorporated into each by reference include important information about us, the securities being offered and other information
you should know before investing in our securities. You should also read and consider information in the documents we have referred
you to in the section of this prospectus supplement and the accompanying prospectus entitled &ldquo;Where You Can Find More Information.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You should rely only on this prospectus
supplement, the accompanying prospectus and any free writing prospectus we may provide to you in connection with this offering
and the information incorporated or deemed to be incorporated by reference therein. We have not authorized anyone to provide you
with information that is in addition to or different from that contained or incorporated by reference in this prospectus supplement
and the accompanying prospectus. If anyone provides you with different or inconsistent information, you should not rely on it.
We are not offering to sell these securities in any jurisdiction where the offer or sale is not permitted. You should not assume
that the information contained or incorporated by reference in this prospectus supplement or the accompanying prospectus is accurate
as of any date other than as of the date of this prospectus supplement or the accompanying prospectus, as the case may be, or in
the case of the documents incorporated by reference, the date of such documents regardless of the time of delivery of this prospectus
supplement and the accompanying prospectus or any sale of our securities. Our business, financial condition, liquidity, results
of operations and prospects may have changed since those dates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We further note that the representations,
warranties and covenants made by us in any agreement that is filed as an exhibit to any document that is incorporated by reference
in the accompanying prospectus were made solely for the benefit of the parties to such agreement, including, in some cases, for
the purpose of allocating risk among the parties to such agreements, and should not be deemed to be a representation, warranty
or covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly,
such representations, warranties and covenants should not be relied on as accurately representing the current state of our affairs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No action has been or will be taken in
any jurisdiction by us or the underwriter that would permit a public offering of the common stock or the possession or distribution
of this prospectus supplement and the accompanying prospectus in any jurisdiction, other than in the United States. Persons outside
the United States who come into possession of this prospectus supplement and the accompanying prospectus must inform themselves
about, and observe any restrictions relating to, the offering of the common stock and the distribution of this prospectus supplement
and the accompanying prospectus outside the United States. This prospectus supplement and the accompanying prospectus do not constitute,
and may not be used in connection with, an offer to sell, or a solicitation of an offer to buy, any securities offered by this
prospectus supplement and the accompanying prospectus by any person in any jurisdiction in which it is unlawful for such person
to make such an offer or solicitation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_002"></A><B>INDUSTRY AND MARKET DATA</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We obtained the industry and market data
in this prospectus supplement from our own research as well as from industry and general publications, surveys and studies conducted
by third parties. These data involve a number of assumptions and limitations, and you are cautioned not to give undue weight to
such estimates. In addition, projections, assumptions and estimates of our future performance and the future performance of the
industry in which we operate is necessarily subject to a high degree of uncertainty and risk due to a variety of factors, including
those described in &ldquo;Risk Factors&rdquo; and elsewhere in this prospectus supplement. These and other factors could cause
results to differ materially from those expressed in the estimates made by the independent parties and by us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<DIV STYLE="border: Black 1pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_003"></A>PROSPECTUS SUPPLEMENT SUMMARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.75pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6pt; text-align: justify"><I>The items in the following summary are
described in more detail elsewhere in this prospectus supplement and in the documents incorporated by reference herein. This summary
provides an overview of selected information and does not contain all the information you should consider before investing in our
common stock accompanying warrants. Therefore, you should read the entire prospectus supplement and the accompanying prospectus
and any free writing prospectus that we have authorized for use in connection with this offering carefully, including the &ldquo;Risk
Factors&rdquo; section and other documents or information included or incorporated by reference in this prospectus supplement and
the accompanying prospectus before making any investment decision. Unless the context requires otherwise, references in this prospectus
supplement to &ldquo;Synthetic,&rdquo; &ldquo;the Company,&rdquo; &ldquo;we,&rdquo; &ldquo;us&rdquo; and &ldquo;our&rdquo; refer
to Synthetic Biologics, Inc.</I></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6pt; text-align: justify"><B>Our Business </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6pt; text-align: justify">We are a clinical stage company developing
therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. Our lead candidates poised for Phase 3 development
are: (1) SYN-010 which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying
cause of irritable bowel syndrome with constipation (IBS-C), and (2) SYN-004 (ribaxamase) which is designed to protect the gut
microbiome from the effects of certain commonly used intravenous (IV) beta-lactam antibiotics for the prevention of <I>C. difficile</I>
infection (CDI), antibiotic-associated diarrhea (AAD) and the emergence of antibiotic-resistant organisms. In collaboration with
Intrexon Corporation (&ldquo;Intrexon&rdquo;), we are also developing preclinical stage monoclonal antibody therapies for the prevention
and treatment of pertussis, and novel discovery stage biotherapeutics for the treatment of phenylketonuria (PKU).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6pt; text-align: justify"><I>Product Pipeline:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><IMG SRC="image_002.jpg"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6pt; text-align: justify">* Two Phase 2 studies completed. Planning Phase 2b/3 pivotal trial</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6pt; text-align: justify">C&ndash;Cedars-Sinai Medical Center Collaboration</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6pt; text-align: justify">I&ndash;Intrexon Collaboration</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6pt; text-align: justify">T&ndash;The University of Texas at Austin Collaboration</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<DIV STYLE="border: Black 1pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6pt; text-align: justify"><B>Summary of Clinical and Preclinical Programs</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50.25pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center; padding-right: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Therapeutic Area</B></FONT></TD>
    <TD NOWRAP STYLE="text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="3" STYLE="border-bottom: black 1pt solid; text-align: center; padding-right: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Product Candidate</B></FONT></TD>
    <TD NOWRAP STYLE="text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="3" STYLE="border-bottom: black 1pt solid; text-align: center; padding-right: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Status</B></FONT></TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: top; padding-left: 10pt; text-indent: -10pt; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: top; text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify; padding-right: 6pt">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: top; padding-left: 10pt; text-align: center; text-indent: -10pt; padding-right: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Treatment of IBS-C</FONT></TD>
    <TD STYLE="text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: top; text-align: center; padding-right: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SYN-010<BR>(oral modified-release
</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; padding-right: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify; padding-right: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reported supportive topline data from two Phase 2 clinical trials (4Q 2015 &amp; 1Q 2016)</FONT></TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: top; padding-left: 10pt; text-align: center; text-indent: -10pt; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: top; text-align: center; padding-right: 6pt">lovastatin lactone)</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify; padding-right: 6pt">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="padding-left: 10pt; text-align: center; text-indent: -10pt; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; padding-right: 6pt; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; padding-right: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify; padding-right: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Received Type C meeting responses from U.S. Food and Drug Administration (the &ldquo;FDA&rdquo;) regarding late-stage aspects of clinical pathway (2Q 2016)</FONT></TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="padding-left: 10pt; text-align: center; text-indent: -10pt; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 6pt">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="padding-left: 10pt; text-align: center; text-indent: -10pt; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; padding-right: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify; padding-right: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Presented detailed data supporting previously reported positive topline data from two Phase 2 clinical trials at Digestive Disease Week Conference 2016 (DDW) (May 2016)</FONT></TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="padding-left: 10pt; text-align: center; text-indent: -10pt; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 6pt">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="padding-left: 10pt; text-align: center; text-indent: -10pt; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; padding-right: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify; padding-right: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Held End of Phase 2 meeting with FDA (July 2016)</FONT></TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="padding-left: 10pt; text-align: center; text-indent: -10pt; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 6pt">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="padding-left: 10pt; text-align: center; text-indent: -10pt; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; padding-right: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify; padding-right: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Plan to initiate first Phase 2b/3 pivotal adaptive clinical trial (1Q 2017)</FONT></TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="padding-left: 10pt; text-align: center; text-indent: -10pt; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 6pt">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="padding-left: 10pt; text-align: center; text-indent: -10pt; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; padding-right: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Collaboration with Cedars-Sinai Medical Center</FONT></TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="padding-left: 10pt; text-align: center; text-indent: -10pt; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 6pt">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: top; padding-left: 10pt; text-align: center; text-indent: -10pt; padding-right: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prevention
of CDI and AAD</FONT></TD>
    <TD STYLE="text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: top; text-align: center; padding-right: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SYN-004
(ribaxamase) </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; padding-right: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 6pt">Reported supportive Phase 1a/1b data (1Q 2015)</TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: top; padding-left: 10pt; text-align: center; text-indent: -10pt; padding-right: 6pt">(Degrade IV beta-lactam</TD>
    <TD STYLE="text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: top; text-align: center; padding-right: 6pt">(oral enzyme)</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 6pt">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="padding-right: 6pt; text-align: center">antibiotics)</TD>
    <TD STYLE="text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding-right: 6pt; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; padding-right: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Initiated Phase 2b proof-of-concept clinical trial (3Q 2015)</FONT></TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 6pt">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="padding-left: 10pt; text-align: center; text-indent: -10pt; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; padding-right: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify; padding-right: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reported supportive topline data from first Phase 2a clinical trial (4Q 2015)</FONT></TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="padding-left: 10pt; text-align: center; text-indent: -10pt; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify; padding-right: 6pt">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="padding-left: 10pt; text-align: center; text-indent: -10pt; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 6pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&bull;</P></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 6pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Reported supportive topline data from second
Phase 2a clinical trial (2Q 2016)</P></TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="padding-left: 10pt; text-align: center; text-indent: -10pt; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 6pt">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="padding-left: 10pt; text-align: center; text-indent: -10pt; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; padding-right: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Received USAN approval of the generic name &ldquo;ribaxamase&rdquo; for SYN -004 (July 2016)</FONT></TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="padding-left: 10pt; text-align: center; text-indent: -10pt; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 6pt">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="padding-left: 10pt; text-align: center; text-indent: -10pt; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; padding-right: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify; padding-right: 6pt">Completed Enrollment of Phase 2b proof-of concept clinical trial (3Q 2016) &nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="padding-left: 10pt; text-align: center; text-indent: -10pt; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify; padding-right: 6pt">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="padding-left: 10pt; text-align: center; text-indent: -10pt; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; padding-right: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Awarded contract by the Centers for Disease Control and Prevention (CDC) (4Q 2016)</FONT></TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="padding-left: 10pt; text-align: center; text-indent: -10pt; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 6pt">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="padding-left: 10pt; text-align: center; text-indent: -10pt; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; padding-right: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Plan to announce topline data from Phase 2b proof-of-concept clinical trial (1Q 2017)</FONT></TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="padding-left: 10pt; text-align: center; text-indent: -10pt; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 6pt">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="padding-left: 10pt; text-align: center; text-indent: -10pt; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; padding-right: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Plan to initiate Phase 3 clinical trial(s)&nbsp;(end of 2017)</FONT></TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="padding-left: 10pt; text-align: center; text-indent: -10pt; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 6pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-left: 10pt; text-align: center; text-indent: -10pt; padding-right: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prevention of CDI and AAD </FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Degrade oral beta-lactam</FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">antibiotics)</FONT></TD>
    <TD STYLE="padding-right: 6pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; padding-right: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SYN-007 </FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(oral enzyme)</FONT></TD>
    <TD STYLE="text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-right: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="padding-right: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preclinical work ongoing to determine ability of SYN-007 to protect the gut microbiome and degrade oral beta-lactam antibiotics</FONT></TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="padding-left: 10pt; text-align: center; text-indent: -10pt; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="padding-right: 6pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 6pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-left: 10pt; text-align: center; text-indent: -10pt; padding-right: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prevention
and Treatment</FONT></TD>
    <TD STYLE="padding-right: 6pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; padding-right: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SYN-005</FONT></TD>
    <TD STYLE="text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-right: 6pt; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="padding-right: 6pt; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reported supportive preclinical research findings (2014)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-left: 10pt; text-align: center; text-indent: -10pt; padding-right: 6pt">of pertussis</TD>
    <TD STYLE="padding-right: 6pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; padding-right: 6pt">(monoclonal antibody </TD>
    <TD STYLE="text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-right: 6pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="padding-right: 6pt; text-align: left; vertical-align: bottom">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="padding-left: 10pt; text-align: center; text-indent: -10pt; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: top; text-align: center; padding-right: 6pt">therapies)</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; padding-right: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The University of Texas at Austin (&ldquo;UT Austin&rdquo;) received a grant from the Bill and Melinda Gates Foundation to support a preclinical study to evaluate the prophylactic capability of SYN-005 (4Q 2015)</FONT></TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="padding-left: 10pt; text-align: center; text-indent: -10pt; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 6pt">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="padding-left: 10pt; text-align: center; text-indent: -10pt; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; padding-right: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Collaborations with Intrexon and UT Austin</FONT></TD></TR>
<TR>
    <TD STYLE="width: 162px; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="width: 35px; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="width: 60px; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="width: 8px; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="width: 60px; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="padding-right: 6pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<DIV STYLE="border: Black 1pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6pt; text-align: justify"><I>Recent Developments </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6pt; text-align: justify"><I>SYN-010</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6pt; text-align: justify">On July 20, 2016, we participated in an
End of Phase 2 meeting with the FDA. Following a review of data from the two Phase 2 clinical trials of SYN-010 conducted by us,
a collaborative and positive discussion ensued with the FDA to determine the optimal pathway to advance SYN-010 into Phase 3 development.
In accordance with guidance from the FDA, we plan to conduct a Phase 2b/3 adaptive design study for our first pivotal trial of
SYN-010. In addition to IBS-C patients who present with high breath methane levels, further dose exploration will evaluate the
potential efficacy of SYN-010 in IBS-C patients who may have low breath methane levels. We have submitted a study protocol design
and corresponding statistical analysis plan to the FDA and are awaiting feedback on the protocol design from the FDA. The proposed
Phase 2b/3 study design anticipates enrolling approximately 840 patients to be randomized in a 1:1:1 ratio to one of three treatment
groups, including two different SYN-010 dose groups (21 mg and 42 mg) and a placebo group. Breath methane levels at screening will
be used to ensure each treatment group has approximately the same ratio of high and low breath methane subjects. We anticipate
initiating this clinical trial during the first quarter of 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<DIV STYLE="border: Black 1pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6pt; text-align: justify"><I>SYN-004</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6pt; text-align: justify">In September 2016, we completed enrollment
in our Phase 2b proof-of-concept clinical trial intended to evaluate the ability of SYN-004 (ribaxamase) to prevent CDI, <I>C.
difficile</I> associated diarrhea (CDAD) and AAD in patients hospitalized for a lower respiratory tract infection and receiving
IV ceftriaxone.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6pt; text-align: justify">On October 6, 2016, we announced the award
of a government contract by the CDC&rsquo;s <FONT STYLE="color: #333333">Broad Agency Announcement (BAA) 2016-N-17812</FONT>. The
contract amount is up to $521,014. The award will support research conducted during our ongoing, randomized, placebo-controlled
Phase 2b proof-of-concept clinical study of SYN-004 (ribaxamase) and the CDC&rsquo;s efforts to assess how selective pressure from
IV antibiotics may lead to the emergence of antibiotic resistance in the gut microbiome. The funding will also support research
to evaluate SYN-004&rsquo;s (ribaxamase&rsquo;s) ability to reduce selective pressure associated with the emergence of antibiotic-resistant
organisms in the gut microbiomes of patients enrolled in our Phase 2b clinical trial. We will examine DNA isolated from longitudinal
samples obtained during the clinical trial and look for changes to the patient's gut resistome, specifically examining for alterations
in the presence and/or abundance of antibiotic resistance genes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6pt; text-align: justify"><B>Company History</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6pt; text-align: justify">Our predecessor, Sheffield Pharmaceuticals,
Inc., was incorporated in 1986, and in 2006 engaged in a reverse merger with Pipex Therapeutics, Inc., a Delaware corporation formed
in 2001. After the merger, we changed our name to Pipex Pharmaceuticals, Inc., and in October 2008 we changed our name to Adeona
Pharmaceuticals, Inc. On October 15, 2009, we engaged in a merger with a wholly owned subsidiary for the purpose of reincorporating
in the State of Nevada. After reprioritizing our focus on the emerging area of synthetic biologics and entering into our first
collaboration with Intrexon Corporation, we changed our name to Synthetic Biologics, Inc. on February 15, 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6pt; text-align: justify"><B>Corporate Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6pt; text-align: justify">Our principal executive offices are
located at 9605 Medical Center Drive, Suite 270, Rockville, Maryland 20850. Our telephone number is (301) 417-4364, and our
website address is <I>www.syntheticbiologics.com</I>. The information contained on, or that can be accessed through, our
website is not part of, and should not be construed as being incorporated by reference into, this prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6pt; text-align: justify">For further information regarding us and
our financial information, you should refer to our recent filings with the SEC. See &ldquo;Where You Can Find More Information.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<DIV STYLE="border: Black 1pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><A NAME="a_004"></A><B>The
Offering</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.6pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.6pt; text-indent: 22.3pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; padding-left: 6pt; padding-right: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common stock offered by us</FONT></TD>
    <TD STYLE="width: 60%; padding-right: 6pt; text-align: justify; padding-left: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 6pt; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="padding-right: 6pt; text-align: justify; padding-left: 6pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 6pt; padding-left: 6pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.2pt; text-indent: -4.2pt">Warrants offered by us</P></TD>
    <TD STYLE="padding-right: 6pt; padding-left: 6pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Series A          warrants
        to         purchase up to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of         our
        common stock,         which may be         exercised beginning on their date of issuance. The Series A warrants are
        exercisable until the         four year anniversary of the issuance date.                The
        Series A warrants have an         exercise                 price of $1.43         per         share         of         common
        stock,         subject to         adjustment.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Series B warrants to purchase up to
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;         shares of our common stock, which may be
        exercised beginning on their date of issuance. The Series B warrants are exercisable until December 31,         2017.
        The         Series&nbsp;B         warrants         have         an         exercise         price         of $1.72 per share
        of common         stock, subject         to          adjustment.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to applicable laws, the warrants
        are separately tradeable immediately after issuance at the option of the holders and may be transferred at the option of the holders.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus supplement also relates
        to the offering of the shares of common stock issuable upon exercise of the warrants.</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 6pt; padding-left: 6pt">&nbsp;</TD>
    <TD STYLE="padding-right: 6pt; padding-left: 6pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 6pt; padding-left: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.2pt; text-indent: -4.2pt">Option to purchase additional
shares and warrants</P>



</TD>
    <TD STYLE="padding-right: 6pt; padding-left: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0; text-align: justify">We have granted the
                                                      underwriter the option, exercisable for 30 days from the date of this prospectus supplement, to purchase up to
                                                      &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;additional shares of our common stock and warrants to
                                                      purchase up to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional&nbsp;shares of our common
                                                      stock.</P>



</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 6pt; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="padding-right: 6pt; text-align: justify; padding-left: 6pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 6pt; padding-left: 6pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.2pt; text-indent: -4.2pt">Common stock to be outstanding</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.2pt; text-indent: -4.2pt">after this offering</P></TD>
    <TD STYLE="padding-right: 6pt; padding-left: 6pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        shares (assuming none of the warrants issued in this offering are exercised and
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares if the warrants are
        exercised if full). If the underwriter&rsquo;s option to purchase additional shares and warrants is exercised in full, the
        total number of shares of common stock outstanding immediately after this offering would be
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares (assuming none of the warrants are exercised
        and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares if the warrants are
        exercised in full).</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 6pt; padding-left: 6pt">&nbsp;</TD>
    <TD STYLE="padding-right: 6pt; padding-left: 6pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 6pt; padding-left: 6pt">Risk Factors&nbsp;</TD>
    <TD STYLE="padding-right: 6pt; padding-left: 6pt">Investing in our
        securities involves a high degree of risk.&nbsp;See &ldquo;Risk Factors&rdquo; section of this prospectus supplement and in
        the documents incorporated by reference into this prospectus supplement and the accompanying prospectus for a discussion of
        factors that you should consider before investing in our securities.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 6pt; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="padding-right: 6pt; text-align: justify; padding-left: 6pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 6pt; padding-right: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use of proceeds</FONT></TD>
    <TD STYLE="padding-right: 6pt; text-align: justify; padding-left: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We intend to use the net proceeds from this offering primarily to provide the necessary funding for the continued clinical development of SYN-010, including initiation of our planned Phase 2b/3 clinical trial, and progression of SYN-004 to Phase 2 data readout and initiation of the planned Phase 3 clinical trial for SYN-004. The net proceeds from this offering may also be used for general corporate purposes, which may include, among other things, payment of general and administrative expenses and accounts payable, increasing our working capital and funding research and development, clinical trials and capital expenditures. In addition, we may use a portion of the net proceeds for licensing or acquiring intellectual property to incorporate into our products and product candidates or our research and development programs and to in-license, acquire or invest in complementary businesses or partnerships and intellectual property. See &ldquo;Use of Proceeds&rdquo; on page S-9.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 6pt; padding-right: 6pt">&nbsp;</TD>
    <TD STYLE="padding-right: 6pt; text-align: justify; padding-left: 6pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 6pt; padding-right: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Listing</FONT></TD>
    <TD STYLE="padding-right: 6pt; text-align: justify; padding-left: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our common stock is listed on the NYSE MKT under the trading symbol &ldquo;SYN.&rdquo; There is no established public trading market for the offered warrants and we do not expect a market to develop. In addition, we do not intend to apply for listing of the warrants on any securities exchange or recognized trading system. The warrants will be issued in book-entry form pursuant to a warrant agreement between us and Corporate Stock Transfer, Inc., as warrant agent.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.6pt; text-indent: 22.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6pt; text-align: justify">The number of shares of our common stock
to be outstanding immediately after the offering is based on 91,652,351 shares of common stock outstanding as of September 30,
2016 and excludes as of that date:&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;&nbsp;&nbsp;&#9;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="width: 91%; padding-right: 6pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,513,552 shares of our common stock subject to options outstanding having a weighted-average exercise price of $2.15 per share;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="width: 91%; padding-right: 6pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,655,176 shares of our common stock that have been reserved for issuance in connection with future grants under our stock option plans; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="width: 91%; padding-right: 6pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,858,899 shares of our common stock that have been reserved for issuance upon exercise of outstanding warrants having a weighted-average exercise price of $1.77 per share.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6pt; text-align: justify">Except as otherwise indicated, all
information in this prospectus supplement assumes no exercise by the underwriter of its option to purchase additional shares
of our common stock and warrants and excludes shares of our common stock that may be issuable upon exercise of the warrants
offered hereby.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_005"></A>RISK FACTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Investing in our securities involves
a high degree of risk. You should consider carefully the risks discussed under the section captioned &ldquo;Risk Factors&rdquo;
contained in our Annual Report on Form 10-K for the year ended December&nbsp;31, 2015, as updated by our subsequent filings under
the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), each of which is incorporated by reference in
this prospectus supplement, together with other information in this prospectus supplement and the accompanying prospectus, and
the information and documents incorporated by reference in this prospectus supplement, the accompanying prospectus, and any free
writing prospectus that we have authorized for use in connection with this offering before you make a decision to invest in our
common stock and accompanying warrants. If any of these events actually occur, our business, operating results, prospects or financial
condition could be materially and adversely affected. This could adversely affect the value of an investment in our common stock
and accompanying warrants and you may lose all or part of your investment. Moreover, the risks described below are not the only
ones that we face. Additional risks not presently known to us or that we currently believe are immaterial may also significantly
impair our business operations. Please also read carefully the section below titled &ldquo;Special Note Regarding Forward-Looking
Statements.&rdquo;</I></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Additional Risks Relating to the Offering</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our management team may invest or
spend the proceeds of this offering in ways with which you may not agree or in ways which may not yield a significant return.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our management will have broad discretion
over the use of proceeds from this offering. The net proceeds from this offering will be used primarily to provide the necessary
funding for the continued clinical development of SYN-010, including initiation of our planned Phase 2b/3 clinical trial and progression
of SYN-004 to Phase 2 data readout and initiation of our planned Phase 3 clinical trial for SYN-004. The net proceeds from this
offering may also be used for general corporate purposes, which may include, among other things, increasing our working capital
and funding research and development, clinical trials and capital expenditures. In addition, we may use a portion of the net proceeds
for licensing or acquiring intellectual property to incorporate into our products and product candidates or our research and development
programs and to in-license, acquire or invest in complementary businesses or products and intellectual property, although we have
no current commitments or obligations to do so. Our management will have considerable discretion in the application of the net
proceeds, and you will not have the opportunity, as part of your investment decision, to assess whether the proceeds are being
used appropriately. The net proceeds may be used for corporate purposes that do not increase our operating results or enhance the
value of our securities. Pending their use, we may invest the net proceeds from this offering in short-term, investment-grade,
interest-bearing securities. These investments may not yield a favorable return to our stockholders. If we do not invest or apply
the net proceeds from this offering in ways that enhance stockholder value, we may fail to achieve expected financial results,
which could cause our stock price to decline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If you purchase securities sold in
this offering, you will experience immediate dilution in your investment. You will experience further dilution if we issue additional
equity securities in future fundraising transactions and if shares of our common stock underlying our significant number of outstanding
warrants and options are purchased by the holders thereof.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The portion of the public offering price
per share and accompanying warrants in this offering attributable to our common stock exceeds the net tangible book value
per share of our common stock outstanding prior to this offering. Assuming we sell all of the securities in this offering at the
public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, after deducting the estimated underwriting discounts and commissions and estimated offering
expenses payable by us, you will experience immediate dilution of approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, representing the difference between
our as adjusted net tangible book value per share as of September 30, 2016 after giving effect to this offering and the public
offering price, without giving effect to the potential exercise of the warrants being offered in this offering. See the section
entitled &ldquo;Dilution&rdquo; below for a more detailed illustration of the dilution you would incur if you participate in this
offering.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If in the future we issue additional
common stock, or securities convertible into or exchangeable or exercisable for common stock, our stockholders, including
investors who purchase shares offered under this prospectus supplement, will experience additional dilution, and any such
issuances may result in downward pressure on the price of our common stock. We have a significant number of outstanding
securities convertible into, or allowing the purchase of our common stock. Investors will be subject to increased dilution
upon the exercise of outstanding stock options and warrants. There were 92,172,714 shares of our common stock outstanding as
of November 11, 2016. As of that date, stock options and warrants outstanding represented 16,322,868 shares of our
common stock that could be issued in the future. Most of the outstanding shares of our common stock, as well as the vast
majority of the shares of our common stock that may be issued under our outstanding options and warrants, are not restricted
from trading. Also, the issuance of additional shares as a result of such conversion or purchase, or their subsequent sale,
could adversely affect the price of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>You may experience future dilution
as a result of future equity offerings. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In order to raise additional
capital, we may in the future issue additional shares of our common stock, including, but not limited to, in an &ldquo;at the
market offering,&rdquo; or other securities convertible into or exchangeable for our common stock at prices that may not be
the same as the price per share in this offering. We may sell shares or other securities in any other offering at a price per
share that is less than the offering price paid by investors in this offering, and investors purchasing shares or other
securities in the future could have rights superior to existing stockholders. The price per share at which we sell additional
shares of our common stock, or securities convertible or exchangeable into common stock, in future transactions may be higher
or lower than the price per share attributable to the common stock paid by investors in this offering. You will incur
dilution upon any such sale of additional shares if the price at which such shares are sold is higher than the net tangible
book value per share of our common stock at the time of such sale.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>There is no public market for the
warrants to purchase common stock in this offering. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There is no established public trading
market for the warrants being sold in this offering, and we do not expect a market to develop. In addition, we do not intend to
apply to list the warrants on any securities exchange or recognized trading system. Without an active market, the liquidity of
the warrants will be limited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The warrants are a risky investment.
You may not be able to recover your investment in the warrants, and the warrants may expire worthless. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Whether
the warrants will have any value will depend on the results of certain of our clinical trials as well as market conditions
for our common stock generally, which conditions will depend on factors related and unrelated to the success of our
clinical development program, and cannot be predicted at this time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If our common stock price does not increase
to an amount sufficiently above the exercise prices of the warrants during the periods the warrants are exercisable, you will be
unable to recover any of your investment in the warrants. There can be no assurance that any of the factors that could impact the
trading price of our common stock will result in the trading price increasing to an amount that will exceed the exercise price
or the price required for you to achieve a positive return on your investment in the warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Holders of the warrants will have
no voting rights as common stockholders until they acquire our common stock. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Until you acquire shares of
our common stock upon exercise of the warrants, you will have no voting rights with respect to our common stock issuable upon
exercise of the warrants voting. Upon exercise of your warrants, you will be entitled to exercise all the voting rights of a
common stockholder only as to matters for which the record date occurs after the exercise date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Because we do not intend to declare
cash dividends on our shares of common stock in the foreseeable future, stockholders must rely on appreciation of the value of
our common stock for any return on their investment. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have never declared or paid cash dividends
on our common stock. We currently anticipate that we will retain future earnings for the development, operation and expansion of
our business and do not anticipate declaring or paying any cash dividends in the foreseeable future. In addition, the terms of
any existing or future debt agreements may preclude us from paying dividends. As a result, we expect that only appreciation of
the price of our common stock, if any, will provide a return to investors in this offering for the foreseeable future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt"><B>Significant
holders or beneficial holders of our common stock may not  be permitted to exercise warrants that they hold.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-align: left; text-indent: 24pt; background-color: transparent">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify">The
warrant agreement governing the warrants being offered hereby will prohibit a holder from exercising its warrants if doing
so would result in such holder (together with such holder&rsquo;s affiliates and any other persons acting as a group together
with such holder or any of such holder&rsquo;s affiliates) beneficially owning more than 9.99% of our common stock outstanding
immediately after giving effect to the exercise, provided that, at the election of a holder and notice to us, such beneficial
ownership limitation shall be 4.99% of our common stock outstanding immediately after giving effect to the exercise. As a result,
you may not be able to exercise your warrants for shares of our common stock at a time when it would be financially beneficial
for you to do so. In such circumstance you could seek to sell your warrants to realize value, but you may be unable to do so.</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; background-color: transparent">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt"><B>We may not
have the ability to repurchase the warrants.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-align: left; text-indent: 24pt; background-color: transparent">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify">Under
certain circumstances, if an extraordinary transaction (as defined in the warrant agreement) occurs, holders of the warrants
may require us to repurchase the remaining unexercised portion of such warrants for an amount of cash equal to the value of the
warrant as determined in accordance with the Black Scholes option pricing model and the terms of the warrants. Our ability to
repurchase the warrants depends on our ability to generate cash flow in the future. To some extent, this is subject to general
economic, financial, competitive, legislative and regulatory factors and other factors that are beyond our control. We cannot
assure you that we will maintain sufficient cash reserves or that our business will generate cash flow from operations at levels
sufficient to permit us to repurchase the warrants.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_006"></A><B>SPECIAL NOTE REGARDING FORWARD-LOOKING
STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus supplement, the accompanying
prospectus and the documents we file with the SEC that are incorporated by reference herein and therein contain &ldquo;forward-looking
statements&rdquo; within the meaning of Section&nbsp;27A of the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;),
and Section&nbsp;21E of the Exchange Act. These forward-looking statements reflect our current views with respect to our ongoing
and planned clinical trials, business strategy, business plan, financial performance and other future events. These statements
include forward-looking statements both with respect to us, specifically, and the biotechnology sector, in general. We make these
statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements that include
the words &ldquo;expect,&rdquo; &ldquo;intend,&rdquo; &ldquo;plan,&rdquo; &ldquo;believe,&rdquo; &ldquo;project,&rdquo; &ldquo;estimate,&rdquo;
&ldquo;may,&rdquo; &ldquo;should,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;will&rdquo; and similar statements of a future or forward-looking
nature identify forward-looking statements for purposes of the federal securities laws or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All forward-looking statements involve
inherent risks and uncertainties, and there are or will be important factors that could cause actual results to differ materially
from those indicated in these statements. We believe that these factors include, but are not limited to, those factors set forth
under the caption &ldquo;Risk Factors&rdquo; in this prospectus supplement and in the accompanying prospectus and under the captions
&ldquo;Risk Factors,&rdquo; &ldquo;Business,&rdquo; and &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition
and Results of Operations,&rdquo; in our most recent Annual Report on Form&nbsp;10-K and our subsequent Quarterly Reports on Form
10-Q, all of which you should review carefully. Please consider our forward-looking statements in light of those risks as you read
this prospectus supplement and the accompanying prospectus. It is not possible for our management to predict all risks, nor can
we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual
results to differ materially from those contained in any forward-looking statements we may make. Given these uncertainties, you
should not place undue reliance on these forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You should not assume that the information
contained in this prospectus supplement is accurate as of any date other than the date on the front of this prospectus supplement,
or that any information incorporated by reference into this prospectus is accurate as of any date other than the date of the document
so incorporated by reference. Except as required by law, we assume no obligation to update these forward-looking statements publicly,
or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even
if new information becomes available in the future. Thus, you should not assume that our silence over time means that actual events
are bearing out as expressed or implied in such forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If one or more of these or other risks
or uncertainties materializes, or if our underlying assumptions prove to be incorrect, actual results may vary materially from
what we anticipate. All subsequent written and oral forward-looking statements attributable to us or individuals acting on our
behalf are expressly qualified in their entirety by this Note. Before purchasing any shares of common stock, you should consider
carefully all of the factors set forth or referred to in this prospectus supplement, the accompanying prospectus and in the documents
we file with the SEC that are incorporated by reference herein that could cause actual results to differ.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_007"></A>USE OF PROCEEDS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We estimate that the net
proceeds from the sale of the &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock
and accompanying warrants that we are offering, excluding the proceeds, if any, from the exercise of the warrants issued in
this offering, will be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million ($
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million if the underwriter&rsquo;s option to purchase additional shares of
common stock and warrants is exercised in full) based on the public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share of common stock and accompanying warrants, after deducting the
estimated underwriting discounts and commissions and estimated offering expenses payable by us.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We intend to use the net proceeds from
this offering primarily to provide the necessary funding for the continued clinical development of SYN-010, including initiation
of our planned Phase 2b/3 clinical trial, and progression of SYN-004 to Phase 2 data readout and initiation of our planned Phase
3 clinical trial for SYN-004. We may also use the net proceeds from this offering for general corporate purposes, which may include,
among other things, payment of general and administrative expenses and accounts payable, increasing our working capital and funding
research and development, clinical trials and capital expenditures. In addition, we may use a portion of the net proceeds for licensing
or acquiring intellectual property to incorporate into our products and product candidates or our research and development programs
and to in-license, acquire or invest in complementary businesses or products and intellectual property, although we have no current
commitments or agreements to do so.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The amounts and timing of our actual expenditures
will depend on numerous factors, including our development and commercialization efforts, as well as the amount of cash used in
our operations. We therefore cannot estimate with certainty the amount of net proceeds to be used for the purposes described above.
We may find it necessary or advisable to use the net proceeds for other purposes, and we will have broad discretion in the application
of the net proceeds. Pending the uses described above, we plan to invest the net proceeds from this offering in short-term, investment-grade,
interest-bearing securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_008"></A>DIVIDEND POLICY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We currently do not plan to declare dividends
on shares of our common stock in the foreseeable future. We expect to retain all future earnings, if any, for use in the operation
and expansion of our business. The payment of cash dividends in the future, if any, will be at the discretion of our board of directors
and will depend upon such factors as any other factors our board deems relevant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_009"></A>DILUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If you invest in our securities, your
interest will be diluted immediately to the extent of the difference between the public offering price and the adjusted net
tangible book value per share of our common stock immediately after this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our net tangible book value on September
30, 2016 was approximately $(6.0) million, or $(0.07) per share. &ldquo;Net tangible book value&rdquo; is total assets minus the
sum of liabilities and intangible assets. &ldquo;Net tangible book value per share&rdquo; is net tangible book value divided by
the total number of shares outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">After giving effect to our sale
of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock and warrants to purchase
an additional &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock offered by us
at the public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share and accompanying warrants
(excluding shares of common stock to be issued and any proceeds received upon exercise of the warrants), after deducting the
estimated underwriting discounts and commissions and estimated offering expenses payable by us, our as adjusted net tangible
book value as of September&nbsp;30, 2016 would have been approximately $
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, or $ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share.
Assuming the completion of the offering, this represents an immediate increase in net tangible book value of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share to existing stockholders and immediate dilution in net tangible
book value of $ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share to new investors participating in this offering at
the public offering price. The following table illustrates this dilution on a per share basis:</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 72%; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Public offering price per share and accompanying warrants</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 27pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net tangible book value per share as of September 30, 2016</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.07</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 27pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increase in net tangible book value per share attributable to new investors participating in this offering</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As adjusted net tangible book value per share after giving effect to this offering</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dilution per share to new investors purchasing participating in this offering</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;<B>&nbsp;</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the underwriter exercises in full its
option to purchase up to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional shares of common stock and warrants to purchase an additional &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock at the
public offering price of $ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share and accompanying warrant (excluding shares of common stock to be issued and any proceeds to
be received upon exercise of the warrants), the as adjusted net tangible book value after this offering would be $ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, representing
an increase in net tangible book value of $ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share to existing stockholders and immediate dilution in net tangible book value
of $ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share to investors purchasing our common stock in this offering at the public offering price.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The above discussion and table are based
on 91,652,351 shares of our common stock outstanding as of the close of business on September&nbsp;30, 2016. This number excludes,
as of the close of business on September&nbsp;30, 2016, the shares of our common stock issuable upon exercise of the warrants offered
hereby and also excludes:</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">8,513,552 shares issuable upon the exercise of outstanding
stock options with a weighted-average exercise price of $2.15 per share;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">6,655,176 shares of common stock which were reserved for future equity awards that may be granted
in the future under our equity incentive plans; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">7,858,899 shares of our common stock reserved for issuance upon the exercise of outstanding warrants,
each with a weighted-average exercise price of $1.77 per share.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To the extent that any of these outstanding options or warrants
are exercised, there will be further dilution to new investors. In addition, investors that purchase common stock upon the exercise
of the warrants offered hereby may experience dilution depending on our net tangible book value at the time of exercise.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_100"></A>DESCRIPTION OF SECURITIES WE ARE OFFERING
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">We are offering&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
shares of our common stock and warrants to purchase an additional &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares
of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">The common stock and
warrants will be sold together. Each share of common stock will be sold with one Series A warrant and one Series B warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">The shares of common
stock and warrants are immediately separable and will be issued separately. The shares of common stock issuable from time to time
upon exercise of the warrants, if any, are also being offered pursuant to this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Common Stock </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">The material terms
and provisions of our common stock and each other class of our securities which qualifies or limits our common stock are described
under the caption &ldquo;Description of Capital Stock&mdash;Common Stock&rdquo; starting on page&nbsp;9 of the accompanying prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Warrants </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><I>The material terms
and provisions of the warrants being issued in this offering are summarized below. The following description is subject to, and
qualified in its entirety by, the form of warrant and the warrant agreement between us and the warrant agent, each of which
will be filed as an exhibit to a Current Report on Form&nbsp;8-K to be filed by us with the SEC in connection with this offering
and incorporated by reference into the registration statement of which this prospectus forms a part. You should review the form
of warrant and the warrant agreement for a complete description of the terms and conditions applicable to the warrants.
See &ldquo;Where You Can Find More Information&rdquo; on page S-18. </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">Each purchaser of
shares will receive, for each share of common stock purchased, one Series A warrant and one Series B warrant, each representing
the right to purchase one share of common stock. The number of shares of common stock underlying the warrants issued to each purchaser
will be equal to the number of shares of common stock purchased by such purchaser in this offering multiplied by two.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><I>Exercisability.</I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Series A and Series B warrants may be exercised at any time on or after their date of issuance. The Series A warrants
will have an exercise price of $1.43 per share and are exercisable until
the four year anniversary of the issuance date. The Series B warrants will have an exercise price of
$1.72 per share and are exercisable until December 31, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">The warrants will
be exercisable, at the option of each holder, in whole or in part by delivering to the warrant agent a duly executed exercise
notice accompanied by payment in full for the number of shares of our common stock purchased upon such exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><I>Exercise
Limitations.</I>&nbsp;&nbsp;&nbsp;&nbsp; A holder of a warrant will not have the right to exercise any portion of the warrant if
the holder (together with its affiliates) would beneficially own in excess of 9.99% of the number of shares of our common
stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance
with the terms of the warrants provided that at the election of a holder and notice to us such percentage ownership
limitation shall be 4.99% of the number of shares of our common stock outstanding immediately after giving effect to
the exercise. However, any holder may increase or decrease such percentage to any other percentage not in excess of 9.99%
upon at least 61 days&rsquo; prior notice from the holder to us.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Options: NewSection; Value: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><I>Exercise Price.</I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
initial per share exercise price of the Series A warrants is $1.43 and the initial per share exercise price of the Series B warrant
is $1.72. The respective exercise prices are subject to adjustment in the event of stock dividends and distributions, stock splits,
stock combinations, reclassifications or similar events affecting our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><I>Transferability.</I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject
to applicable laws, the warrants are separately tradeable immediately after issuance at the option of the holders and may be transferred
at the option of the holders. The warrants will be issued in book-entry form under a warrant agreement between the warrant
agent and us, and shall initially be represented by one or more book-entry certificates deposited with The Depository Trust Company,
or DTC, and registered in the name of Cede&nbsp;&amp; Co., a nominee of DTC, or as otherwise directed by DTC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><I>No
Listing.</I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There is no established public trading market for the warrants and we do not expect
a market to develop. In addition, we do not intend to apply for listing of the warrants on any securities exchange or
recognized trading system. Without an active market, the liquidity of the warrants will be limited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><I>Extraordinary
Transactions.</I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the event of an extraordinary transaction, as described in the
warrant agreement and generally including any reorganization, recapitalization or reclassification of our common stock,
the sale, transfer or other disposition of all or substantially all of our properties or assets, our consolidation or merger
with or into another person, the acquisition of more than 50% of our outstanding common stock, or any person or group
becoming the beneficial owner of 50% of the voting power represented by our outstanding common stock, the holders of the
warrants will be entitled to receive upon exercise of the warrants the kind and amount of securities, cash or other property
that the holders would have received had they exercised the warrants immediately prior to such fundamental transaction. In the event of an extraordinary transaction, we or any successor entity will pay at the holder&rsquo;s
option, exercisable at any time concurrently with or within 30 days after the consummation of the extraordinary transaction, an
amount of cash equal to the value of the warrant as determined in accordance with the Black Scholes option pricing model and the
terms of the warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><I>Cashless Exercise</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-align: left; background-color: transparent">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">If, at the time
a holder exercises its warrant, there is no effective registration statement registering, or the prospectus contained therein
is not available for an issuance of the shares underlying the warrant to the holder, then in lieu of making the cash payment
otherwise contemplated to be made to us upon such exercise in payment of the aggregate exercise price, the holder may elect
instead to receive upon such exercise (either in whole or in part) the net number of shares of our common stock determined
according to a formula set forth in the warrant. In the event of a cashless exercise, if we fail to timely deliver the
shares underlying the warrants, we will be subject to certain buy-in provisions.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; background-color: transparent">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><I>Rights as a
Stockholder.</I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except as otherwise provided in the warrants or warrant agreement or by
virtue of a holder&rsquo;s ownership of shares of our common stock, the holders of the warrants do not have the rights or
privileges of holders of our common stock, including any voting rights, until they exercise their warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><I>Variable Rate
Transactions</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">For the period that our lock-up agreement with Cantor Fitzgerald
&amp; Co., as described under &ldquo;Underwriting- No Sales of Similar Securities,&rdquo; is in effect, we are prohibited from
effecting or entering into any issuance of common stock or Common Stock Equivalents (as defined in the warrant agreement) involving
a Variable Rate Transaction (as defined in the warrant agreement).</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><I>Amendments.</I>
&nbsp;&nbsp;&nbsp;&nbsp;Amendments and waivers of the terms of the Series A warrants or the Series B warrants require the
written consent of the holders of sixty- seven percent (67%) of such series of warrants then outstanding and us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Transfer Agent and Registrar </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; text-align: justify">The transfer agent and registrar for our
common stock is Corporate Stock Transfer, Inc. Corporate Stock Transfer, Inc. will act as the registrar and transfer agent for
the warrants. Its address is 3200 Cherry Creek Drive South, Denver, Colorado 80209.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NYSE MKT Listing </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">Our common stock
is listed on the NYSE MKT under the symbol &ldquo;SYN.&rdquo; There is no established public trading market for the warrants
and we do not expect a market to develop. We do not plan on making an application to list the warrants on the NYSE MKT, any
securities exchange or any recognized trading system.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_010"></A>UNDERWRITING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> Subject to the terms and conditions
of the underwriting agreement, dated November &nbsp;&nbsp;&nbsp;, 2016, between us and Cantor Fitzgerald &amp; Co., as
underwriter, we have agreed to sell to the underwriter, and the underwriter has agreed to purchase from us, the shares of
common stock and accompanying warrants offered by this prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The underwriting agreement provides that
the obligations of the underwriter are subject to certain conditions precedent such as the receipt by the underwriter of officers&rsquo;
certificates and legal opinions and approval of certain legal matters by its counsel. The underwriting agreement provides that
the underwriter will purchase all of the shares of common stock and accompanying warrants if any of them are purchased. We have
agreed to indemnify the underwriter and certain of its controlling persons against certain liabilities, including liabilities under
the Securities Act, and to contribute to payments that the underwriter may be required to make in respect of those liabilities.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The underwriter has advised us that, following
the completion of this offering, it currently intends to make a market in the common stock as permitted by applicable laws and
regulations. However, the underwriter is not obligated to do so, and the underwriter may discontinue any market-making activities
at any time without notice in its sole discretion. Accordingly, no assurance can be given as to the liquidity of the trading market
for the common stock, that you will be able to sell any of the common stock held by you at a particular time or that the prices
that you receive when you sell will be favorable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The underwriter is offering the shares
of common stock and accompanying warrants, subject to prior sale, when, as and if issued to and accepted by it, subject to approval
of legal matters by its counsel and other conditions specified in the underwriting agreement. The underwriter reserves the right
to withdraw, cancel or modify offers to the public and to reject orders in whole or in part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Commissions and Expenses </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table shows the
public offering price, the underwriting discounts and commissions and the proceeds, before expenses, to us in connection with
this offering. Such amounts are shown assuming both no exercise and full exercise of the underwriter&rsquo;s option to
purchase additional shares and warrants.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We estimate expenses payable by us in connection
with this offering, other than the underwriting discounts and commissions referred to above, will be approximately $200,000. We
also have agreed to reimburse the underwriter for up to $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; of expenses related to the review of this offering by the Financial Industry
Regulatory Authority, Inc. (&ldquo;FINRA&rdquo;). In accordance with FINRA Rule 5110, this reimbursed FINRA expense is deemed underwriting
compensation for this offering.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">PER SHARE AND ACCOMPANYING WARRANTS</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">TOTAL</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>WITHOUT</B><BR> <B>OPTION TO</B><BR> <B>PURCHASE</B><BR> <B>ADDITIONAL</B><BR> <B>SHARES AND </B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>ACCOMPANYING </B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>WARRANTS</B></P></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>WITH</B><BR> <B>OPTION TO</B><BR> <B>PURCHASE</B><BR> <B>ADDITIONAL</B><BR> <B>SHARES</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>AND </B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>ACCOMPANYING </B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>WARRANTS</B></P></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>WITHOUT</B><BR> <B>OPTION TO</B><BR> <B>PURCHASE</B><BR> <B>ADDITIONAL</B><BR> <B>SHARES AND </B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>ACCOMPANYING </B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>WARRANTS</B></P></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>WITH</B><BR> <B>OPTION TO</B><BR> <B>PURCHASE</B><BR> <B>ADDITIONAL</B><BR> <B>SHARES</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>AND </B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>ACCOMPANYING </B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>WARRANTS</B></P></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 48%; font-size: 10pt; text-align: justify; text-indent: -12pt; padding-left: 12pt">Public offering price</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify; text-indent: -12pt; padding-left: 12pt">Underwriting discounts and commissions paid by us</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: justify; text-indent: -12pt; padding-left: 12pt">Proceeds to us, before expenses</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The underwriter proposes to offer the common
stock and accompanying warrants offered by us to the public at the public offering price set forth on the cover of this prospectus
supplement. If all of the common stock and accompanying warrants offered by us are not sold at the public offering price, the underwriter
may change the offering price and other selling terms.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Other</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">One<FONT STYLE="font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif">of our directors
has indicated an interest in purchasing up to $300,000 of shares of our common stock and warrants to purchase shares of our common
stock in this offering. An indication of interest is not binding and the director may purchase some, none or all of the securities
for which he has indicated an interest.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 17; Value: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Option to Purchase Additional Shares and Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have granted the underwriter an
option, exercisable for 30 days from the date of this prospectus supplement, to purchase, from time to time, in whole or in
part, up to an aggregate of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional shares
and accompanying warrants to purchase up to an additional
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares from us at the public offering price set
forth on the cover page of this prospectus supplement, less underwriting discounts and commissions.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Discretionary Accounts</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The underwriter has advised us that it
does not intend to confirm sales of the securities offered hereby to any account over which it exercises discretionary authority.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>No Sales of Similar Securities </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We, our officers, directors and
certain of our stockholders have agreed, subject to specified exceptions, not to directly or indirectly for a period of 90
days after the date of this prospectus supplement without the prior written consent of Cantor Fitzgerald &amp;
Co.&nbsp;&nbsp;:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 3%; padding-bottom: 8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 3%; padding-bottom: 8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%; padding-bottom: 8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-bottom: 8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant for the sale of, or otherwise dispose of, or publicly announce the intention to otherwise dispose of or transfer any shares of common stock or any securities convertible into or exchangeable or exercisable for common stock, or file, or cause to be filed, any registration statement under the Securities Act with respect to any of the foregoing; or</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">enter into any swap or any other agreement or any transaction that transfers, in whole or in part, directly or indirectly, the economic consequence of ownership of any shares of common stock or any securities convertible into or exchangeable or exercisable for common stock.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cantor Fitzgerald &amp; Co. may, in its
sole discretion and at any time or from time to time before the termination of the 90-day period release all or any portion of
the securities subject to lock-up agreements. There are no existing agreements between the underwriter and any of our shareholders
who will execute a lock-up agreement, providing consent to the sale of shares prior to the expiration of the lock-up period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Stabilization </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The underwriter has advised us that, pursuant
to Regulation&nbsp;M under the Exchange Act, certain persons participating in the offering may engage in short sale transactions,
stabilizing transactions, syndicate covering transactions or the imposition of penalty bids in connection with this offering. These
activities may have the effect of stabilizing or maintaining the market price of the common stock at a level above that which might
otherwise prevail in the open market. Establishing short sales positions may involve either &ldquo;covered&rdquo; short sales or
&ldquo;naked&rdquo; short sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;Covered&rdquo; short sales are sales
made in an amount not greater than the underwriter&rsquo;s option to purchase additional shares of our common stock in this offering.
The underwriter may close out any covered short position by either exercising its option to purchase additional shares of our common
stock or purchasing shares of our common stock in the open market. In determining the source of shares to close out the covered
short position, the underwriter will consider, among other things, the price of shares available for purchase in the open market
as compared to the price at which they may purchase shares through the option to purchase additional shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;Naked&rdquo; short sales are sales
in excess of the option to purchase additional shares of our common stock. The underwriter must close out any naked short position
by purchasing shares in the open market. A naked short position is more likely to be created if the underwriter is concerned that
there may be downward pressure on the price of the shares of our common stock in the open market after pricing that could adversely
affect investors who purchase in this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A stabilizing bid is a bid for the purchase
of shares of common stock on behalf of the underwriter for the purpose of fixing or maintaining the price of the common stock.
A syndicate covering transaction is the bid for or the purchase of shares of common stock on behalf of the underwriter to reduce
a short position incurred by the underwriter in connection with the offering. Similar to other purchase transactions, the underwriter&rsquo;s
purchases to cover the syndicate short sales may have the effect of raising or maintaining the market price of our common stock
or preventing or retarding a decline in the market price of our common stock. As a result, the price of our common stock may be
higher than the price that might otherwise exist in the open market. A penalty bid is an arrangement permitting the underwriter
to reclaim the selling concession otherwise accruing to a syndicate member in connection with the offering if the common stock
originally sold by such syndicate member are purchased in a syndicate covering transaction and therefore have not been effectively
placed by such syndicate member.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Neither we nor the underwriter make any
representation or prediction as to the direction or magnitude of any effect that the transactions described above may have on the
price of our common stock. The underwriter is not obligated to engage in these activities and, if commenced, any of the activities
may be discontinued at any time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Passive Market Making</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The underwriter may also engage in passive
market making transactions in our common stock on the NYSE MKT in accordance with Rule 103 of Regulation M during a period before
the commencement of offers or sales of shares of our common stock in this offering and extending through the completion of distribution.
A passive market maker must display its bid at a price not in excess of the highest independent bid of that security. However,
if all independent bids are lowered below the passive market maker&rsquo;s bid, that bid must then be lowered when specified purchase
limits are exceeded.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Notice to Investors </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>United Kingdom</B>.&nbsp;In the United Kingdom, this document
is being distributed only to, and is directed only at, and any offer subsequently made may only be directed at persons who are
&ldquo;qualified investors&rdquo; (as defined in the Prospectus Directive) (i) who have professional experience in matters relating
to investments falling within Article 19 (5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as
amended (the Order) and/or (ii) who are high net worth companies (or persons to whom it may otherwise be lawfully communicated)
falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as &ldquo;relevant persons&rdquo;).
This document must not be acted on or relied on in the United Kingdom by persons who are not relevant persons. In the United Kingdom,
any investment or investment activity to which this document relates is only available to, and will be engaged in with, relevant
persons.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>European Economic Area</B>.&nbsp;In relation to each
Member State of the European Economic Area (each, a Relevant Member State), no offer of securities may be made to the public
in that Relevant Member State other than:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 3%; padding-bottom: 8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 3%; padding-bottom: 8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%; padding-bottom: 8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-bottom: 8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to any legal entity which is a qualified investor as defined in the Prospectus Directive; </FONT></TD></TR>
<TR>
    <TD STYLE="padding-bottom: 8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-bottom: 8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD>
    <TD STYLE="vertical-align: top; padding-bottom: 8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-bottom: 8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to fewer than 100 or, if the Relevant Member State has implemented the relevant provision of the 2010 PD Amending Directive, 150, natural or legal persons (other than qualified investors as defined in the Prospectus Directive), as permitted under the Prospectus Directive, subject to obtaining the prior consent of the underwriter; or </FONT></TD></TR>
<TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in any other circumstances falling within Article 3(2) of the Prospectus Directive, </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">provided that no such offer of securities  shall
require us or the underwriter to publish a prospectus pursuant to Article 3 of the Prospectus Directive or supplement a prospectus
pursuant to Article 16 of the Prospectus Directive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each person in a Relevant Member State
who initially acquires any securities  or to whom any offer is made will be deemed to have represented, acknowledged and agreed that
it is a &ldquo;qualified investor&rdquo; within the meaning of the law in that Relevant Member State implementing Article 2(1)(e)
of the Prospectus Directive. In the case of any  securities being offered to a financial intermediary as that term is used in Article
3(2) of the Prospectus Directive, each such financial intermediary will be deemed to have represented, acknowledged and agreed
that the securities acquired by it in the offer have not been acquired on a non-discretionary basis on behalf of, nor have they been
acquired with a view to their offer or resale to, persons in circumstances which may give rise to an offer of any  securities to the
public other than their offer or resale in a Relevant Member State to qualified investors as so defined or in circumstances in
which the prior consent of the underwriter has been obtained to each such proposed offer or resale.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We, the underwriter and its affiliates
will rely upon the truth and accuracy of the foregoing representations, acknowledgements and agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus supplement has been prepared
on the basis that any offer of securities  in any Relevant Member State will be made pursuant to an exemption under the Prospectus Directive
from the requirement to publish a prospectus for offers of  securities. Accordingly, any person making or intending to make an offer
in that Relevant Member State of  securities which are the subject of the offering contemplated in this prospectus supplement may only
do so in circumstances in which no obligation arises for us or the underwriter to publish a prospectus pursuant to Article 3 of
the Prospectus Directive in relation to such offer. Neither we nor the underwriter have authorized, nor do they authorize, the
making of any offer of securities  in circumstances in which an obligation arises for us or the underwriter to publish a prospectus
for such offer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the purpose of the above provisions,
the expression &ldquo;an offer to the public&rdquo; in relation to any  securities in any Relevant Member State means the communication
in any form and by any means of sufficient information on the terms of the offer and the  securities to be offered so as to enable an
investor to decide to purchase or subscribe the  securities, as the same may be varied in the Relevant Member State by any measure implementing
the Prospectus Directive in the Relevant Member State and the expression &ldquo;Prospectus Directive&rdquo; means Directive 2003/71/EC
(including the 2010 PD Amending Directive, to the extent implemented in the Relevant Member States) and includes any relevant implementing
measure in the Relevant Member State and the expression &ldquo;2010 PD Amending Directive&rdquo; means Directive 2010/73/EU.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Hong Kong</B>.&nbsp;The  securities may not
be offered or sold in Hong Kong, by means of any document, other than (a) to &ldquo;professional investors&rdquo; as defined in
the Securities and Futures Ordinance (Cap. 571) of Hong Kong and any rules made under that Ordinance; or (b) in other circumstances
which do not result in the document being a &ldquo;prospectus&rdquo; as defined in the Companies Ordinance (Cap. 32) of Hong Kong
or which do not constitute an offer to the public within the meaning of that Ordinance. No advertisement, invitation or document
relating to the securities has been or may be issued or has been or may be in the possession of any person for the purposes of
issue, whether in Hong Kong or elsewhere, which is directed at, or the contents of which are likely to be accessed or read by,
the public of Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to securities
which are or are intended to be disposed of only to persons outside Hong Kong or only to &ldquo;professional investors&rdquo; as
defined in the Securities and Futures Ordinance and any rules and regulations made under that Ordinance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Japan</B>.&nbsp;The  securities have not
been and will not be registered under the Financial Instruments and Exchange Law of Japan (Law No. 25 of 1948, as amended) and,
accordingly, will not be offered or sold, directly or indirectly, in Japan, or for the benefit of any Japanese Person or to others
for re-offering or resale, directly or indirectly, in Japan or to any Japanese Person, except in compliance with all applicable
laws, regulations and ministerial guidelines promulgated by relevant Japanese governmental or regulatory authorities in effect
at the relevant time. For the purposes of this paragraph, &ldquo;Japanese Person&rdquo; shall mean any person resident in Japan,
including any corporation or other entity organized under the laws of Japan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Canada</B>.&nbsp;The securities  may be sold
only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in National Instrument&nbsp;45-106
<I>Prospectus Exemptions</I> or subsection 73.3(1) of the <I>Securities Act</I> (Ontario), and are permitted clients, as defined
in National Instrument&nbsp;31-103 Registration Requirements, <I>Exemptions and Ongoing Registrant Obligations</I>. Any resale
of the  securities must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements
of applicable securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Securities legislation in certain provinces
or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus supplement (including
any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the
purchaser within the time limit prescribed by the securities legislation of the purchaser&rsquo;s province or territory. The purchaser
should refer to any applicable provisions of the securities legislation of the purchaser&rsquo;s province or territory for particulars
of these rights or consult with a legal advisor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to section&nbsp;3A.3 of National
Instrument&nbsp;33-105 <I>Underwriting Conflicts</I> (&ldquo;NI&nbsp;33-105&rdquo;), the underwriter is not required to comply
with the disclosure requirements of NI 33-105 regarding underwriter conflicts of interest in connection with this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Electronic Distribution</B>. A prospectus
supplement and the accompanying prospectus in electronic format may be made available by e-mail or on the web sites or through
online services maintained by the underwriter or its affiliates. In those cases, prospective investors may view offering terms
online and may be allowed to place orders online. The underwriter may agree with us to allocate a specific number of  securities for sale to online brokerage account holders. Any such allocation for online distributions will be made by the underwriter
on the same basis as other allocations. Other than the prospectus supplement and the accompanying prospectus in electronic format,
the information on the underwriter&rsquo;s web site and any information contained in any other web site maintained by the underwriter
is not part of this prospectus supplement and the accompanying prospectus, has not been approved and/or endorsed by us or the underwriter
and should not be relied upon by investors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Other Relationships</B>.&nbsp;The underwriter
and its affiliates have provided, and may in the future provide, various investment banking, commercial banking and other financial
services for us and our affiliates for which they have received, and may in the future receive, customary fees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Listing on the NYSE
MKT</B>.&nbsp;Our common stock is traded on the NYSE MKT under the symbol &ldquo;SYN.&rdquo; The transfer agent for our
common stock is Corporate Stock Transfer, Inc. There is no established public trading market for the offered warrants and we
do not expect a market to develop. In addition, we do not intend to apply for listing of the warrants on any
securities exchange or recognized trading system. The warrants will be issued in book-entry form pursuant to a warrant agreement between us and Corporate Stock Transfer, Inc., as warrant agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_011"></A>LEGAL MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Gracin &amp; Marlow, LLP, New York, New
York is representing us in connection with this offering and will pass upon certain matters relating to the issuance of the warrants.
Parsons Behle &amp; Latimer, Reno, Nevada will pass upon certain legal matters relating to the validity of the common stock offered
hereby and the common stock issuable upon exercise of the warrants. Latham &amp; Watkins LLP, San Diego, California is counsel
for the underwriter in connection with this offering.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_012"></A><B>EXPERTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The financial statements of Synthetic Biologics,
Inc. as of December 31, 2015 and 2014 and for each of the three years ended in the period ended December 31, 2015 and management&rsquo;s
assessment of the effectiveness of internal control over financial reporting as of December 31, 2015 incorporated by reference
in this prospectus supplement and the accompanying prospectus have been so incorporated in reliance on the reports of BDO USA,
LLP, an independent registered accounting firm, incorporated herein by reference, given on authority of said firm as experts in
auditing and accounting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_013"></A><B>WHERE YOU CAN FIND MORE INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have filed with the SEC a registration
statement on Form S-3 under the Securities Act, of which this prospectus supplement forms a part. The rules and regulations of
the SEC allow us to omit from this prospectus supplement certain information included in the registration statement. For further
information about us and the securities we are offering under this prospectus supplement, you should refer to the registration
statement and the exhibits and schedules filed with the registration statement. With respect to the statements contained in this
prospectus regarding the contents of any agreement or any other document, in each instance, the statement is qualified in all respects
by the complete text of the agreement or document, a copy of which has been filed as an exhibit to the registration statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We file reports, proxy statements and other
information with the SEC under the Exchange Act. You may read and copy this information from the Public Reference Room of the SEC,
100 F Street, N.E., Room 1580, Washington, D.C. 20549, at prescribed rates. You may obtain information on the operation of the
Public Reference Room by calling the SEC at 1-800-SEC-0330. The SEC also maintains an Internet website that contains reports, proxy
statements and other information about issuers, like us, that file electronically with the SEC. The address of that website is
<I>www.sec.gov</I>. In addition, all of the documents incorporated by reference into this prospectus supplement may be accessed
via the Internet at our website: www.syntheticbiologics.com. We have not incorporated by reference into this prospectus supplement
the information on our website, and you should not consider it to be a part of this prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_014"></A>INCORPORATION OF CERTAIN INFORMATION
BY REFERENCE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The SEC allows us to &ldquo;incorporate
by reference&rdquo; the information we file with it which means that we can disclose important information to you by referring
you to those documents instead of having to repeat the information in this prospectus supplement. The information incorporated
by reference is considered to be part of this prospectus supplement, and later information that we file with the SEC will automatically
update and supersede this information. We incorporate by reference the documents listed below and any future filings made with
the SEC under Sections&nbsp;13(a), 13(c), 14 or 15(d) of the Exchange Act between the date of this prospectus supplement and the
termination of the offering, however, we are not incorporating by reference any documents or portions thereof, whether specifically
listed below or filed in the future, that are not deemed &ldquo;filed&rdquo; with the SEC pursuant to General Instructions of Form
8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.2in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our Annual Report on Form&nbsp;10-K for
the fiscal year ended December 31, 2015 filed with the SEC on March 10, 2016 (File No. 001-12584);&nbsp;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.2in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our Quarterly Reports on Form 10-Q for
the quarter ended March 31, 2016 filed with the SEC on May 5, 2016, for the quarter ended June 30, 2016 filed with the SEC on August
3, 2016 and for the quarter ended September 30, 2016 filed with the SEC on November 1, 2016 (File No. 001-12584);</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.2in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our Current Reports on Form 8-K filed
with the SEC on February 2, August 5 and August 26, 2016 (File No. 001-12584)<FONT STYLE="color: #1F497D">;</FONT></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.2in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our Definitive Proxy Statement on Schedule
14A filed with the SEC on July 6, 2016 (File No. 001-12584); and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.2in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
description of our common stock set forth in our registration statement on Form 8-A12B, filed with the SEC on June 20, 2007 (File
No.&nbsp;000-12584).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any statement contained in this prospectus
supplement or in a document incorporated or deemed to be incorporated by reference into this prospectus supplement will be deemed
to be modified or superseded for purposes of this prospectus supplement to the extent that a statement contained in this prospectus
supplement or any other subsequently filed document that is deemed to be incorporated by reference into this prospectus supplement
modifies or supersedes the statement. Any statement so modified or superseded will not be deemed, except as so modified or superseded,
to constitute a part of this prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will furnish without charge to you,
on written or oral request, a copy of any or all of the documents that are incorporated by reference into this prospectus supplement
and the accompanying prospectus but not delivered with the prospectus supplement, including exhibits which are specifically incorporated
by reference into such documents. You should direct any requests for documents to Synthetic Biologics, Inc., Attn: Steve Shallcross,
Chief Financial Officer, 9605 Medical Center Drive, Suite 270, Rockville, Maryland 20850, or telephoning us at (301) 417-4364.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You should rely only on information contained
in, or incorporated by reference into, this prospectus supplement and the accompanying prospectus. We have not authorized anyone
to provide you with information different from that contained in this prospectus or incorporated by reference in this prospectus
supplement or the accompanying prospectus. We are not making offers to sell the securities in any jurisdiction in which such an
offer or solicitation is not authorized or in which the person making such offer or solicitation is not qualified to do so or to
anyone to whom it is unlawful to make such offer or solicitation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<B>PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_003.jpg" ALT="" STYLE="height: 41px; width: 203px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>$200,000,000</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Units</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may offer and sell up to $200 million
in the aggregate of the securities identified above from time to time in one or more offerings. This prospectus provides you with
a general description of the securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each time we offer and sell securities,
we will provide a supplement to this prospectus that contains specific information about the offering and the amounts, prices and
terms of the securities. The supplement may also add, update or change information contained in this prospectus with respect to
that offering. You should carefully read this prospectus and the applicable prospectus supplement before you invest in any of our
securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may offer and sell the securities described
in this prospectus and any prospectus supplement to or through one or more underwriters, dealers and agents, or directly to purchasers,
or through a combination of these methods. If any underwriters, dealers or agents are involved in the sale of any of the securities,
their names and any applicable purchase price, fee, commission or discount arrangement between or among them will be set forth,
or will be calculable from the information set forth, in the applicable prospectus supplement. See the sections of this prospectus
entitled &ldquo;About this Prospectus&rdquo; and &ldquo;Plan of Distribution&rdquo; for more information. No securities may be
sold without delivery of this prospectus and the applicable prospectus supplement describing the method and terms of the offering
of such securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>This prospectus may not be used to sell
securities unless it is accompanied by a prospectus supplement.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>INVESTING IN OUR SECURITIES INVOLVES
RISKS. SEE THE &ldquo;RISK FACTORS&rdquo; ON PAGE 5 OF THIS PROSPECTUS AND ANY SIMILAR SECTION CONTAINED IN THE APPLICABLE PROSPECTUS
SUPPLEMENT CONCERNING FACTORS YOU SHOULD CONSIDER BEFORE INVESTING IN OUR SECURITIES.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our common stock is traded on NYSE MKT
under the symbol &ldquo;SYN&rdquo;. On August 6, 2015, the last reported sale price for the common stock was $3.10 per share. We
urge prospective purchasers of our common stock to obtain current information about the market prices of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our executive offices are located at 9605
Medical Center Drive, Suite 270, Rockville, Maryland 20850 and our administrative offices are located at 617 Detroit Street, Suite
100, Ann Arbor, Michigan 48104. Our telephone number is (734) 332-7800.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Neither the Securities and Exchange
Commission nor any state securities commission has approved or disapproved of these securities or passed upon the accuracy or adequacy
of the prospectus. Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The date of this prospectus is August 18,
2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 95%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 5%; padding-right: 0.8pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt"><A HREF="#a_015"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">About this Prospectus</FONT></A></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right">1</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-right: 0.8pt"><A HREF="#a_016"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prospectus Summary</FONT></A></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right">2</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt"><A HREF="#a_017"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk Factors</FONT></A></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right">7</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-right: 0.8pt"><A HREF="#a_018"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Special Note Regarding Forward-Looking Statements</FONT></A></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right">7</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt"><A HREF="#a_019"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use of Proceeds</FONT></A></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right">8</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-right: 0.8pt"><A HREF="#a_020"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend Policy</FONT></A></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right">8</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt"><A HREF="#a_021"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description of Capital Stock</FONT></A></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right">9</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-right: 0.8pt"><A HREF="#a_022"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description of Warrants</FONT></A></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right">9</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt"><A HREF="#a_023"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description of Units</FONT></A></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right">11</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-right: 0.8pt"><A HREF="#a_024"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Plan of Distribution</FONT></A></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right">13</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt"><A HREF="#a_025"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal Matters</FONT></A></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right">14</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-right: 0.8pt"><A HREF="#a_026"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Experts</FONT></A></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right">14</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt"><A HREF="#a_027"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Where You Can Find More Information</FONT></A></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right">15</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-right: 0.8pt"><A HREF="#a_028"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporation of Certain Documents by Reference</FONT></A></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right">15</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt"><A HREF="#a_029"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosure of the Securities and Exchange Commission Position on Indemnification for Securities Act Liabilities</FONT></A></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right">15</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The registration statement containing
this prospectus, including the exhibits to the registration statement, provides additional information about us and the common
stock offered under this prospectus. The registration statement, including the exhibits and the documents incorporated herein by
reference, can be read on the Securities and Exchange Commission website or at the Securities and Exchange Commission offices mentioned
under the heading &ldquo;Where You Can Find More Information.&rdquo;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_015"></A><B>ABOUT THIS PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus is not an offer or solicitation
in respect to these securities in any jurisdiction in which such offer or solicitation would be unlawful.&nbsp;&nbsp;This prospectus
is part of a registration statement that we filed with the Securities and Exchange Commission (the &ldquo;SEC&rdquo;).&nbsp;&nbsp;The
registration statement that contains this prospectus (including the exhibits to the registration statement) contains additional
information about our company and the securities offered under this prospectus.&nbsp;&nbsp;That registration statement can be read
at the SEC website or at the SEC&rsquo;s offices listed under the heading &ldquo;Where You Can Find More Information.&rdquo;&nbsp;We
have not authorized anyone else to provide you with different information or additional information.&nbsp;&nbsp;You should not
assume that the information in this prospectus, or any supplement or amendment to this prospectus, is accurate at any date other
than the date indicated on the cover page of such documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 25; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_016"></A><B>PROSPECTUS SUMMARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Our Business</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-indent: -1.5pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are a clinical-stage company developing
therapeutics to protect the microbiome while targeting pathogen-specific diseases. Our lead candidates in Phase 2 development include
SYN-004 which is designed to protect the gut microbiome (gastrointestinal (GI) microflora) from the effects of certain commonly
used intravenous (IV) antibiotics for the prevention of <I>C. difficile</I> infection and antibiotic-associated diarrhea (AAD),
and SYN-010 which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat the underlying
cause of irritable bowel syndrome with constipation (IBS-C). In addition, we are developing a Phase 2 oral estriol drug, Trimesta&trade;,
for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS, and in collaboration with Intrexon
Corporation (NYSE:XON), a preclinical stage monoclonal antibody combination for the treatment of Pertussis, and novel discovery
stage biotherapeutics for the treatment of phenylketonuria (PKU).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Product Pipeline:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="image_004.jpg" ALT="" STYLE="height: 355px; width: 669px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Summary of Microbiome Programs:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 0.8pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="width: 94%; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>C. difficile</I> infections (CDI):</B> We are in clinical development of a novel second-generation oral enzyme, SYN-004, to degrade commonly used IV beta-lactam antibiotics in the GI tract, intended to protect the microbiome and prevent the development of and severe effects from CDI and AAD. CDIs are a leading type of hospital acquired infection (HAI) and are frequently associated with IV antibiotic treatment. Designed to be given orally and co-administered with certain IV beta-lactam antibiotics (e.g., penicillins and cephalosporins), SYN-004 is intended to protect the gut while the IV antibiotics fight the primary infection. SYN-004 is believed to not only have a similar profile to its first-generation predecessor, which demonstrated protection of the microbiome (gut flora) during treatment with certain penicillins, but also has the potential to protect the gut from a broader spectrum of IV beta-lactam antibiotics. Beta-lactam antibiotics are a mainstay in hospital infection management and include the commonly used penicillin and cephalosporin classes of antibiotics. SYN-004&rsquo;s target market is significant and represented by annual U.S. hospitals purchases of approximately 118 million doses of IV beta-lactam antibiotics which are administered to approximately 14 million patients.* Currently there are no approved treatments designed to protect the gut microbiome from the damaging effects of IV antibiotics. This worldwide market could represent a multi-billion dollar opportunity for us. In November 2014, the U.S. Patent and Trademark Office (USPTO) issued Patent No. 8,894,994 that has claims to compositions of matter and pharmaceutical compositions of beta-lactamases, including SYN-004, and carries a patent term to at least 2031. We also have an extensive patent estate on other aspects of this program which includes patent applications that could carry a term to at least 2035. In the fourth quarter of 2014, we initiated our randomized, double-blind placebo-controlled Phase 1a clinical trial, reported positive topline safety and tolerability results from the Phase 1a clinical trial, and initiated the Phase 1b clinical trial evaluating multiple ascending doses of SYN-004. In February 2015, we reported positive topline results from the Phase 1b clinical trial of escalating doses of oral SYN-004, with no safety or tolerability issues reported at dose levels and dose regimens both meeting and exceeding those expected to be studied in upcoming clinical trials. In March 2015, we reported positive pharmacokinetics data from both Phase 1 clinical trials, with supportive evidence that SYN-004 should have no effect on the IV antibiotic in the bloodstream, allowing the antibiotic to fight the primary infection. In March 2015, we also initiated a Phase 2a clinical trial to evaluate the GI antibiotic-degrading effects and the safety of SYN-004. In June 2015, the first participant was dosed in a second Phase 2a clinical trial of SYN-004, to evaluate the GI antibiotic-degrading effects and the safety of SYN-004, in the presence of the proton pump inhibitor (PPI), esomeprazole. Topline data is expected from the first Phase 2a clinical trial during the third quarter of 2015, and from the second Phase 2a clinical trial during the second half of 2015. In July 2015, we reported data from the first four of 12 expected participants in the first Phase 2a open-label clinical trial; the data showed that SYN-004 degraded IV ceftriaxone in the chyme of the four healthy participants with functioning ileostomies without affecting the ceftriaxone in the bloodstream. The initiation of a Phase 2b proof-of-concept clinical trial of SYN-004 is expected in the third quarter of 2015. This randomized, placebo-controlled clinical trial is expected to enroll approximately 370 patients at up to 75 global clinical sites. An interim analysis of blinded data from the Phase 2b clinical trial is anticipated during the second half of 2015. The initiation of pivotal Phase 3 clinical trial(s)
are anticipated during 2016.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>*</B></FONT></TD>
    <TD STYLE="width: 91%; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This information is an estimate derived from the use of information under license from the following IMS Health Incorporated information service: CDM Hospital database for full year 2012. IMS expressly reserves all rights, including rights of copying, distribution and republication.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="width: 94%; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IBS-C:</B> In December 2013, through our majority-owned subsidiary, Synthetic Biomics, Inc., we entered into a worldwide exclusive license agreement with Cedars-Sinai Medical Center (CSMC) for the right to develop products for therapeutic and prophylactic treatments of acute and chronic diseases, including the development of SYN-010 to target IBS-C. SYN-010 is our proprietary modified-release formulation of the classic statin, lovastatin, that is intended to reduce methane-production by certain microorganisms (<I>M. smithii</I> ) in the gut while minimizing disruption to the microbiome. SYN-010 is intended to act primarily in the intestinal lumen while avoiding systemic absorption, thereby targeting the cause of IBS-C, not just the symptoms. An investigational team led by Mark Pimentel, M.D. at CSMC discovered that lovastatin may reduce the production of methane gas by certain gastrointestinal (GI) microorganisms. Methane produced by these organisms is perceived as an underlying cause of pain, bloating, and constipation associated with IBS-C, and may contribute to the pathology of other diseases. In May 2015, preclinical results were presented in a poster at Digestive Disease Week <SUP>&reg;</SUP> (DDW) 2015 demonstrating that lovastatin prevented proliferation of methanogens in the small intestines of rats with minimal impact on remaining microbiome. In his practice, Dr. Pimentel translated the use of statins to reduce methane in humans by evaluating commercial lovastatin formulations in select IBS-C patients, demonstrating that lovastatin prevented methane production by methanogens in human stool. Using stringent disease diagnosis criteria to ensure market relevance and a population most likely to receive a diagnosis and prescription drug treatment, there are an estimated 40.7 million cases of IBS reported in the U.S., Europe and Japan, and it has been reported that up to 20 percent of all IBS patients have IBS-C. The estimated global sales for IBS therapeutics for 2015 are $669.3 million, and global sales are expected to be greater than $1.5 billion in 2023*. A 505(b)(2) regulatory pathway is anticipated for the development of SYN-010. We licensed an intellectual property portfolio from CSMC including granted use patents and pending patent applications for SYN-010. Additional worldwide patent filings having composition of matter claims, which were recently filed by CSMC and licensed to us, could extend patent protection of SYN-010 to 2035. Our Investigational New Drug (IND) application was submitted to the U.S. Food and Drug Administration (FDA) in May 2015. In June 2015, we initiated our first Phase 2 placebo-controlled clinical trial of SYN-010. This clinical trial is expected to enroll approximately 60 patients who will be randomly assigned in a 1:1:1 ratio to one of three groups, including two different SYN-010 dose groups and a placebo group. Patients are scheduled to receive single oral doses of SYN-010 each day for 28 days. The primary objective of this clinical trial is to evaluate the change from baseline in breath methane, as determined by a lactulose breath test, in methane-positive patients with IBS-C after seven days of treatment with one of two formulations of SYN-010 compared with placebo. Secondary endpoints include Improvement in the number of complete spontaneous bowel movements (CSBM) per week, and improvement in abdominal pain and bloating per standard scales required per FDA guidance. We anticipate reporting topline results from the first Phase 2 clinical trial during the second half of 2015. We also anticipate initiating the second SYN-010 Phase 2 clinical trial during the second half of 2015, with topline results from this trial expected during the first half of 2016. The primary endpoint of the second Phase 2 is to evaluate the ability of SYN-010 to sustain the reduction in breath methane levels, and secondary endpoints include evaluating pain, bloating and CSBM. The initiation of pivotal Phase 3 clinical trial(s) are anticipated
during 2016.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="width: 91%; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">GlobalData, Irritable Bowel Syndrome - Global Drug Forecast and Market Analysis to 2023, December 2014</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Summary of Multiple Sclerosis Program:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="width: 94%; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Relapsing-Remitting MS:</B> We have licensed issued method of treatment patents in the U.S. for MS therapy with estriol and estriol combination therapies (including estriol with Copaxone<SUP>&reg;</SUP>) from University of California, Los Angeles (UCLA). In April 2014, positive Phase 2 topline efficacy and safety results was presented by the lead principal investigator of the UCLA Phase 2 investigator initiated randomized (n=158) double-blinded placebo trial which evaluated our drug candidate, Trimesta, in woman with relapsing remitting MS at 16 sites in the U.S. In September 2014, the lead principal investigator presented additional Phase 2 clinical outcome data, including more detailed results on improvements in cognitive and disability measures, at the 2014 Joint Americas and European Committees for Treatment and Research in Multiple Sclerosis Meeting (ACTRIMS-ECTRIMS) in Boston. The data as reported by the lead principal investigator for the UCLA-led Phase 2 study supported the potential of Trimesta to have a novel dual mechanism of action for both the anti-inflammatory effects that improve relapse rate, and a neuroprotective effect that improves standard measures of disability and cognition. Numerous new provisional patent applications have been filed based on the Phase 2 clinical results. This investigator-initiated Phase 2 clinical trial was supported by grants exceeding $8 million, awarded primarily by the National Multiple Sclerosis Society (NMSS) in partnership with the NMSS&rsquo;s Southern California chapter, and the National Institutes of Health. Annual worldwide sales of MS therapies are forecasted to be approximately $17.8 billion in 2019. In July 2015, through our wholly owned subsidiary, we entered into amended license and clinical trial agreements with The Regents of UCLA. We were also informed by UCLA that MRI analyses are ongoing to evaluate changes in the brain that correlate with improvements seen in clinical outcomes, and we expect to report topline MRI data 30 days following our receipt of this data from UCLA. We continue to engage the neurology community and potential strategic partners, as we determine next steps for Trimesta.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="width: 94%; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cognitive Dysfunction in MS:</B> Trimesta is also being developed for the treatment of cognitive dysfunction in female MS patients. This 12-month, UCLA-led, randomized, double-blind, placebo-controlled investigator-initiated Phase 2 clinical trial is being conducted at four sites in the United States. The primary endpoint is the effect on cognitive function as assessed by Paced Auditory Serial Addition Test (PASAT). Patient enrollment is ongoing. The majority of the costs of this trial are being funded by grants from foundations and charitable organizations through direct funding to the lead principal investigator and we have pledged approximately $500,000 to UCLA to partially fund this trial, payable over three years. An estimated 50 - 65% of MS patients are expected to develop disabilities due to cognitive dysfunction and there is currently no approved treatment for this indication.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="width: 94%; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pertussis:</B> In December 2012, in collaboration with Intrexon Corporation, we initiated development of a monoclonal antibody (mAb) therapy for the treatment of Pertussis infections, more commonly known as whooping cough. Combining two mAbs, SYN-005 is designed to target and neutralize pertussis toxin as a prophylaxis for high-risk newborns and in order to reduce the mortality rate in infected infants. To further the development of this potential therapy for Pertussis, we entered into an agreement with The University of Texas at Austin (UT) to license the rights to certain research and pending patents related to pertussis antibodies. We have patents pending on compositions and uses of SYN-005 and we have an issued U.S. patent on other pertussis mAbs from UT. According to the World Health Organization, each year, <I>B. pertussis</I> infection is estimated to cause up to 300,000 deaths worldwide, primarily among unvaccinated infants. Positive preclinical research findings for SYN-005 were reported in April 2014, and again in September 2014, for our proprietary mAb combination therapy for treating Pertussis, in non-human primate studies. In September 2014 we received a U.S. Orphan Drug designation for SYN-005 for the treatment of Pertussis. In April 2015, positive preclinical findings were reported in two posters at ECCMID 2015 (European Congress of Clinical Microbiology and Infectious Diseases). We are seeking non-dilutive funding to support preclinical and clinical development of SYN-005 for prophylaxis and treatment of Pertussis, including the anticipated filing of an IND application and the anticipated initiation of a Phase 1 clinical trial.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="width: 94%; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Phenylketonuria (PKU):</B> In August 2015, we entered into a third worldwide exclusive channel collaboration with Intrexon Corporation through which we intend to develop and commercialize novel biotherapeutics for the treatment of patients with PKU. We will utilize Intrexon Corporation&rsquo;s ActoBiotics&trade; platform providing a proprietary method of delivering therapeutic protein and peptides to the gastrointestinal tract through food-grade microbes. This program is in the discovery stage.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="width: 94%; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Acinetobacter infections:</B> In September 2012, in collaboration with Intrexon, we initiated efforts to develop a mAb therapy for the treatment of <I>Acinetobacter</I> infections. Many strains of <I>Acinetobacter</I> are multidrug-resistant and pose an increasing global threat to hospitalized patients, wounded military personnel and those affected by natural disasters. A treatment for <I>Acinetobacter</I> infections represents a billion dollar market opportunity. This program is in the discovery stage and the generation of a panel of antibodies to treat this infection is ongoing.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All of our programs are supported by growing
patent estates that we either own or exclusively license. In total, each potential product has issued patents that provide protection,
and we have approximately 100 U.S. and foreign patents and over 55 U.S. and foreign patents pending.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Since our inception in January 2001, our
efforts and resources have been focused primarily on acquiring and developing our product candidates, our clinical trials, raising
capital, manufacturing and recruiting personnel. To date, we have financed our operations primarily through public and private
sales of our common stock, and we expect to continue to seek to obtain the required capital in a similar manner. We have incurred
an accumulated deficit of $127.0 million through June 30, 2015. We cannot provide any assurance that we will be able to achieve
profitability on a sustained basis, if at all, obtain the required funding, obtain the required regulatory approvals, or complete
additional corporate partnering or acquisition transactions.&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Recent Developments</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 10, 2015, we expanded our relationship
with Intrexon Corporation and entered into an Exclusive Channel Collaboration Agreement (the &ldquo;Channel Agreement&rdquo;) with
Intrexon Corporation that governs a &ldquo;channel collaboration&rdquo; arrangement in which we will use Intrexon Corporation&rsquo;s
technology relating to the development and commercialization of novel biotherapeutics (a &ldquo;Collaboration Product&rdquo;) for
the treatment of patients with PKU. We have agreed to pay Intrexon Corporation a technology access fee by the issuance of 937,500
shares of common stock, having a value equal to $3 million as of August 7, 2015, within ten days of approval of the issuance by
the NYSE MKT. In addition, upon the achievement of certain milestones, we agreed to pay Intrexon Corporation milestone payments
of up to $27 million for each product developed. We will pay Intrexon Corporation royalties on annual net sales of Collaboration
Products, calculated on a product-by-product basis equal to a percent of net sales (ranging from mid-single digits on the first
$100 million of net sales to mid-teen digits on net sales in excess of $750 million).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>


<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 21, 2015, we completed a public
offering of 15.3 million shares of common stock, including the fully exercised over-allotment option by the underwriters covering
2.0 million shares, at an offering price of $3.00 per share. The total gross proceeds of the offering, including the exercise in
full of the over-allotment option, were approximately $46.0 million. Net proceeds, after deducting the underwriters&rsquo; discount
and other estimated expenses, were approximately $42.6 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 8, 2015, Putney Drug Corp., our
subsidiary, and The Regents of UCLA, entered into an amendment to the License Agreement, dated July 11, 2005 (as amended previously),
and an amendment to the Clinical Trial Agreement, dated as of April 29, 2010.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Since our inception in January 2001, our
efforts and resources have been focused primarily on acquiring and developing our product candidates, our clinical trials, raising
capital, manufacturing and recruiting personnel. To date, we have financed our operations primarily through public and private
sales of our common stock, and we expect to continue to seek to obtain the required capital in a similar manner. We have incurred
an accumulated deficit of $127.0 million through June 30, 2015. We cannot provide any assurance that we will be able to achieve
profitability on a sustained basis, if at all, obtain the required funding, obtain the required regulatory approvals, or complete
additional corporate partnering or acquisition transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Company History</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our predecessor, Sheffield Pharmaceuticals,
Inc., was incorporated in 1986, and in 2006 engaged in a reverse merger with Pipex Therapeutics, Inc., a Delaware corporation formed
in 2001. After the merger, we changed our name to Pipex Pharmaceuticals, Inc., and in October 2008 we changed our name to Adeona
Pharmaceuticals, Inc. On October 15, 2009, we engaged in a merger with a wholly owned subsidiary for the purpose of reincorporating
in the State of Nevada. After reprioritizing our focus on the emerging area of synthetic biologics and entering into our first
collaboration with Intrexon, we amended our Articles of Incorporation to change our name to Synthetic Biologics, Inc. on February
15, 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Corporate Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our executive offices are located at 9605
Medical Center Drive, Suite 270, Rockville, Maryland 20850. We also maintain an administrative and finance office in Ann Arbor,
Michigan. Our telephone number is (732) 332-7800, and our website address is <I>www.syntheticbiologics.com</I> . The information
contained on our website is not part of, and should not be construed as being incorporated by reference into this prospectus supplement.
As used in this prospectus supplement, unless the context otherwise requires, references to &ldquo;Synthetic,&rdquo; &ldquo;we,&rdquo;
&ldquo;us,&rdquo; &ldquo;our,&rdquo; and similar references refer to Synthetic Biologics, Inc. and our subsidiaries.&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_017"></A>RISK FACTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>An investment in our common stock involves
a high degree of risk. You should consider carefully the risks discussed under the section captioned &ldquo;Risk Factors&rdquo;
contained in our most recent annual report on Form 10-K and in our subsequent quarterly reports on Form 10-Q, as updated by our
subsequent filings under the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), each of which is incorporated
by reference in this prospectus in its entirety, together with other information in this prospectus, and the information and documents
incorporated by reference in this prospectus, and any free writing prospectus that we have authorized for use in connection with
this offering before you make a decision to invest in our common stock. If any of these events actually occur, our business, operating
results, prospects or financial condition could be materially and adversely affected. This could cause the trading price of our
common stock to decline and you may lose all or part of your investment.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_018"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING
STATEMENTS</B> &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Some of the statements contained or incorporated
by reference in this prospectus may include forward-looking statements that reflect our current views with respect to our ongoing
and planned clinical trials, business strategy, business plan, financial performance and other future events. These statements
include forward-looking statements both with respect to us, specifically, and the biotechnology sector, in general. We make these
statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements that include
the words &ldquo;expect,&rdquo;&ldquo;intend,&rdquo;&ldquo;plan,&rdquo;&ldquo;believe,&rdquo;&ldquo;project,&rdquo;&ldquo;estimate,&rdquo;&ldquo;may,&rdquo;&ldquo;should,&rdquo;&ldquo;anticipate,&rdquo;&ldquo;will&rdquo;and
similar statements of a future or forward-looking nature identify forward-looking statements for purposes of the federal securities
laws or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All forward-looking statements involve
inherent risks and uncertainties, and there are or will be important factors that could cause actual results to differ materially
from those indicated in these statements. We believe that these factors include, but are not limited to, those factors set forth
under the caption &ldquo;Risk Factors&rdquo; in this prospectus and under the captions &ldquo;Risk Factors,&rdquo; &ldquo;Business,&rdquo;
and &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations,&rdquo; in our most recent
Annual Report on Form&nbsp;10-K and our subsequent Quarterly Reports on Form10-Q, all of which you should review carefully. Please
consider our forward-looking statements in light of those risks as you read this prospectus supplement and the accompanying prospectus.
We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information,
future developments or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If one or more of these or other risks
or uncertainties materializes, or if our underlying assumptions prove to be incorrect, actual results may vary materially from
what we anticipate. All subsequent written and oral forward-looking statements attributable to us or individuals acting on our
behalf are expressly qualified in their entirety by this Note. Before purchasing any shares of common stock, you should consider
carefully all of the factors set forth or referred to in this prospectus that could cause actual results to differ.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_019"></A>USE OF PROCEEDS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless otherwise set forth in the applicable
prospectus supplement, we intend to use the net proceeds, if any, from the sales of securities offered by this prospectus for general
corporate purposes, which may include, among other things, payment of general and administrative expenses and accounts payable,
increasing our working capital and funding research and development, clinical trials and capital expenditures. In addition, we
may use a portion of the net proceeds for licensing or acquiring intellectual property to incorporate into our products and product
candidates or our research and development programs. We may also use a portion of the net proceeds to in-license, acquire or invest
in complementary businesses or products, and intellectual property, however, we have no current commitments or obligations to do
so.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The amounts and timing of our actual expenditures
will depend on numerous factors, including our development and commercialization efforts, as well as the amount of cash used in
our operations. We therefore cannot estimate with certainty the amount of net proceeds to be used for the purposes described above.
We may find it necessary or advisable to use the net proceeds for other purposes, and we will have broad discretion in the application
of the net proceeds. Pending the uses described above, we plan to invest the net proceeds from this offering in short-term, investment-grade,
interest-bearing securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_020"></A>DIVIDEND POLICY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have never paid cash dividends on our
common stock. Moreover, we do not anticipate paying periodic cash dividends on our common stock for the foreseeable future. We
intend to use all available cash and liquid assets in the operation and growth of our business. Any future determination about
the payment of dividends will be made at the discretion of our board of directors and will depend upon our earnings, if any, capital
requirements, operating and financial conditions and on such other factors as our board of directors deems relevant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_021"></A>DESCRIPTION OF CAPITAL STOCK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Authorized Capital</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our authorized capital consists of 250
million shares of common stock, par value $0.001 per share, and 10 million shares of preferred stock, par value $0.001 per share.
As of August 6,&nbsp;2015, 88,596,568 and 88,515,086 of common stock were issued and outstanding, and no shares of preferred stock
were issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Common Stock</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may issue shares of our common stock
from time to time. Holders of shares of common stock have the right to cast one vote for each share of common stock in their name
on our books, whether represented in person or by proxy, on all matters submitted to a vote of holders of common stock, including
election of directors. There is no right to cumulative voting in election of directors. Except where a greater requirement is provided
by statute, by our articles of incorporation, or by our bylaws, the presence, in person or by proxy duly authorized, of the one
or more holders of a majority of the outstanding shares of our common stock constitutes a quorum for the transaction of business.
The vote by the holders of a majority of outstanding shares is required to effect certain fundamental corporate changes such as
liquidation, merger, or amendment of our articles of incorporation. Upon our liquidation, dissolution or winding up, holders of
our common stock are entitled to share ratably in all assets remaining after payment of liabilities and the liquidation preferences
of any outstanding shares of preferred stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There are no restrictions in our articles
of incorporation or bylaws that prevent us from declaring dividends. We have not declared any dividends, and we do not plan to
declare any dividends in the foreseeable future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Holders of shares of our common stock are
not entitled to preemptive or subscription or conversion rights, and no redemption or sinking fund provisions are applicable to
our common stock. All outstanding shares of common stock are, and the shares of common stock sold in the offering will when issued
be fully paid and non-assessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_022"></A>DESCRIPTION OF WARRANTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Warrants</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of August 6,&nbsp;2015, we had issued
and outstanding a total of 7,908,899 warrants to purchase our common stock outstanding at a weighted-average price of $1.79.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may issue warrants for the purchase
of common stock. We may issue warrants independently or in combination with common stock. In this prospectus, we have summarized
certain general features of the warrants. We urge you, however, to read the applicable prospectus supplement (and any related free
writing prospectus that we may authorize to be provided to you) related to the particular series of warrants being offered, as
well as any warrant agreements and warrant certificates that contain the terms of the warrants. We will file as exhibits to the
registration statement of which this prospectus is a part, or will incorporate by reference from reports that we file with the
SEC, the form of warrant and/or the warrant agreement and warrant certificate, as applicable, that contain the terms of the particular
series of warrants we are offering, and any supplemental agreements, before the issuance of such warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any warrants issued under this prospectus
may be evidenced by warrant certificates. Warrants also may be issued under an applicable warrant agreement that we enter into
with a warrant agent. We will indicate the name and address of the warrant agent, if applicable, in the prospectus supplement relating
to the particular series of warrants being offered.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following description, together with
the additional information that we include in any applicable prospectus supplement and in any related free writing prospectus that
we may authorize to be distributed to you, summarizes the material terms and provisions of the warrants that we may offer under
this prospectus, which may be issued in one or more series. While the terms we have summarized below will apply generally to any
warrants that we may offer under this prospectus, we will describe the particular terms of any series of warrants in more detail
in the applicable prospectus supplement and in any related free writing prospectus that we may authorize to be distributed to you.
The following description of warrants will apply to the warrants offered by this prospectus unless we provide otherwise in the
applicable prospectus supplement. The applicable prospectus supplement for a particular series of warrants may specify different
or additional terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The summary below and that contained in
any prospectus supplement is qualified in its entirety by reference to all of the provisions of the warrant and/or the warrant
agreement and warrant certificate, as applicable, applicable to a particular series of securities. We urge you to read the applicable
prospectus supplements and any related free writing prospectuses related to the warrants that we may offer under this prospectus,
as well as the complete warrant and/or the warrant agreement and warrant certificate, as applicable, that contains the terms of
the warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>General</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We will describe in the applicable prospectus supplement the
terms of the series of warrants being offered, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 0.8pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="width: 91%; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the offering price and aggregate number of warrants offered;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 0.8pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="width: 91%; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the currency for which the warrants may be purchased;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 0.8pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="width: 91%; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if applicable, the number of warrants issued with each such security;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 0.8pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="width: 91%; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the number of shares of common stock, as the case may be, purchasable upon the exercise of one warrant and the price at which these shares may be purchased upon such exercise;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 0.8pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="width: 91%; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the effect of any merger, consolidation, sale or other disposition of our business on the warrant agreements and the warrants;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 0.8pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="width: 91%; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the terms of any rights to redeem or call the warrants;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 0.8pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="width: 91%; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any provisions for changes to or adjustments in the exercise price or number of securities issuable upon exercise of the warrants;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the dates on which the right to exercise the warrants will commence and expire;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 0.8pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="width: 91%; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the manner in which the warrant agreements and warrants may be modified;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 0.8pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="width: 91%; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a discussion of any material or special U.S. federal income tax considerations of holding or exercising the warrants;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 0.8pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="width: 91%; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the terms of the securities issuable upon exercise of the warrants; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 0.8pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="width: 91%; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any other specific terms, preferences, rights or limitations of or restrictions on the warrants.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Before exercising their warrants, holders
of warrants will not have any of the rights of holders of the securities purchasable upon such exercise, including the right to
receive dividends, if any, or, payments upon our liquidation, dissolution or winding up or to exercise voting rights, if any:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Exercise of Warrants</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each warrant will entitle the holder to
purchase the securities that we specify in the applicable prospectus supplement at the exercise price that we describe in the applicable
prospectus supplement. The warrants may be exercised as set forth in the prospectus supplement relating to the warrants offered.
Unless we otherwise specify in the applicable prospectus supplement, warrants may be exercised at any time up to the close of business
on the expiration date set forth in the prospectus supplement relating to the warrants offered thereby. After the close of business
on the expiration date, unexercised warrants will become void.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon receipt of payment and the warrant
or warrant certificate, as applicable, properly completed and duly executed at the corporate trust office of the warrant agent,
if any, or any other office, including ours, indicated in the prospectus supplement, we will, as soon as practicable, issue and
deliver the securities purchasable upon such exercise. If less than all of the warrants (or the warrants represented by such warrant
certificate) are exercised, a new warrant or a new warrant certificate, as applicable, will be issued for the remaining warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Enforceability of Rights by Holders of Warrants</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each warrant agent, if any, will act solely
as our agent under the applicable warrant agreement and will not assume any obligation or relationship of agency or trust with
any holder of any warrant. A warrant agent may act as warrant agent for more than one issue of warrants. A warrant agent will have
no duty or responsibility in case of any default by us under the applicable warrant agreement or warrant, including any duty or
responsibility to initiate any proceedings at law or otherwise, or to make any demand upon us. Any holder of a warrant may, without
the consent of the related warrant agent or the holder of any other warrant, enforce by appropriate legal action its right to exercise,
and receive the securities purchasable upon exercise of, its warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Governing Law</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless we otherwise specify in the applicable
prospectus supplement, the warrants and any warrant agreements will be governed by and construed in accordance with the laws of
the State of New York.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_023"></A>DESCRIPTION OF UNITS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Units</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may issue units consisting of any combination
of our common stock and warrants. We will issue each unit so that the holder of the unit is also the holder of each security included
in the unit. As a result, the holder of a unit will have the rights and obligations of a holder of each included security. The
unit agreement under which a unit is issued may provide that the securities included in the unit may not be held or transferred
separately, at any time or at any time before a specified date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The summary below and that contained in
any prospectus supplement is qualified in its entirety by reference to all of the provisions of the unit agreement and/or unit
certificate, and depositary arrangements, if applicable. We urge you to read the applicable prospectus supplements and any related
free writing prospectuses related to the units that we may offer under this prospectus, as well as the complete unit agreement
and/or unit certificate, and depositary arrangements, as applicable, that contain the terms of the units.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will file as exhibits to the registration
statement of which this prospectus is a part, or will incorporate by reference from reports that we file with the SEC, the form
of unit agreement and/or unit certificate, and depositary arrangements, as applicable, that contain the terms of the particular
series of units we are offering, and any supplemental agreements, before the issuance of such units.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The applicable prospectus supplement, information
incorporated by reference or free writing prospectus may describe:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD STYLE="width: 6%; padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 3%; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 91%; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the designation and terms of the units and of the securities comprising the units, including whether and under what circumstances those securities may be held or transferred separately;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD STYLE="width: 6%; padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 3%; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 91%; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any provisions for the issuance, payment, settlement, transfer, or exchange of the units or of the securities composing the units;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD STYLE="width: 6%; padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 3%; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 91%; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether the units will be issued in fully registered or global form; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD STYLE="width: 6%; padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 3%; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 91%; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any other terms of the units.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The applicable provisions described in
this section, as well as those described under &ldquo;Common Stock&rdquo; and &ldquo;Warrants&rdquo; above, will apply to each
unit and to each security included in each unit, respectively&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_024"></A><B>PLAN OF DISTRIBUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may sell the securities from time to
time pursuant to underwritten public offerings, negotiated transactions, block trades or a combination of these methods or through
underwriters or dealers, through agents and/or directly to one or more purchasers. The securities may be distributed from time
to time in one or more transactions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD STYLE="width: 6%; padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 3%; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 91%; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">at a fixed price or prices, which may be changed;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD STYLE="width: 6%; padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 3%; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 91%; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">at market prices prevailing at the time of sale;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD STYLE="width: 6%; padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 3%; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 91%; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">at prices related to such prevailing market prices; or</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD STYLE="width: 6%; padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 3%; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 91%; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">at negotiated prices.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each time that we sell securities covered
by this prospectus, we will provide a prospectus supplement or supplements that will describe the method of distribution and set
forth the terms and conditions of the offering of such securities, including the offering price of the securities and the proceeds
to us, if applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Offers to purchase the securities being
offered by this prospectus may be solicited directly. Agents may also be designated to solicit offers to purchase the securities
from time to time. Any agent involved in the offer or sale of our securities will be identified in a prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If a dealer is utilized in the sale of
the securities being offered by this prospectus, the securities will be sold to the dealer, as principal. The dealer may then resell
the securities to the public at varying prices to be determined by the dealer at the time of resale.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an underwriter is utilized in the sale
of the securities being offered by this prospectus, an underwriting agreement will be executed with the underwriter at the time
of sale and the name of any underwriter will be provided in the prospectus supplement that the underwriter will use to make resales
of the securities to the public. In connection with the sale of the securities, we, or the purchasers of securities for whom the
underwriter may act as agent, may compensate the underwriter in the form of underwriting discounts or commissions. The underwriter
may sell the securities to or through dealers, and those dealers may receive compensation in the form of discounts, concessions
or commissions from the underwriters and/or commissions from the purchasers for which they may act as agent. Unless otherwise indicated
in a prospectus supplement, an agent will be acting on a best efforts basis and a dealer will purchase securities as a principal,
and may then resell the securities at varying prices to be determined by the dealer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any compensation paid to underwriters,
dealers or agents in connection with the offering of the securities, and any discounts, concessions or commissions allowed by underwriters
to participating dealers will be provided in the applicable prospectus supplement. Underwriters, dealers and agents participating
in the distribution of the securities may be deemed to be underwriters within the meaning of the Securities Act, and any discounts
and commissions received by them and any profit realized by them on resale of the securities may be deemed to be underwriting discounts
and commissions. We may enter into agreements to indemnify underwriters, dealers and agents against civil liabilities, including
liabilities under the Securities Act, or to contribute to payments they may be required to make in respect thereof and to reimburse
those persons for certain expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any common stock will be listed on the
NYSE MKT, but any other securities may or may not be listed on a national securities exchange. To facilitate the offering of securities,
certain persons participating in the offering may engage in transactions that stabilize, maintain or otherwise affect the price
of the securities. This may include over-allotments or short sales of the securities, which involve the sale by persons participating
in the offering of more securities than were sold to them. In these circumstances, these persons would cover such over-allotments
or short positions by making purchases in the open market or by exercising their over-allotment option, if any. In addition, these
persons may stabilize or maintain the price of the securities by bidding for or purchasing securities in the open market or by
imposing penalty bids, whereby selling concessions allowed to dealers participating in the offering may be reclaimed if securities
sold by them are repurchased in connection with stabilization transactions. The effect of these transactions may be to stabilize
or maintain the market price of the securities at a level above that which might otherwise prevail in the open market. These transactions
may be discontinued at any time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If indicated in the applicable prospectus
supplement, underwriters or other persons acting as agents may be authorized to solicit offers by institutions or other suitable
purchasers to purchase the securities at the public offering price set forth in the prospectus supplement, pursuant to delayed
delivery contracts providing for payment and delivery on the date or dates stated in the prospectus supplement. These purchasers
may include, among others, commercial and savings banks, insurance companies, pension funds, investment companies and educational
and charitable institutions. Delayed delivery contracts will be subject to the condition that the purchase of the securities covered
by the delayed delivery contracts will not at the time of delivery be prohibited under the laws of any jurisdiction in the United
States to which the purchaser is subject. The underwriters and agents will not have any responsibility with respect to the validity
or performance of these contracts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may engage in at the market offerings
into an existing trading market in accordance with Rule 415(a)(4) under the Securities Act. In addition, we may enter into derivative
transactions with third parties, or sell securities not covered by this prospectus to third parties in privately negotiated transactions.
If the applicable prospectus supplement so indicates, in connection with those derivatives, the third parties may sell securities
covered by this prospectus and the applicable prospectus supplement, including in short sale transactions. If so, the third party
may use securities pledged by us or borrowed from us or others to settle those sales or to close out any related open borrowings
of stock, and may use securities received from us in settlement of those derivatives to close out any related open borrowings of
stock. The third party in such sale transactions will be an underwriter and, if not identified in this prospectus, will be named
in the applicable prospectus supplement (or a post-effective amendment). In addition, we may otherwise loan or pledge securities
to a financial institution or other third party that in turn may sell the securities short using this prospectus and an applicable
prospectus supplement. Such financial institution or other third party may transfer its economic short position to investors in
our securities or in connection with a concurrent offering of other securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The specific terms of any lock-up provisions
in respect of any given offering will be described in the applicable prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The underwriters, dealers and agents may
engage in transactions with us, or perform services for us, in the ordinary course of business for which they receive compensation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_025"></A>LEGAL MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Gracin &amp; Marlow, LLP, New York, New
York will pass upon certain legal matters related to the issuance and sale of the warrants and units offered hereby on our behalf
and Parsons Behle &amp; Latimer, Reno, Nevada will pass upon certain legal matters relating to the issuance and sale of the common
stock offered hereby on our behalf. Additional legal matters may be passed upon for us or any underwriters, dealers, of agents,
by counsel that we will name in the applicable prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_026"></A>EXPERTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The financial statements of Synthetic Biologics,
Inc. as of December 31, 2014 and 2013 and for each of the three years ended in the period ended December 31, 2014 and management&rsquo;s
assessment of the effectiveness of internal control over financial reporting as of December 31, 2014 incorporated by reference
in this prospectus have been so incorporated in reliance on the reports of BDO USA, LLP, an independent registered accounting firm,
incorporated herein by reference, given on authority of said firm as experts in auditing and accounting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_027"></A>WHERE YOU CAN FIND MORE INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We file annual, quarterly and special reports,
proxy statements and other information with the SEC. You may read and copy any document we file at the SEC&rsquo;s public reference
room located at 100&nbsp;F&nbsp;Street N.E., Washington,&nbsp;D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information
on the operation of the public reference room. Our public filings are also available to the public at the SEC&rsquo;s web site
at http://www.sec.gov.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus is part of a registration
statement on Form&nbsp;S-3 that we have filed with the SEC under the Securities Act. This prospectus does not contain all of the
information in the registration statement. We have omitted certain parts of the registration statement, as permitted by the rules
and regulations of the SEC. You may inspect and copy the registration statement, including exhibits, at the SEC&rsquo;s public
reference room or Internet site.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_028"></A><B>INCORPORATION OF CERTAIN DOCUMENTS BY
REFERENCE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The SEC allows us to &ldquo;incorporate
by reference&rdquo; the information we file with it which means that we can disclose important information to you by referring
you to those documents instead of having to repeat the information in this prospectus. The information incorporated by reference
is considered to be part of this prospectus, and later information that we file with the SEC will automatically update and supersede
this information. We incorporate by reference the documents listed below and any future filings made with the SEC (other than any
portions of any such documents that are not deemed &ldquo;filed&rdquo; under the Exchange Act in accordance with the Exchange Act
and applicable SEC rules) under Sections&nbsp;13(a), 13(c), 14 or 15(d) of the Exchange Act between the date of this prospectus
and the termination of the offering:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="width: 91%; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our annual report on Form&nbsp;10-K for the fiscal year ended December 31, 2014 filed with the SEC on March 16, 2015 (File No. 001-12584);&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="width: 91%; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our quarterly report on Form 10-Q for the quarter ended March 31, 2015 filed with the SEC on May 11, 2015 and our quarterly report on Form 10-Q for the quarter ended June 30, 2015 filed with the SEC on August 10, 2015 (File No. 001-12584);</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="width: 91%; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our current reports on Form 8-K filed with the SEC on January 12, 2015, March 19, 2015, May 4, 2015, May 18, 2015, June 16, 2015, July 9, 2015, July 17, 2015 and August 10, 2015 (File No. 001-12584);</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="width: 91%; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our definitive proxy statement on Schedule 14A filed with the SEC on April 13, 2015 (File No. 001-12584); and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="width: 91%; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The description of our common stock set forth in our registration statement on Form&nbsp;8-A12B, filed with the SEC on June 20, 2007 (File No.&nbsp;000-12584).</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You may obtain, free of charge, a copy
of any of these documents (other than exhibits to these documents unless the exhibits are specifically incorporated by reference
into these documents or referred to in this prospectus) by writing or calling us at the following address and telephone number:
Synthetic Biologics, Inc., 617 Detroit Street, Suite 100 Ann Arbor, Michigan 48104. (734) 332-7800.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_029"></A><B>DISCLOSURE OF SECURITIES AND EXCHANGE
COMMISSION POSITION ON INDEMNIFICATION<BR>
FOR SECURITIES ACT LIABILITIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our amended and restated bylaws and Articles
of Incorporation contain provisions that permit us to indemnify our directors and officers to the full extent permitted by Nevada
law, and our Articles of Incorporation, as amended, contains provisions that eliminate the personal liability of our directors
in each case for monetary damages to us or our stockholders for breach of their fiduciary duties, except to the extent that Nevada
law prohibits indemnification or elimination of liability. These provisions do not limit or eliminate our rights or the rights
of any stockholder to seek an injunction or any other non-monetary relief in the event of a breach of a director&rsquo;s or officer&rsquo;s
fiduciary duty. In addition, these provisions apply only to claims against a director or officer arising out of his or her role
as a director or officer and do not relieve a director or officer from liability if he or she engaged in willful misconduct or
a knowing violation of the criminal law or any federal or state securities law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The rights of indemnification provided
in our amended and restated bylaws are not exclusive of any other rights that may be available under any insurance or other agreement,
by vote of stockholders or disinterested directors or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Insofar as indemnification for liabilities
arising under the Securities Act may be permitted to directors, officers or persons controlling us pursuant to the foregoing provisions,
we have been informed that in the opinion of the SEC this type of indemnification is against public policy as expressed in the
Securities Act and is therefore unenforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_001.jpg" ALT="" STYLE="height: 67px; width: 224px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Shares</B> <B>of Common
Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Warrants to Purchase &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Shares of Common Stock </B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PROSPECTUS SUPPLEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Cantor Fitzgerald &amp; Co.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>November&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2016</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 41; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ 0P#@ P$1  (1 0,1 ?_$ ,    $$ @,! 0
M      @ !PD* @,!! 8%"P$   8# 0$               0%!@<( @,) 0H0
M   & 0," P8"!P4&!P$   $" P0%!@< $0@A$C$3"4%1(A05"C(687&1H5(C
M%X&QP>$8T4)BDC-C\$-3)$0U-B<1  $# @0#!08#!08%! ,   $1 @,$!0 A
M,09!$@=187$B$X&A,A05")'!0O!2(S,6L='A8G)#@I*R)!?QPG,E-!@)_]H
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MQ*5"1CE?B 6\DP.?SV:P"4=@,&Q@ZE$0'?75SISU4V1U8M,-\VA6LFBEB;(
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MX,N\LE#4&G4L!L-J;0JR1TW#X[ANV$Y#B3N3+Y@V*M'3ZH^DMN^X91! [@U
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M$Q?;9M##1[(L\$+0(_I\2)_IU\3J>_'GCR/: B!NH (CW&V "@&YC"([!L0
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MFX'EF(S!PWWJ<V>0CZ%C:!07%&.F[=*NI$A0V%RI#1:2C$HB!P'R2*/SG[1
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M19/EX=]_4V77^2E46JZJL<\!$X'%-8"' G7;;2ITD-52;9JY9&.],O/#/X>
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M4CH7>]AOEKX89:JP DD,!+N;/1,P$]F.QO1+[K^F/5JDBIJVK;9]]3. D@E
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@V_V=WQ;?KTZ'_&==>.&_#_*;\.@^'3V=V-FL<;,?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" %\ K0# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]6/\ @H[_
M ,%1/A__ ,$P?#?A?6/B%IOB6]L?%5U)8VSZ/:K-Y4D:*YW99>N:^5S_ ,'9
M?[-,?+:5\35'JVCQ#_VI7FW_  >&<_LV?!W'_0SW/_I*.U?B]^S)^Q[\1_VP
MO$%WI/PW\/MXCU.R6-I[9+^VMWVR9"[4F==^1GA03QTK[S(^'<#B<%];Q+M^
M!\[F6:5J5?V-$_>V7_@[%_9MC)5M(^)X8=5.BQY'_D2F#_@[*_9K_P"@3\3N
M./\ D#1__'*_#WXK?\$V_BW\#_ACXR\4^+M TGP[I_@&33TUB,:O9S30/?S2
MPP ) SY+26\@*E@R["2.F?!WF6V16F98=V&(<A>N0"<],X.#W'/2O<H\'Y16
MCS4IN2_#[SAGG&-CHU^!_1U_Q%E?LT_] KXG?^":+_XY2'_@[+_9J'_,)^)W
M_@FB_P#CE?SD27"1-M:1589R"0,8ZTPWT. WVB,*W0[A_GN/S%;?ZCY9_3,8
MYYBV?T<_\19G[-7_ $"?B=_X)H__ (Y1_P 19G[-7_0)^)W_ ()H_P#XY7\X
M[74:0^8TJB/GY_X. 2>>G0'ZTXSJ <RJ,*7Y(&5')('?'M1_J/EOG]YI_;>+
M[']&W_$6=^S3_P! KXF?^">+_P".4#_@[._9I)Q_97Q-SZ?V-'_\<K^=?3/"
M]_KD<$EI8W=S#=7<5A%.D+&![B4XCB\W&S>QZ*6R?I6Q\9OA'XB_9[^*&L>"
M?&6FR:+XI\/S+;ZAITUPDS6<K('"%D)&[:P. 3C.#@U*X+RIOE3U]1_VUC+7
MM^!_0BO_  =F?LU9_P"03\3O_!-'_P#'*=_Q%D_LTE"1I7Q-8#J1HT?_ ,<K
M^??X!? 3QE^U'\5-/\$_#[0[KQ1XKU1))+73K9T2218P6=B6("A0"3DC QZU
M@>-O"&J?#OQEJN@Z]9S:;K6A7<MA?6MSQ+:SQL4>/W(8$'K4SX)RQ3]FWKVO
MK]PGGF,2N]C^B3_B++_9I_Z!/Q._\$T?_P <IR?\'9?[-1_YA7Q-'_<&C_\
MCE?SBM=1HY5ID5E .TL W/MU^OIWQ3A,K2^6LJM)S\JD,>#@\#Z?EST(K2/
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M_G&C;SH5D5MT; $,.A!R ?T/Y4[!]:V_U%RYJZO]YE+/L4F?T:_\197[-/\
MT"OB=_X)HO\ XY0O_!V5^S4?^85\3O\ P31__'*_G*P?6C!]:/\ 47+O,G^W
M\4?T:O\ \'97[-2_\PKXG'_N#1__ !RF_P#$69^S5_T"?B=_X)H__CE?SED'
M^]1M;^]^E'^HN7>92S_$^1_1I_Q%F?LU?] GXG?^":/_ ..4?\19G[-7_0)^
M)W_@FC_^.5_.7AO[Q_*C!_O4?ZB9=Y_>'^L&)/Z-?^(LK]FLC_D$_$XCU_L:
M/_XY1_Q%E_LU#_F$_$[_ ,$T?_QROYZOA#\(/$GQY^*.C^#/"&DR:]XH\03_
M &;3K&-U1KN3!.U2Q"@X!/) XKU3XC_\$T/CI\']=\+Z?K_P]U2SF\;:L-$T
M2>&XM;NWO+\G M1/$[(DN>-K$'(/H:Y9\)Y-"?LYU&I=F:QSK&27,EIZ'[@?
M\19G[-7_ $"?B=_X)H__ (Y1_P 19G[-7_0)^)W_ ()H_P#XY7\[_P 0O VK
M?"SQ[JWAGQ#:R:7X@T&ZDL=0LYG626WGC8*\9P2,AB!QU)P,UD^:H8KYGS#J
M/PS6\>",K:NG^)#SS%+<_HX3_@[+_9J/_,*^)H_[@T?_ ,<H?_@[+_9J'_,*
M^)I_[@T?_P <K^<7[3'\O[Y?G^[R/F^G^>:)+E(H][2KLR1NR,9'7FG_ *CY
M9_3#^W,6?T<?\19G[-7_ $"?B=_X)H__ (Y1_P 19G[-7_0)^)W_ ()H_P#X
MY7\X[W,<;LK31AEZC<O'^<C\ZD!SM_>+\X##D<@C(-"X'RQNR_,/[>Q2W/Z-
M/^(LS]FK_H$_$[_P31__ !RC_B+,_9J_Z!/Q._\ !-'_ /'*_G+'(^\?RH/3
MJ?RJO]0\NO;47]O8D_HU/_!V7^S6.ND_$[_P2Q__ !='_$67^S3_ - OXG?^
M":/_ ..5_/M\!_V?_&'[3/Q1TOP3X!T.X\1>+-:$IL=-AE1);@11M+(0SD*
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M$,O=6\767S#N/O&OUSAW$X-94J.(J*+E?<^/S*G4>.<X*YVW[+/[5?AOX%?
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MV="&EC=.O0BN9\6>#?V>/C1K7Q3T7P_8? CX>ZQI?Q!\'^)+CSM7T^2UBTV
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M&"03)R&&:\%B_P"#;7]JZ.<2?\(SX.#*NT-_PE]CN],DA@22.#@C&!S39/\
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M*?E\+^"54GE1XOL@..F/G/ZY/O7S^.>6XFNZTL0E=)?=M^9Z^&J5J4/9\A]
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M$5\#E<YVCQ;8*IYZ8R<#KUW=:>?^#;+]J@_*WA?P3(@R5#^++ D'G'\6W&,
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MX-L/VJ=H7_A&?!7WMY9?%UB'+<_-N+$Y^8\=.:KZKEJTCBK+U_K^D'UBH_\
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M<-_QEE^RN6Q_R,FL]1Q_R"Y:XS]J'X<ZYX]\1?":;1]-;4X_#/CNSU74P)%
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M_P BC<O^13Y.X>]T9$;6/T7]:46\8'W4_*GDC_(I=P_R*?LT&O5D?D1^D?\
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MZO\ WQ1]C7^XO_?%<XG[1/A1O^9?U3_P=P?_ !-._P"&A_"?_0OZI_X.X/\
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MY >H>O\ R&X/_B:<?B]X;(^70]0_'6X?_B:A^-W!RT>+C]S_ ,B?^(=<0?\
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M7:1QMQG!SR/>OWRAB,/6H1J4%[KZ]_0_-*E&M3K2A6]UKH-\B/\ NQ_]\_\
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M?"7P5JGB;Q3JUGH?AW18#<ZC?W1*1V460-[$ D#) Z'DBG'E:O<+.]K&YO\
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M_DE_X"C:.=98GI67_@1UT<*JW"XJY&BA/NUQJ?&KPJ'_ .0Q!T[1N?\ V6K
M^.'A51_R&+?\5<?^RU']B8Y?8E_X"C:.>9:W_&C_ .!,Z]8UVCY:ECB0]5_2
MN.'QR\+X_P"0Q:_D_P#\14L?QU\*Q]=7A_[Y?_XBLY9/C5O"7_@**_MO+/\
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MG]W_  #+^VL!_P _8_>=@(5$1;"Y7VJ2. ./FYKD4^.?A5CM.LPA3_TPF_\
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M>9D?O"0>M;8?A_#\DFZ4-/)')B,_Q'M(Q56>OJ?:_P#PM'6O^?Z'_P  X/\
MXFC_ (6AK1_Y?8?_  #@_P#B:^?O^%Y?&#_HB$G_ (5-M1_PO+XP?]$0D_\
M"HMJP_L##=:4/N1T?V_B/^?DOQ/H+_A:&M#_ )?H?_ .#_"@?%/6A_R_1?\
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M^'/PAUJ/3-9T'3/B+9ZMINH^'=2DU1KJR0V\-S;S&6**UMA"[Q7+!AME+@1
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M#U/_ "7_ .2,?^(.YM_,ON-_<O\ >I5 =L!N>F.E80^/^L$9_M[Q!_W[M?\
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MTI(5">/X<]1Z5HWOQXU":]F73O#]K=6J&PC9Y[YHY ]TGR+C;@CUS^M=C=>
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M]G?9!;H1G,DC<*#@YZ[1S2^#?B;HOCX:E_9DUTPTC57T2Y-S:O:@W:D#9$9
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M/[00<M_PGGPI#-]XCPU<#=WY_>T1P^"C_P O/Q"5?'Z?NGI_=_X)\T_LM_\
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M%I_A+1/A[X+7Q1XVMM7OO"&C^+%73Y=)MM/\BWMFO[BWE61UNC(\BO"5D)+
M*<$?>$OPY_:"FC96\??"M@X(.?#=QW4K_P ]N, G&,8S3G^'W[0C3-)_PGWP
MK61L@LOANY#<^_G9]JMX?"2MS52?K./7PTGK_=O^IY?\0OV&=6U7]C;X._!K
MP^8Y-#\.>(M"O/$_]LZL]PYTVUN#=S1B3;FX!G5%7&/W>.!QC'^$?[ _B[3O
M^"A7Q!^(/BR;0Y?A>?%UYX\\'6$4Q:[EUS4+:W@N;BZCVXC,063R\]6)8=C7
MM ^'O[0:LNWQ[\*UVG<H'ANXPIZ<?OO3C\!3?^%<_M @?\CW\*>F,_\ "-W.
M?;_EMV_2J<,'?6>Q/M,QMR^RE9_W?^"?+/[8G_!-SXG?M0_MS>)/%EOI?AJT
M\,ZH/#=GHWBB7QA+;W6A6&G$3W:R:/$A%X;BYDD$8E=E0!21G)KA'_X)!?%S
MX@^/OCUXD\;WFC^(O$GCG3M;@\+:Q)XO7[#J!U"0I';SV:6PFMTAM_NB1Y$C
M<911DY^X3\.OV@F7!\>?"KU&/#5P,?E-^%./P^_:#9F_XKSX4GS#EO\ BFKC
MGT'^NZ"E[#"7O[4KZQF%K>RE_P" _P#!/B3Q)_P2)^(FL_$CP_!!X0^&NG>#
MK-_"2VL\'B>X2Y\&V5@3)JUC86_E!)I+VX;S))B4$BJ%V G</=OVH/V*OC'\
M4?$GAF?2_BK)XD3PTWBC7M+U3Q%!;6,NCZO>:5]@TVWMX[>,;K>(32N97):-
MD4YR:]C7X=?M!( /^$\^%7 ('_%-7'0_]M>?3)YQWH/PY_:"V,/^$\^%*[NN
M/#-P,^W^M[C(/J#3]C@]O:?B'M\?_P ^G_X#_P $^&O#'_!)OXO>&OA'XHCL
MO"/P^T.YU[5?"D>I>#[7QK-)I_B;1]*\V;4;:YU%DW13W=UMEE8)@JI&373_
M !@_X)+>-=;\4>.M2\#^$?ASX=N=6\!:/X9T&>T\374<NCR177F:EID,QC:1
M4NH&FMENV/" ?+@YKZ^'P[_:"657_P"$\^%>Z,DJ?^$;N21P1U\[T)_,T#X=
M?M! K_Q7GPJRH(!_X1JX)YZ\^=2^KX3K5*]OCUK[)_\ @/\ P3Y$\"_\$H/&
M%UIUO9^(/"G@'1_!^H>-M3\8W_A/0_$URVGVUK%I7V71M-BE9$D>'SF=ICPI
M^8X ;%>C_P#!.7_@G!K_ .Q3X^TS6-0ATZ0VWPQT_P .ZDT.M27+:UX@CN'N
M+D_,"!#%E((I  JQ[0!C%>Z?\*Y_:!SSXZ^$[<[N?#-QR?7_ %WX?2A?AS^T
M$H7'CSX597;M/_"-W&1C_MM],^N!Z4>QP2U53\295\P>BI/_ ,!_X)\Q^%?^
M">WQQ\*_&GPC\:+CQCIOB#XC7_B/5/$GBSPU<36]KI&DO<Z=+:6D%G=K$TLT
M5OMM8068H51F506-><WG_!%7QIHGP'\1>'],L?"EYJFL?#;1M'O1?>(967Q!
MX@.KOJ&I2S2L#Y<:6Y6*&1AM49 !)X^XH_AM^T!$FU?'7PI4#.,>&K@8'7'^
MNZ9H_P"%<?M!#_F?/A3P !GPU<= <_\ /:G[/!O_ )>!"MF"WI/_ ,!_X)\E
M?&#_ ()I?$+Q#I/BB/2?!OP_N/#^L>._#%_%X,N?%TEGIS^&]"TJ2.*R2X$;
M&(S:A.VX; V$5V^4YJE9?\$J_C7X<^$FM:)IWB#P_#J$7PX'AG2K2V\02V]N
MMQ=>(EU#5;%9 "8+46.VPCG;+#>2H Z?8:?#O]H1'W+X^^%H;.2X\.7(8G'<
MB;)_^M22?#?]H"5-I\=?"G:W! \-7 R, 8_UW3 _4^M'LL'_ ,_?Q"5;'_\
M/I_^ _\ !/D'1_\ @DGXHET;P3)JG@?X83:./BR?&>J_#U?$TSZ3X>TLZ?\
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M'\"?8XI[T9_>CU0P;OX3^*__ %Z/LZ_\\_\ QW_Z]>5?\*[_ &@O^A\^%/\
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M07_0^?"G_P )JX_^.UEST/YU]YT>PQ/_ #YG_P"!(]3^RK_<_P#(8H^R*?\
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M+G&*C2:UZZGN26JY_P!7_P"."G^0"/\ 5X_X /\ &O*%^'GQ^8_+XZ^%6?\
ML6[C_P"/4_\ X5W^T%_T/GPI_P#":N/_ ([7/&I0E%/VB^;.N6'Q#=O8R=M-
M'9'J9M5/\#?]\_\ UZ7[*!_"?^^?_KUY5_PKO]H+_H?/A3_X35Q_\=I?^%=_
MM!?]#Y\*?_":N/\ X[5>TH_\_%]__!#ZOB?^?,__  )'J@M\?PG_ +X'^-'V
M9?\ GGG_ +9BO*_^%=_M!?\ 0^?"G_PFKC_X[2?\*[_:"_Z'SX4_^$U<?_':
M/:4?^?B^\/88K_GS/[T>K>0H'^K'_? IALU/\+9QC(7!Q^=>6_\ "N_V@O\
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MT9<CM?J?J?$?EHI(3E:*_-:DO>>A]Q%:'QA_P4D"+^V%^RFS;% \2:V"S#.
M-*F'7KTJO^TI\=9O@'HOAF:WTK2[V\\4:NFDP'5M872;&T/E22M-+<,K!8]J
M'DCCBK?_  4I.W]K_P#93/S+CQ%K9R.H_P")3)TI_P ;/A-X5^*$?ANZ\6+8
M-IWA+7$UI8+R&*6TNIUC9 DZS H5PQ/ Z@5[&)LL/3^?YF-%-SFD<?\ "W]O
M+X<?$CP+9ZK/JTV@Z@VAPZ]J6G7%K/<2:/;3R.MN9'C0QL9MC^3AAYZ["BEC
MM/367[5?P[U#3;ZZ7Q1:PKI5@VHWT5U;SVD]C$EPMG()HID26.1;K]VT)3SD
M,L.Z,&2,-SOQ7_97\#_&73/B(NM:N[6WQ%&E6=['%<PK;6<NDQDP-"/NLHW!
MF4\8S67I7["O@.V;P#Y-]%'-X'U2[U^,:19VVF0>(A>/"\HN8HAMDB::WMG+
MKU:U&:\WVE)Z7-I86<5S<C.NU/\ ;#^%_AN'6)]2\76MK;^'@CW<TUE=1Q3*
M;U;$M WE'[1&MTZ0/);B1$F>.-RKR1JW.>)/V^? .E7]O8:7)J>N7>H>'-5\
M0VDHTV\M[11IDB1W=K=2M#FSE!8[GG1$@$;>9M8HK<QX5_X)W?##P1J6JZ?8
MZO#!))<VVH1K'96::AI<5OJD&J%/M(!DDB::")6C9L% N0=BXV-=_94\%ZS-
MJ&I+X]O--A\1P^(M.U-H[FU:#4+;6)8;B[M=[@B-EEMH6BD'0(V>"*F6(HP5
MC6GA:LES)'86W[7?P[&K0Z;=^)K&TU4V#ZA+%]FNWM!Y=B;Z6-+OR1!-(EN7
MD,4;F0)&'95&16K\.?VB_ OQ<\.:EJWA_P 3V=SI.AP+<ZC>3Q2V2V=L\7FQ
MW4@N$C80F+]Z)=AB=>5)KS8?\$_O"^N^'UTMO%7B2[\&RM<:E9Z)''#]EBU"
MXTN2PDOQ(!YC,T4CLJ,=HD=67!P:[BW_ &9/#JZ#XPTR\FU;4+/QQX9M_"FJ
M0M,H:2T@L6LAL95W+(\;$;B?D;ZFMX\C7-$RGSI\LCA_BG_P4#\(:5X;\.MX
M1OX]8UCQ1K]AH4,5UHNJ(+);N-YX[J2!8!.8GC1O+D $4G#*Y56-=]X@^,^J
M77QFN?!?@_PS!XHU#1;2TO=;FGU5;.*Q2Y=E@AAPC^?<,L<LI7*A50C.:YOP
MW^QC8Z=XJTG7-9\9^)O%&O:-=Z;-'J4T5O;%X=/@F@M;=HXP 5/G2.[$;FR2
M.#74^)O@/)J?Q<_X3;0_%VO>$]8U"SM=/UI;&*WEBUFVMG+PAO.5C'*NYQYR
M#>-[!E#$T[(CE1Y=IG[?\T/P^C\7:QX$N+#PWJEQKUEHEQ;:LMU-<7.ER72^
M1=Q>6/(:;['.8RK."NTUZWK'QT\/^#OAYHGB3Q#-<Z18ZY;QSH@L[F\DMP8$
MG<R>3$Q545R6D(V*J$L0 37FFF_\$_=$C\&1>&M4\7^)]<\.V!UA](TN2&VM
M;?2)]3:Y\^4.BYFD3[3-LWD!5=0%&!6I^T3^Q!X?_:3^&GAOPOJVO:]8Z7X9
MT]]*6"(121WD!ACA7SH9/D\U!'N23&5+DCDTN5"Y5V.AB_;!^%]QXIOM#3QM
MHIU#3_M?VEW6:.UC:WB\Z9/M'E^26C@ E,:.9"A=]H"$B+X!?M+Z3^T'XU^(
M%IH__(%\&W&G1V]_-:W%I)<+<V8NGDDAN(XY$C3L=F&3Y@3N!KG]8_8(\':O
MX'D\.ZAJ6O7&F_V]J.ON)2L;-->Z<UA+&-RCY4A8,#MR'V!RP8*=CPW^RG'H
M?@[XAV.H>-O%6O:A\2+&#3M5U:X6W@NH(H+9;)5A6-510(4!)/S[AN!&< Y4
M4M-C#\%?ML6?B[X(^-_%TGA?5+&[\*W"16.D2W"BXU^*ZDCCTR6%]@51>O)$
MB _=,AST--C_ &N==\9GP+8^"_ <6O>(?&&@ZCK=QIEYK*V+Z;+8SI;W%ANV
M/ON%F9D4':',9.<&L^__ ."9/PGB\0Z7+I^AQZ+X=L?[/&L>&;*)5TGQ-)8&
M0V4U\A.XM%))YB[6 9HT&WY0:L67[ FC^!_$O]I>!?&7B+X?K&VH_9+33;&U
MN[?3DOS 9T@616\L^;")U)^;<\A 8Y-,7*GN>L?!OXJ:/\=?A5X>\9>'VN&T
M3Q-9"\LQ<*%FC7)4I(!QYB,K*V/XE-=$%XK$^&'PYT;X0_#K1?"OAVUDL=!T
M"T6TL+>28S/'&.?F<\LY)+,QY9BQ[XK=H#E0W91MIU% N5=ANW_.*-O^<4ZB
MERH.5=A-M&VEHICY4-V_YQ2[:6BE9"Y4)MI/+IU%.R'9#=E&W_.*=12Y4'*A
MNVC;3J*8<J #%%%%3RHKF:V.1^/T:M\ _'[%5+#PSJ6"1R,6DV/YFO!/^")B
MJO\ P3 ^'*]FEU8GW_XFUW_\2/RKWSX^?\F__$#_ +%G4_\ TDEKXR_X)!?M
M5:7X0_8%\(^'1I&I7UYH=QJ"W+PRQJJ^;>S2I]X]]Q_,^IHQV:83 8&=;$5%
M32E%:F^69;B\PQDL/@X.H[;+H??'4_\ UJ,5Y$/VN;5A_P BSK'(S_KX/_BJ
M5?VL[9F _P"$;UO\9H/\:^/_ -><@O\ [RON/J/]1,^_Z!6>N_YZ4AKRM?VJ
M[1DY\,ZNOOYT7'_CU6+;]IBUG^[X?U;..\T7_P 51_KYP]_T$K[B7P+G25_J
MS/3,T$UYO_PT5#+T\/ZF/^VL7_Q520_M!PD'=H>IK_VVB_\ BJ3X^X=2N\2O
MN,_]2<[_ .?)Z)FBN!A^/L,O']AZACWFB_QJ<?&N.0;O[%OO^_\ %_C64O$/
MAI*_UE$O@O.5\5$[<DUI>)_^/NU8<;K.VSCC/R,?Y\UYU'\8$G_Y@]]_W_B_
MQK1U7XPG5KFW:/0[[Y((H?\ 7Q=1G_:K*7B3PQ'XL4C*7".:1^*D=$>!_P#6
MH'UKEO\ A9EP>FAWI_[;1?XTG_"RKINGA^^/L)XO\:REXG<++1XM$?ZKYBMZ
M1U).U6;^%58G_ODX_7%86K_$S1=!^(6E>%[R]CM=8UZ"2>QCF.R.X"$*RACP
M&[X/6JH^(EZZNO\ PCNH;MC%?W\/) )QU]J\A_:1^&UU\;/%^DW6HZ3<:?I.
MF:?/&+@WB>=9W!<2)*K(=R%3SNR,=^#7BY]XP</83!RQ&%KJ<XM6C;>^YW9?
MPCBJM=1KKE70^A@?D'!W#@GMGN/J.] YKQ+]GO\ :"U(ZY'\/O'LJCQ;",:;
MJ(4+'XCB &&;'W;G&W<HX.01U->VJV_<?F'.!D8/IR.W.1^%?HF19O@,VP<,
M9@G>,DG\^OXW/G\RR[$8&LZ-==0"\4NVE7I17K**:V.%Q2T$"\U?U48T/2O1
MHG4CV$F[^?-4:OZK_P @32/]R3_T*J S\48I:*GE78!,4;:6BCE78!,4;:6B
MCE78!-M&*6BCE78 C'[Q?J*TG.? UN/^GU__ $ ?XFLY/OK]16B__(D6_P#U
M^O\ ^@+3LEL!FD9I-M+11RH!-M&VEHI<J[ )MHVTM%'*NP";:-M+11RKL F,
M&M&P^;PUJ7_72$\\GK6>:T-/_P"1:U+_ *Z0_P Z.5=@L9Y7(I"M+15!NK,3
M;_G%*.***GE01TV"BBBCE78KF848HHHY5V#F8C'8I(ZBO"OVL/\ DX?]EO\
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M#:V4.G6<<%K$L-M;QJD:+TCC&%4?A\J_7%/#+M+9XP6)] .I^@[^E>">)?\
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M>HHWCU% "D8/WM_/WL8W>]%)O'J*-X]10 M%)O'J*-X]10 M%)O'J*-X]10
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MX@N%!NM6G;[Q!Z1PJ=P1%X"^Y->E#D>@Z #^$4/)O;=E=S?,V/E4-WP.R\#
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MKU]Z ,^BFA_7C\:7>/44 +12;QZBC>/44 +12;QZBC>/44 +12;QZBC>/44
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MZ$M\L7B&R>>+1K]+B5)(KCRVC65C;R)(@!VD##L'#KZ]KGC[QA\1_P!K37O
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M^$1TG_H%V7_?)_QH_P"$1TG_ *!=E_WR?\:T:* ,[_A$=)_Z!=E_WR?\:/\
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M![=2/\C_ #FEH @TW3+71=.M;.QM;6QLK&(06UM;0K##;Q@85$10%50.
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M5OD=9:G<ZAMS+@\'IS5'XG:1X?UGP#J4/B:2UAT5(#)<23/L%OMY63=_#@@
M,#G(Q6%8_$F;2]2U>V\3:#J_@NXT2W2XNH]7"1ND3 GS0 2"HV-GG/'2K/[-
M7[.VH?\ !0_Q#:^,/%5O<Z7\&=,E#:7I3[H9_&+JY"SR+]Y;,2*P7D&0KTQ@
MG#A/P_S7-<W6'I*5-P>LM?=?^9\OQ#GV%PV$]JVGS+1'N_\ P2_^+?C;XM_
MR\O/$=M?S>&=/OA:>$M=U$>7>^(;%4VM-)'U\L-A5E_Y: YKZ;NL[ER,'R8L
MCTZU3MK"WL+:"WMX(;>"UC6&&*- B0QJ,*BJ.%4 8"C@5<N_O+_UQB_K7^@N
M68.>#PL,)*;GR)+F>[?4_FS&8AUZTJMK7?0A'2B@=**[CF"BBB@ HHHH ***
M* #K4S\V%N?]EC_X]C^50U-)_P >5O\ 1Q_7^= $-%%% !1110 4444 %%%%
M  OWE^HJ9O\ D&Q_[Y_K4*_>7ZBIF_Y!L?\ OG^M $-%%% !1110 4444 %%
M%% !W_&IO^7>;_>6H>_XU-_R[S?[RT 0T444 %%%% !1110 4444 -E^X:^9
M_P#@H!_R67]EG_LKEM_Z0WE?3$OW#7S/_P % /\ DLW[+/\ V5RV_P#2&\KL
MP/Q2]/T9S8K9>I]D1_Q?7^@HHC_B^O\ 045YDMSI/DK]N)L?MT_LE-S_ ,C)
MKO09/_(*>M']NOXCS>"- \"Z7=>(-0\'^$_%'B>/2O%.O6MTUL^E68CED\LW
M*\V_GO&D7G9#+YF RD@C*_;TOX=/_;@_9-EN)/)C'B#6^6&<?\2IZ]Z'C72T
M\QEU2U^7@X#<?6O0K1O2IO\ K=F%.7O3MW/BSX0_&_QSX6\?:_IOP^N+W6?A
MG>7^L>+M#D\1R7NLZA+H&GZ=IT;_ &&2:7S6BO-4:]$'GROA 9(\QF-1SN@?
MM;>-/VQ;^W\)WEWX=O/#6MZYX/)N_#]E=0_99[QKK4KVP:<MBXC@L[)5>9=F
M7N70[-N&^]AXWTV4;O[9C.S'1WX].U.?QUI[_P"LUB/D;3AWZ?E6'-(Z9235
MK(^3_BY^WYXVT+]JKQUX:TO1_#-MX=^&L9FU.+4YA_:NM6J6+74LUK&LGF;%
MEGMHXL1.K[9<LIP*Y/Q%_P % ?B9X(T";1?$FI_#CPW\0-6U71M-\.27>G7,
M&DSW5QIPOM0@N)))5V1VD;Q$3[OWCNL0C9WC ^VE\;:6H4+J\>U>A+/G^5#>
M.M-B5I&U>-MN''+G.WKZ9(SD*2!GD]!4^:)TV9\A^(OV]_B1'XA\4^$_#^@^
M'+OQ-X*\5VWA"[NKJPN5T^ZU#4-1LH=.4!6+!?L<MU<3L2WE[8\@=*P=2_X*
M'_%[X;>#]=U[5-"\)^*K33=-U^?3X+#3[FP:Y-EJMOIMG>3RR.R10322RNX(
MVK% 7#8)"_7?PZT/P=\*M"NM-\/RV^F6]]>3:C/(TT]S->7$S;Y)I9)"7>1C
MR6)]AP!70?\ "=Z6LS,NK1!C\IP7 Z?2@#Y3^(?[2WQ(;_@FCXX^(+>(O!^E
M>(9I39:!XATA5O+*WMI+F&S%W,D<LL2-&7ED++(ZJJ!CDC;4_P /_P!M7QKX
MG_:9L? L<WAC65TOQ WA_6=-@TJ>+4KFRCL5GDU_>'9(+-Y)(EA3YO,1U(D)
M)KZD'C'2Y'\S^UH]RYZ,^T#\L4?\)OIQS'_;$>W&"=S]/RH ^#_VD/VV_$GC
M'XWZII$%F;S3?ACXLU2YG\,V-E.-8U.'1-.$XN;BZ!*PV]U.^R.-U+/$AD#N
M<J&ZC_P4Z^(7AGX.6?B#6K[X<Z?#XB&I7^F:W;6\FJ6L<>GZ=;RR::T=O*RM
M>2W<[QQ*L@/DPN[1JXVU]Z)XZT]FC5M9BVJ1CYF/Y\5Q?Q8^''@/XX+IZ^*&
MN-2ALV</##J][9Q72;\F"X2!T%S;]Q%/O7/:@#YOU']N/XG:5X,U'Q-JQ\$>
M'_#_ /PD^D^"8;VXL;@PZ==3VMO->ZG<N9%'V>)C-!'$H!DE" NI?=7F'C[]
MNWXD_'SX(+X1NIO#_AK7O'&F:=:6@AT/4$U#Q''K.KO9026D)8/:K;6Z)+/(
M^Y5DF1#LP-WZ&Q>,=*4KLU.%55 @QN4*,D@# Z$$?*  NS'>I6\<:>RD'6(]
MK#!^=\_RH ^;?V#OVJO&'[27Q!\1->:7X5T'P'X;BEMHM,2\636=*>"Y:"%)
MU$A.U[:-V?S$CV.R[0QP:\:\)?'+XI!_ ZZ/JGB:]\4?M&>']6C\/)J,EQ-9
M>&ICJKR+?O&XQ"EII<XDQM4R-#$@ZU][?\)CID@7_B:6["-L@D,3_*@>,=+E
M.Y=4MCYG(PK<CVH ^8OV@O$6D^ /B_\ #WX>^-O&_B[PO\,=.\(33KJ<NLWE
MGJ/B[5(GCMX[>:_@9+J281LTIBB=7FD<$%L**\RU7_@HE\0/"/B#6M#\-V>B
MZK:^%(M<T>#1]0M;VYU>SDTV[@TNPEU"]SCS+RX83LK+N\AO,#'.:^PO%?AG
MPYXTU=;V;Q#K5K*J[%73]8N+*,GNP5#C<1P2>PK'_P"%1^$#M\KQ'XHACCP(
MUC\07:K$!PFT;N D>8AZ*WXUGS3Z([(TL/;6H_N_X)\L>-_VC/B)\,OV[/$$
M4=]X?\5>)O#>B:#X:O\ PO8:3>QSZPLIN]3OYM/3S-L:06DMLIF)9=R!&*$A
M:J:+_P %1_&^J"XO&U?X;QZ'>)X<C&ISZ9>QZ?X<O]4GO))[2:<LHNC:65HQ
MD*[ )FVL(R,'ZT/PD\&PP[8_$GB>W2,$JL7B&[ @[H!STC7Y4]$)!JO>? _P
M+=:A:W$VO^)5FTQG^Q2GQ!=YM&V[$>/G@JA9 ?0GK4^TJ?RC]EA?^?C_ / ?
M^"?-7A;_ (*,?%?Q+X[\,^&Y/#_A'2KQM*AUJ[O=6WZ?'XELYKZZ DLX)'$R
M*MC9&7Y%E?S)E0[<,:B\2?\ !1OXM> ?!%[K&L>'/#LMOJUEH%S8W264UC:>
M&_[6O+Y5:]EG<"3R[*T$C >6%GG@C)7S-P^H$^%'@]ON>(_%$>X  )XBNUP.
M=@R3UB;<R_[4AZ]GO\(_!T7*>)/%$)(^1E\0W>%'\& 3TC;)C'\+,2:KFGV'
M[/"_SO[O^"?/1_;(^.%U'IUGI^G_  Y_M*"_\,Z5([6MW<PZS=ZO?,2L4D;L
MB1P:7MN7=6E >-TS@[JZ[4OVN?'FE_L<P:U9Z39^(_BKXLUW4/"G@NSTZR>W
MMM8NH[B:""]DBE9Q';QQQRW,A9]K)#C=\RUZI_PJ;P:X62/Q)XH3S" NWQ%=
M_*1]W'S?P29E_P!_<>1Q6]X#T7P[\/UOOLNLZA-)=CRB;_4)[IH5_B"E\E=Q
MRQ [M3BY=49U:=!1O"=WZ?\ !/B/P3^U?\5O@)\ -8\,63ZIJ7B#X;CQ;J^M
MWWCP3:QJK65DD=W91>9"ZK+-</=")0'941,+P@%=-XD_:E\<+\4_&T/B+Q-'
M)I^@^)=*M)/#&CVMS::AX?CL]$75]0G$L3F62*60M"%8,LP41X;E6^VCXSTM
MO^8Q"1C W!FX_*D_X3735;Y=8C_ N,_I5G*?G!^S9^U+XVT?]G+PGX8N&D\<
MV>FV.E:K-J?AF74+6YGU%8;S5=3TI[@-YEQ-'$EJCG@$S"-U&2M=MJ/[</Q*
M^*EII%GH_CCP/H^F:QXB\,6W_"8:7H\TFFV$]YY\M_HN^9]DSPQQP S9&'N5
MB98Y"H7[I'CC3QTUB,=^'?\ PI!XYTWSC_Q.(?.[@.W'X8H ^-_@A^V9XCU?
MQTVFS:QHGAB/5+.?QTZ^)#?7<OB*&>_OK:.VTX$DVL%O;:='+,JHZQM>)^[&
M2Q]P_85^/FO_ +27P4;Q-XA_L<WRZK>:<3I4++8L(F7_ %$A9A<1@Y43K@-@
M<(=ZGUG_ (3C35(;^UXSM_VG_P *0^,])E7_ )"T.U1G#%]H'7IC% &A16>/
M%&DMMQJEH=QP,*W)_P D?G0/%>DG_F*69^@:@#0HS6?_ ,)3I/\ T%+3_OEJ
M/^$NTI./[4M?P5J .9_:4'_&-?Q(_P"Q5U3_ -)):^<?^"! Q_P21^%>W@?:
M-;8 =C_:]Z<_6OH+]I+Q;I4G[-GQ&4:A!)(_A350H4,#_P ><O>OF_\ X((^
M(-.T_P#X)-?"U+B]BAF6?6O[VX?\3>]Z_F*[H6>&<?[R?W'+4M]9YENU8^T=
MW'>CS.>^?6J \4Z3C_D*6O\ WRU'_"8Z7_T%+?\ [Y:N&_DON.K4T3,Q_C;_
M +ZIK/N'7\ZH?\)EI?\ T%+;_OEJ/^$OTN3_ )BEK^*M2<(/H&O<O@E3P2/I
M2EFE"J3N^8$Y.<  UG_\)3I0_P"8I:_]\M1_PE6E?]!2U_[Y:FE%+1*Y*B_M
M-_>?-/QC_8%?]I#]LJ^\1>+IE/PS@LM.N?['B8[O$=[#O95FQTACWABO\>\@
MY -?4%G:0Z;9PV]M%';V]NJI%%$ L<0"A0J@<!0H"C;QM  XP*J_\)3I7_04
MM?\ OEJ/^$ITG_H*6O\ WRU<&7Y;1P56=;#Q2E4=Y:;L[,1C:U>,8U7=15D7
MLXJS>??7_KE%_6LC_A,-+'_,4MN/]EJFOO$^EI*GFW\,>88B,;N>M=^RMYG+
MY(M#I16?_P )3I/_ $%+3_OEJ/\ A*=)_P"@I:?]\M0!H45G_P#"4Z3_ -!2
MT_[Y:C_A*=)_Z"EI_P!\M0!H45G_ /"4Z3_T%+3_ +Y:@>*=)+;?[4L]WIM:
M@#0S1FL__A,-*CX_M2U_)J/^$JTEAG^U+7GGHU5RI-7#7J:%32_\>=O]'_E6
M2/%6D[O^0I:?]\M4MSXHTL6=J6OX5C96V/\ -\WSU(%NBL__ (2G2?\ H*6G
M_?+4?\)3I/\ T%+3_OEJ -"BL_\ X2G2?^@I:?\ ?+4?\)3I/_04M/\ OEJ
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MA/#?BW3]'\$ZCI.@^(?$%Q9VDI:&;1+'4DMFB>S+V\JK)!-!(PC.!F<D-C.
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M?L5/WCX3G36FY0Q1BBB@L,48HHH ,48HHH ,48HHH $'[Q?J*TG_ .1(M_\
MK]?_ - 6LY/OK]16B_\ R)%O_P!?K_\ H"T 9N*,444 &*,444 &*,444 &*
M,444 (1BM'3_ /D6M2_WX?YUGFM#3_\ D6M2_P"ND/\ .@#/Q1BBB@ Q1BBB
M@ Q1BBB@ Q1BBB@!K\(WTKPO]J\?\9#_ ++?_95H#_Y)7=>Z2+O1OI7AO[6
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M_B:O0>,+I5^;PGX[7_N7KG_XFN6IP]FO*[TI,[/]9LK_ .?\?O.I@^;\/?\
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M%N/^7/3_ ,847/MG'?I]:'LX8H6=K2';"<2?Z&H*X Z_+C+9! ]#0!\-S?\
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M&!7U1^[6)(UPL,:JBQHJK&$ X4+G &<'VQ7L'V:W/WK2Q;Y0OS6ZG@?A0MK
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MM[6TGE@DMF80+A&98IY64XRA4D8)- '3;MS'[OH<>O>BFK^'3J!C/X>W2G4
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <7^TF-W[-WQ&
M';_A$]5/_DI+7P1_P1(_;<\._#W_ ()Q^ _"<FDZUJ6I:#<ZF+I[98S&HFU"
MXG4<L#]V45]Z_M)<?LU?$C_L5-5_](Y:_#W_ ()Q.T?[/UGM9EW7,Q.TXSB0
MC^6!7R?'_$.+R;))8G!V;YX[_D?:>'?#F$SS.XX3%II<DMO+J?L.W[;&BZGI
MTD:^'?$@::)TW!8A@D$==W%?)/[.'Q8\0?L5>(WU2>VNKOPGK,AE\1Z+"?,:
MR?>Z_;;8#NH="ZCAAN.,\URVA3L&C^9N_>NZT<)*%24+(C@95AD'MS^9_.OY
M9SKQ6SIXBCB[I>RZ+KY'[U5\+\KP5&K1@N93VOT].Q^@GACQ7IWC;P_8ZMH]
M[#J.FZE"ES:W$'S1SPLN0XYZ$]#VY!&3FM 'FO@/X'?'Q?V'?&MII^K72-\+
M/%6HK;F'=F;P_?3L%#0J/F:*21D4J.%WEOX:^_!@A6#!L\[E^ZQ..W48&./>
MOZDX+XNPO$66PQ^$WVFNTNJ1_-O$&25,KQ<J$_AZ/N.HHHKZX\,****  ]*G
MO/OK_P!<HOZU >E3WGWU_P"N47]: (!THH'2B@ HHHH ****-M@#%&***.MP
MNP[_ (U,W_(.M_\ =;_T.H>_XU,W_(.M_P#=;_T.@"&BBB@ HHHH **** "B
MBB@ 7[R_45,W_(-C_P!\_P!:A7[R_45,W_(-C_WS_6@"&BBB@ HHHH ****
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MM<2ZPLEY=Z9;S37 75[U5#.T9/RQX49/:O!XNX;>>9-+"QJ<OOQ/I>"^*O[
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M-3?\N\W^\M0!N?QJ<,#;S?[RT 0T4FZC=0 M%)NHW4 +12;J-U "T4FZC=0
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MK_P'/^%'_"R=!_Y^+K_P'/\ A7FGE+1Y:_Y%%GV_!C/2_P#A9.@_\_%U_P"
MY_PH_P"%DZ#_ ,_%U_X#G_"O-/+7W_*CRU]_RHU?_#,#TO\ X63H/_/Q=?\
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M6;3]*L[1Y(-/>./4IK36SJ2&YV-N\AXSY#C+-M P0H"UWZ?LHZUH_P"RS9^
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M.V3Q@8&T'7M#T*ULO#OA?3+6Q2S>"SNY=(N[ZXE\\1,#Y=PU[G:!\C0JQ+]
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M*^>8>1WJQ&NP<_Q>]1_Q$GB!:_6/P)EX8Y#;X#Z"7]J;4G./.\,_A]HJ2/\
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M "I]]?J*T7_Y$BW_ .OU_P#T!:SD^^OU%:+_ /(D6_\ U^O_ .@+0!FT444
M%%%% !1110 4444 !K0T_P#Y%K4O^ND/\ZSS6AIY_P"*:U+_ *Z0_P Z ,^B
MBB@ HHHH **** "BBB@!LHS&U>&_M8'_ (R(_9;]_BK /_)*[KW1AN5OI7A?
M[6:;?VAOV6O^RK0?^D5W77@?CEZ&.(DE%>I^@03-%.C7<M%<<K7.OFT/C/\
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MQA\/]3?3(_#_ (^T_05MFT?1BB:Y8;M/T:RN([@V=LQ!:X8RP1^6+HRJNZ3
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M (2CPPS,068:Q;, 0,8SYOH.!T&#C%'U.O\ RAS+N;%%8G_"Q/#O_0T>%_\
MP;VO_P <H_X6)X=_Z&CPO_X-[7_XY3^IU_Y6',NYMT5B?\+$\._]#1X7_P#!
MO:__ !RC_A8GAW_H:/"__@WM?_CE'U.O_*PYEW-NBL3_ (6)X=_Z&CPO_P"#
M>U_^.4?\+$\._P#0T>%__!O:_P#QRCZG7_E8<R[FW16)_P +$\._]#1X7_\
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M_P#0T>%__!O:_P#QRC_A8GAW_H:/"_\ X-[7_P".5#P]5.W*Q<T>YM45B_\
M"Q/#O_0T>%__  ;VO_QRC_A8GAW_ *&CPO\ ^#>U_P#CE3["K_*PYH]S:-:&
MG_\ (M:E_P!=(?YURH^(?ALL-WBKPN%[G^U[7_XY6E9_$CPR?#.HX\4^%0S3
M1[1_;5J20#_UTH]C4_E8<T>Y8HK%_P"%A^'?^AH\+_\ @WM?_CE'_"Q/#O\
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M .(KZ6Q1BCV]7^;\P]G'L?-/_#G[]EW_ *-\^$/_ (3=M_\ $4?\.?OV7?\
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M]M4_F?WA[./8\[_X<_\ [+O_ $;W\(?_  G+;_XBC_AS_P#LN_\ 1O?PA_\
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MHTIP<^;^\U^C/T+@SP[J<0T9U:-11Y7:W+>_XH_0P_\ !(+]EL#G]GWX0_\
MA-VW_P 136_X)"?LM@_-^S[\(?P\-V__ ,17SS^P+XJAU+]J'PW"+-HV,-V?
M,,[M@"!CW_K7KW[<^OQZ?^T1X#LY+7SFG^S8?SF78?M:#./:N/!^)TZ^3O.%
M!J*J*%N9]>76]O/:W0,Q\.ZN$S:.4RJ)R<'._+LES:6O_=W\SJ$_X)$_LL]5
M_9^^$?X>&[?_ .(H/_!(?]EO!_XQ_P#A'[C_ (1RW_ELK/\ ^"BNJVNER>%Q
M<6(O@\D^ 9F7;POI70?&">U_X8N\/RS6RW4+6.G9B>5@H_=IWZUV8SQ"GA\3
MCL.X-_58*;=W[UU>R73[V>#3X7G+#X;$-Z5I.*TVL[?,S5_X)%?LL[]O_#/W
MPAW>A\-VV?\ T"G'_@D+^RT?^;??A%_X3=O_ /$5I?L\BQF_9(U%H;/R;1A?
MY@$K,#RV><YKYT'A;PG?V\DDWAB-O+C=L&]N,=2>1NZY Z5\IQ-XW0R;#X.O
M7HR?UB'.KR:MY-ZW_ ]# <%RQ-:M24[>S=GIOY[H]X_X=#?LM!MO_#/GPCY_
MZEJW_P#B*>/^"/\ ^RX?^;?/A%_X3=M_\17EO_!'GXAR6G[)/Q-\0:U<7,L.
MA^./$,Y4RO,;>VA,;[$W'. %X7.,DUG_  B_X+U?#OXYP:-'H7@GQQ9WNM>(
MO"VC0VFK106[FSU^[DMK344*O(I0/$Y:-BK@)TK]=RS-*F,PM/%)NTXJ6[TO
MT/E<=@8X:O*AORNU]CV+_AS_ /LN_P#1O?PA_P#"<MO_ (BC_AS_ /LN_P#1
MO?PA_P#"<MO_ (BN\L?VV?A#=>'M6U2'XH_#V32O#]ZNFZK?+K]L;?3+IMP2
M&9]VU&)1E 8@DJ?2GWO[:'PETU_#ZS?$SP#;_P#"6)#)H:R:[;+_ &PLTGE1
M& %LR R J-F?FXZ\5W^VJ?S/[SE]G'L<!_PY_P#V7?\ HWOX0_\ A.6W_P 1
M1_PY_P#V7?\ HWOX0_\ A.6W_P 17J,G[3WPXBU_Q-HS^.O!O]I>"[5KKQ%9
MG5[<3:) HRSW*;OW2*O)+8P*XO\ 8K_;8\._MJ7?Q&F\+QB?1_A[XNE\*Q:M
M!>17EIKQ2TM[DW<#Q':$;[3CZK1[:I_,_O#V<>QA?\.?_P!ET?\ -OOPB'_<
MN6__ ,16IX&_X)>_L\_"SQUI'B?PW\%?AKH/B'0;C[7INHV&B0P7-E-@C>CJ
MH*MR>:^@L44O;5-KL7LX]B@KF,8Q[G)(S^7%%7\45GRQ-^:/8****#,****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH CG7/Y5PO[24+3?L]>/(U5FDD\/7Z*JKN9B;>0  =SDC\Z[TC)J"]A6XPK
MC<K=1ZXKGQ4>:G*'=-&E.7+-2[6_#4_ ?X=>/H]$\+:;:S:3XB,D%NB,3HTY
MYQZ@5V=C\7+9 /\ B5>(\?\ 8(F_PK]N6T>U4_\ 'O!_WZ7_  H_LFU_Y]K?
M_OTO^%?D%;P;H5I.I[;?7;N?LU#QQQ=&"I^QV5M^Q^,NF_%&UD3<NC^*"/7^
MR)?\*UK#XM6:,N[2?$@Y'719A_2OV$&GVY./L]O_ -^Q_A1_95MC_CWA_P"_
M8_PKSZG@71J?%B?_ "7_ ()4O'3%2WH?^3?\ _)2V^-.EV\>Y]-\0#;UQI,I
M/Y8J_;?M!:'$/FT_Q%]/[&F_PK]6SI5LH_X]X/\ OTO^%)_9UO\ \^]O_P!^
MU_PK@J_1WP,W[V(?W/\ ^2..KXS5I[T/Q_X!^6]I^T_X?@/S6/B$8]=&G_PK
MA?VP?C_H?Q#_ &6_'&BZ99Z]+JE_H]Q';1_V//\ O&\MOEZ=37[")I=KC_CV
MM_\ OV/\*;+HMFT8_P!%MQN;:1Y2X(].E9X7Z.N6X3$PQ:Q$FX--*W9^;9YM
M?Q.EBHNG[&UUW_X!\H_$K]BS7?VEO@=\ ?$W@OXA:E\*OB7\+])@NM$UV/1X
M]6MECN;!(+JVN;*1XQ+'(FSC>K*8P1CG/G&K_P#!$+4_%?[13>-M?^,FI>(;
M+6-5TWQ5X@@N?!NGKJFHZ[86J6\<L&HHRR6=BYBB=K*.,Y$;)YP60BOOVP55
MM_E55^9A@# P"0/T 'X5;M_]2M?T+0CRTU'M9'YG.7-)R[L_.JU_X-[_  GI
MG@R33+3Q%I%GJG_"+^%O#UKK%OX0@BN+.ZT;6)]3GU$;9P1)>"1+=@K*ZK&"
M6D' \[^&/_! _P 5_%3P?\1I?'GC2U\&S^*[?Q5HFB:5IWABSDETF#5]7BNY
M;NZO(I@^H,T5I!Y:2"(0M(^,G%?JY16I)^<?B#_@WYT7Q%\5?C/K%QXWM[S0
M_BYI?B*TBM[[PT)M7\/W.LB/SIH[[[5LECB9-Z1&V5B0 9NY?HW_  0<:+]I
M;PG\2M8^(FG:Y>:;9::NO61\'K9_;+ZQLY+6*]TR2WNT72VVR;S#LN(O,!/1
MV%?HS10!\2_\$PO^"0TG_!/+XFW_ (DG^(4/C#S/"%AX'L;6'PC;:$+73[&9
MWMFF:"5A<W6URLL[ -*WS<=*^VJ** "BBB@#YM_X*UP37?\ P3[^)D5M#/<3
MM81XBAC,DC_OHC\JCGH#^5?E+HGQ+MK2&.-M*\4':H&?[(FYX_W:_=[4XEGC
MD615=6*A@R@AAGH:AM= M'CW?9X<Y/\ RS7U^E?"<6\#TL[J1K59\O*??\&\
M>5\BP]2GAX7YGO>Q^77_  37^(-MKO[8OA.U2QUN&22+4 9;O3I88EQ9MP20
M!W'YU[?_ ,%%_%<6D?M3_#FW:TU*:2Z6V57M+)YHXR;Z,89QPHYY)Z#FOM=M
M)M[29&CAC4DXSL&1G@X..XXI+FPAG:-FBC9BH&2@) ]!QTKBPOA_3H92\K53
MW'-3\[KET_ >8>(%?%YNLUG#WU!PM?2SYM?_ "9GR3_P56\6P^#HO"4T]OJ=
MRLDMR/\ 0[5IBF$7KM!Q71?M">,;?P]_P3T\.:K=0W\D/]G:4QCAMFDG4LB=
M4 SP>OI7THUE'/!&SC<S;22P!Z]>OK2"SBF)B:-#&KD!2. !T%=&,X-P^(Q&
M-KRD[XF"@UT22LFNIY-'B*K'#X:@XWC1ES+SN[GSA^RIX\L_$7["VM:U"M\M
MO%_:FY)K1H9SM9L@1D9KY-MOVK/"OV)?]%\2J)X.,:/,,%BX!)(]NU?J!;V$
M44:QA%V[<XV@#)Y)P..339-"M1D>3']P/]Q>#GMQ7S/$G@W@,WPV$P]>I)>P
MAR1>^F^MSLRKC26'K8BHJ=_:2N]=O0^'/^"-WA"\\9_L1?$K1Y5N=,'B7QGX
M@BM[B>T:.2.&X4*LZHP&[AP0/E!]:W_AW_P1:\$_"']EOX8_#?PG+H_AF\\!
M^*O#_BS6/$6D>&K:UO/%MUI4WF(UPN6 D?) D+N8N2,@E:^RDA2R$?E*L:LY
MX50!^E:$/W*_6,LR_P"I82GAD[J,4E\M#Y/'8Q8G$SJVMS:GYI_"G_@WI_X1
M+QGJ&L>+?BPGCM-0\5^'?$<UI<>#(8([J/1KVXN8X)@UTZLTZW!CD=0B$*#Y
M7)%:VO\ _!OQX>USP+XFT&;QI"YUKP]=Z#I5T?"T+'P[Y_B"36/-@4S83:)!
M;A$V952^0217Z,45W'*?FCK7_!N]I>M^*/BY>/\ $/;9_$AM4N-,>3PWYNL>
M'KF^U"+4&WW7VP6][:"XB4F"2U4M$2F]6.ZOIK_@G)^PA??L)^%O'%MJ7BNV
M\8:Q\0O%#^*=1N;+0(M!LK:9[6WMS#!:0R2)'&H@! W=SR>M?2E% !1110 4
&444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ *0#+ P$1  (1 0,1 ?_$ *P   (" @(#
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M,<N90W "ID7Y1K7NUV>P<R5=]2ITHYM]GW&DNMHJ2>*Q#5&*$5 JJ2P.$E
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MU8Y\LP8*2[DH+B[$H*G,=4@'J8YBB-1,:HAW:@U=>X,+Z\%'20G,^004,8!
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MT,)&;MIU  R;D !)1(WI%)0HA]&O/KSU2V95'3X:::ZDOU$25U'BP&+0534
MIZ 8IB@8IAXU 0 0&H_/KT&QE0N;.E>TIX>;3C+)K\RQ,[=%Y81<NX^W2":Y
M  W$M0, #V /<(?+J/=7'!DXJ<>W,HZ+GX&U["*3L$RFF+V-D4$WK%^W,@^;
M.:=!PV.02BBJ!BB!R&] UU(VO=U1<E*G\BT7#DO8GD2MO7T4:LKF;E"37#Q/
M'AZ,NHHJL3=1;.U'?0IM5<04FUMK,4J1W"2(NA4@X981, MF93F$&Y3*<1*
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M2H: YN4I.PK(QU,/+V8M'-J)L4XUY$&:IKH2#8Y>BC%ILA#D5 Y1H!*<0#0
M5VZSF%'#2X(7$EBM,<+(*MWTI IP*-O.G@.2#T'PM42$%5/D'VZ<:Z ,5U81
MQ7?$M"W3>MAVO<\Y!=(\7*S,4T>/8X$3=5(R+A8AC$(B8.8:<= *"^2V<WKE
M->W);!UJ7!+OY@[%Q=SJTXY:-?3"8"!VOBU4>8RI.GV5[0T ?C;/=K1 14#
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M28R?:.1!?' UJ1DG'F:#[*P/! Q*%[*%KVZ +!1*<@D$#% 0H(@(A2OS\*Z
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0_2_Z= =5_P!S_3_\70'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>image_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_004.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!8P*= P$1  (1 0,1 ?_$ 1,   $#!0$! 0
M       ! @,$!@<("04*"P$  @,! 0$!              ,! @0%!@<($  !
M P($ @,&# P*#Q,*!04! @,$!08 $0<((1(Q01-182(4& EQ@9&AT3)2TM,5
M%A>QP4*2(S/4E9976!GPX6*B4Y,D-)16<H*R0U1T)35U)C>7*#A(\<)C<X.C
ML\-$A+1%566%-D8G1V2DQ&9VAG>'MWBEM=6V9^+%IV@I$0 ! @,#!P<'!PD%
M PH& @,!  (1 P0A$@4Q05&1T1,&87&A(E(4%?"!,I)3%@>Q0J+2(],7P>%B
M<H(S5 @80Y,DE%7QHU:RXF-S@S1$9$5EPN-T)35&\K/#)C;_V@ , P$  A$#
M$0 _ .5E0WI[N(M6JB8^X74H)14IR$)%8:"4H3+>"4@=GT) RQ^K*3@&5U8Y
M8<NU?E1W&E1>(@<IT*'RW=X+?A>4+J7F>/\ 7=K+CQS^UX]C1\#R&M@Z'2J^
M^L_19YD>7'O /'R@]2CG_P \-?!8]$.%>%Y+ )SFB:!;UG9<Z/?B?DV)?+BW
M@C_*$U*^_#7P6,<WAKA.8>J]OK.1[\3_ "@E&][> KCY0FI?'_GAKX/')?\
M#SA"IFF:9C0YUOI/1[\3_*"/+@W=)X+W"ZE<PZ<JPU\'W,:I7PVX/L^T$/UG
MJ??BH\H)IWQ;OL_ W":E\O\ 9AH^C_.\#_AMPA>LF"'ZST>_%1Y01Y<6\#\H
M34K[[M_!XI^&W"'M!ZST>_%1Y$;$>7'O _*$U+^^[7P>#\->$?:#UGITOCN<
MT0=^38E\M_=^OCY0>I?#_G=KX/$_AKPC[0>L],]_9GE!'EN;OC[;</J4CN?U
M8:X]WI;&(/PRX0?:Z8/7>EOXWG3;6C)S)1O<W? ^#N'U*7_TPT<OUF(_#C@Z
M7EFML_2>J>^-1H^1)Y;F\ _Y0FI7WW:^#Q'N!P=-,-ZVS])ZAW&M0RTCY$'>
M_O 1Q&X34K/H_KPU\'C1*^'/!V4S&P_6>J^_$\^02>7'O!Z3N$U*^^[7P>'3
M_AQP>Z6 V8W+VGJ\OCJ<UUN3S;$OEQ[O_P H/4O[[M?!XQ_AKPC[0>L]/]_9
MGE#8D\N/>!^4'J7]]VO@\2/AOPBVTS&^L]+F<=S7MNB,?-L1Y<>\#\H/4K[[
M-?!8G\/.#_:-]9ZS^^L_0=81Y<>\#\H/4K[[M?!X@_#KA9PNTTQN_P W6>;>
M96;QI/CD.L)JM\.\$I(\H/4OB/\ EAKX/"A\-*+MM^DG>^=1H/0G'>]O![09
M[A-2,NS)/:UAOL\@./:<K?-R=W+CBS?AEACG79[V[D^EZ0LSI<WC"IFRG2P#
MU@1FSJ^H^Y/SA\BWQ=C&H.X9^RS%\?;NUBGU&5;3%-YNS#J9J8A9[)#O',G+
M(8\[.X>^'^ 8F&/GLL=VWZ>4+LT.*5;\,@0<G)H5A#?-N^4&R-Q^I04ZZMKM
MA4FW%*#>9/[C2WVC? =)'#'N)W"_ .-TS'RIS+P@1UWY=2\Q(KJTU+H!UBD:
MWT;NW/M&XO4E67<K#/?Z@WU8Y6*<(X21&\V,?TEMEXK69PZ"OR!N+W]5+3NM
M:P0=8-4G]-+<JT2@UNZQ7&C%I]9J1"4I<6&^09$XX#>$L(O0WC>:U=!F*UL(
MP/0K&7O>W:M.\OE':D.*=CJ>1(%8:*2EL=(/9\00.G&ZDX1PHF!>WI2&<1U5
MZ !L/(HXF]S>-/D,0J7K_JO49BX[DI;5,J#DZ>ZRD<RG&6*>RZX8:!]L.7 8
M;5<(84&POM!_:6Z7Q%5P%AC'D2JWN[ORV.;<1J0VHCPD)JP2E!X\R4I>:#J0
MD\,E#F'7QQOI^ ,,GRFD.$2 <ZPS.+:B1,=&,8\BI4;W=X',0-PVI9',>/QP
MUQ'[7CH2_AI0LM+@!^TH'',YW5S^95(WQ;P4\/*$U*^^[7P>.97< TX<Z4R!
M8#RK._C2>'$0^1+Y;N[Y7A*W$ZE))Z4_'#0/^Q]S'/I^!I$I]L(>=0.-9^@]
M"3RV]WZW$)3N&U,5RYG,5AKT>'V/JQTG_#SAFK._KGAM01:+SQDR9+$IW'%0
MUT /D1Y;N\(E:QN'U+2$K*<OCAGAE_J??Q7\/^#962:WUGJ@XYJ='R)WES;P
M .3RAM2E'AD?CAHY=7[%WL6' ?![A'>M]9Z8SCBHA;E\R3RX=X*?\H74HY\?
MZ[M?!XGW!X/]JWUGJ_OQ/\H(\N+> >G<'J4?^EVO@\0?AWPA-R3&F'Z3TJ9Q
MU.;",>C8CRXMW_Y0>I7WW:^#Q'X;<(^T'K/2O?V=R]&Q(=\6\#JW!ZE??=KX
M/$CX<\(,RS!ZST^3Q[.B?S;$>7%O!_*$U)^^[?P>)_#S@_VC?6>G^_TWR@CR
MX]X(_P H34KTJNU\%BP^'/#4PPHG@S<_6>;%5W'4Z8( ?(E\N3>!^4)J5]]V
M_@L6_#/#M(^DJ>^D_0=82>7%O 7X/E":E??=KJ_U,8/PSP7_ ,6X"3G,7#F1
M[ZU M@>A.3OGW?H\$[A-2L_[+M9]'^E8M^'/!TL#[5OK/4GCB?Y0V(.^C=^1
MD-PFI>9_YW:^"Q9O O!]X S6^L]3[\S_ "AL3?+<W@+R7Y0NI?=_KPUP_P!;
MPF;P!P>7Q,QOK/1[\3_*"=Y;F\#\H74K[\-?!\,=NGX3X*IZ=\9K+P:8=9V5
M'OQ/\H)/+<W@?E":E??AOX/'+\ X4[;?6=L1[\3^7H1Y;F\#\H34K[\-_!X!
M@'"A,+[?6=L1[\3^7H1Y<&[S\HO4K[[M?!8RUO!7!U39O&^L]'OS/\H;$CV]
M[>!U;A=2^OHK#7P?<Q%'\/N#FQ+IC8?K/4>_%1G_ "* ;W-X&7^,'J5]]V_@
M\9AP/3EYN0+(F&7)FSZ$_P!]:B&3Y%.G?%O!;RSW":E??=KN?Z7C?+X&IP(V
M1\Z/?2HT'H0=\F\%7'RA-2N/'^N[7$'H_G>)/P_X4G?OYC1/^=UGY<]B8[C2
M=<@!;YD>7'O Z/*#U*S_ ++M?!XEOPSX.%IF-]9ZYL[B^H<8V]"4;X=WF?'<
M5J4D^Y^-VN'^M8D\ <' ;L36V?I/3)?&U0R6&'*.;8@[W=WX^R#<-J6H'H(K
M#7'+@?YWU8I^'?!SLDQL?UGJ_OQ4>4$HWQ[NC[?<)J65?V8:'^U86[X;\(D_
MO!ZSUHE\>36M@X6^;8D\N/=[]1N#U+R_LNT>/[7BOX:\(G^T'K/5_?V9Y0V(
M\N/>!Q_PA-2LO[+M?!XL/A]P?(L=,;ZSTB9QU.<Z(_)L2>7'O _*$U*X_P#/
M#7P>(/ O!TWJ[QL?UGI?OQ/\H;$OEQ[P1_E":E??=KX+$R_AKP^Z)H7@MSVN
M/-E0>-I[M.L;$>7)O _*$U*^^[?P6&?AGAVD?24>^D_0=81Y<F\#\H34K[[M
M_!8LWX<X#)MK7AK3DM<+59O&50[,>A WP[P%\#N$U+X<?Z[M?!XM[@\(>U;Z
MSU?WPJ-'R)3O=W@'HW":E]_^J[7P>&2_AYP?.)89K<D?2>LM7QK4RI8=#/R)
M/+<W@#_*$U*S_LNW\'C!.^'/!TN9;,;ZSTJ3QS4.L@8>9 WN[P,_\834KI_Y
M7;[_ /H>'S> N#9M(9>];&(^<]=)G&\YK;Y&3FV(.]W> GPO*$U*^^[77PZV
M\9)7PVX/LC-;ZSTSW^?DA\B3RX]X/Y0FI7WW9^#QT)7PUX.B!O&Q_6>JOX\F
M.:0,OFV)?+BW@DY>4)J5Q_YX:^#Q>;\.^#)=AF-C^L]9O?B?Y0V)?+<W@?E"
MZE??AOX/&!WPYX3<Z_(F SAZ/6?ERBSG1[\3C9L0-\N\%O-)W"ZE=P?U7:Z^
M /VO$^XM/R=*/?2?H^1)Y<F\'\H/4K[[M_!X/<2F-EG2H]])^@ZQL1Y<F\#\
MH34K[[M_!8=^&>':1])'OI/T'6$OEQ[M_P H;4S[\M?!8/PRP_2/I;4>^E1H
M/0D=WN[P.K<+J7ETC^K#7P?<.$#X=<'RQ!\QM[/UGY5/OS4>4%3,[X-WF9'E
M%ZD@\<Q\<-</1^Q]W ?AYP:\0$UOK/4^_,\>052WOBW?\Q'E#:EGB<C\<-9$
M9\/YUUXTLX!X08T-$QM@[3U!XYG^4$Y6^'>!S'_"$U+Z?^6&O@\6]P^$/:-]
M9Z/?FH\H;$P[XMX(/^,)J5]]VO@\+/PXX0>[>;P6_I/6IG'TT2PT_D1Y<>\'
M\H/4K[[M?!XM^'?![/[1H_;>L4WCJ>YT+>A WQ;P/R@]2?ONU\'BX^''!,SK
M/FMO?KO42N-JB[;'+I"4;X-WN?,YN%U* ZOZKM=/[7@_#;@;VK?7>F>^M1H/
M0O3C[Y-XQH=7?.X?48\E8MR,E'QFWVJ6'(%TK<6%]ER\BU-)X=U..*>!.$_>
M)N'"8/#31NF1O._>![6@1R^B39D6T<8S_#C.@8[X#-V25JY4A_5FKGE_XTJ/
M5_Y8[CT-/3536-AD@-.A>;?+I+YYSHTJA(*TJ<RX))X?1X8Z<OO8T]*INZ31
M\BN2UK%O6_9$J+8]F7+>4B(T':E'MJC5*HS([1XH[-F,PYF<NL=..=BV)\.R
M))%1. J!Z0O@0<,MF9:V8?2EH-EOEH63Z/MDW%5=-R*@Z-WO!:M"T9.H===N
M6@OV\Y3K<I[W83GI/Q@$+=#/23RC'G:+&>%YDW_O A_U@5O#J;)8L &3$?CK
M=4['0T5<S2T/@I*2>CG! .6/1,&!S?M)<[[,Y.NCPZFY%$'V"E2W7VD0FTAP
MO<Z2#) ^QM]IU\R>K&^7+P3V^3]-1X=2\B42XKKB V\PI_D2%M\Z1]N&:#R
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M@Z-B^>'<S4)U1W$:Q2ZOIO TNJKNH%:2O3R/SIB41YEU\,NH! [)B0@<Z49
M'/HQ]9X5JL=JJ>02YQ)ECM;5\_XBH:20]X$!:="PJ&VUI :(4DC@L#ESX<2
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MTBV=:MZ RMQ-W;:J#<U6NK5ZJV-<-@671JA=/R!LZB>.QJ7)A4]$A$J-,JY
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MR95(I5KW#+E%VBG/EG4Z#29W:+IW9E)[1*\D<.C&F@X=P.]>GB2YXTW2>D+
MRLJ9;;DMI:W0 0%YU;ONZ*N;;IU3NZM38MGQT*L]B95GE.6T@.!9D6_(!/Q6
M\PKP4J9*,L;JG , F &$@@9C<A\BLRMJF.BP$.YBLNVS)W![FM0;%TEI]]7O
MJ5?M0E!5@T6XKOG.U*CR*>?'TS*7)>D+9,AEAH9+Y@O(#CCP7%%+A3!&6V4U
MHT!H$-BZ@Q.O)ZM^/GVJ[M9H6ZNCV+1KKUMU!O\ J5D7#<<JVJ4U4[^76"[<
M]J3?%>:92G)KS],;8DHS"B@$$9C&' *'!R8S627'E#2I\6Q&&5_3M5/?;^ZQ
M6BEHZIZCZB7Y5M%M1*M(MRV)55O&;5:/4*K:3J%H;%/:D%:'(KB!R+Y>9)2"
M#CI4?#&$LF%T9<8G.VP'(,F1(\;K(VW^G:L=R=9=P%_5FWB=1]4K\K-INKEV
MVQ&N&K5>7;4.-'"7YD.&VZJ8RF,VWES<%Y)XG/&RJP;!9;8.W)]78I./5HR&
M9T[5CJO7%5;HK4^XKEKE3K5Q55QN14+@K3TR;4J^Z!R)14?&U.R(<J*GP2I9
MYN&6.K0UF'R&LDT[F-N@ 72!DYEDQ&BJZR6)SG/-\7LISJ%M265E 4E:1D I
M)S0>OP5<<P,>HIV3:O)/?#]=>;E8:^1-O.!\O,IER$K*@.7CET>AEBM29M*=
MW?=$9XY4UX@Z 5')*7([S3BFU!QMUE*2D!698<4 M76,^.&8DXS<*+F^G=\Z
MURFM)$0%](MO,[N9&R[S9#NV+Y;N3$7]6V[TEVT]V=L-4-NL1D3A>LE><0TD
MP"X5)>S258_-&+2ZB9C$TB+I@A'*3R+Z'PW04TVD;-FW;MXV&&8\J]K<OI?H
M%>WE:W9:UC0[GID7=%H/1*_0[&JW(;BE./0!?=&H%-CJB4-R=4WV5]HHM%2\
M\DJXXR3#C$J1$&8U\+;MX#/#H7N?#\(W7HRHPT-62KCV&[>9&N=IW0C0S3ZG
M6-5M+;\O;271";%J=GWC=EYT2(LT^W;XHU3F+>DR(:P5<C1#<H$%(PNDQ;&)
M4DM=,G.<71B2XV:UQJG",/FS(M#!9FN[%JCIWH4JIZ4:^:US_-ZVL[N6MAVT
MZ3;.U]8F_$_R.FU5;-0OQBWG9BI';3$#L_!'V-(YL5G8EC;_ $)DX GM.VK-
MX+0_H]&Q;#U#8'M<U?U;U2VPZ>698]FZG(LO137$PQ-D+9L6;5V8LG533AF>
MY)4I$>A1BXXIGG]L.7+&:76XVQU^?-J+I,!$O5FX3AS'@.#"3IN[%<&BFW;8
MQ>5-U\U7I.@5)OY-/U^1I"WI_:]JU&\)%KV;9D=-&76Z72F9*$P9MWNMKF*F
M<N2#TG')Q>?Q'*J!<G5(:=#GKI^%X1<]"5J:M,-0*/M@VZ;2KUU@H>UJW-1:
MO4=WU6TVHC^I;LIZN6G9J4IE*HLBGQ)C;13&9[1*"YS=F<ACV^$5>-2Y#W/F
MSKO=P86DEQ.4G+8,D#ERKA5E'ADD-+62R2[0TJZ=WNVO:OHIMDU4W4698MJR
MZ%NGHVEE VY4!F0E"]/;AF4Y2M1'X3+DF0L.1);>2% )Y1GQSQFX7Q?&YF+A
MLZ;.?*C:'%Q&HE8\0D4/=B62I8=R-"^?J.VIDJCK4"]'CQDOE:4MN%\=JRL-
MI1X*F_L )5TDG'Z.-:6TC-TP2YL1$@0)Y(KY?-?_ (XR_FZ,RJ,BXII.9 4L
M!2L^*4Y'-0[F6%2ZBK<8[Q^LP3L7:)<EI9U3R+<#S?<QV)OKVI!I3:T#6"VT
M+<>4C*1'5)R=94XY]C\-(X<W@]W'FN/&U57PQ.IY;GF89DNR).1UO*NQPL9(
MEB=/:UWZPC\J[=;@MQV@%Z[@8>Q^M7#=6XNI7EO48NF]&]1Z6&Z)IG1''76Y
M-FV],8/.[3G&4E(#2@@$@D<,?&Z3!L68P/8)C7 0LO>;-FS+Z-35F$MEPF29
M+G<K6HT0TAV@ZO:N[U)Z=K]E4U6VZXW+*TXTWH=.J]<J%RT=$UI4NZ9=*8E-
MR:^\T@*"$HS(] '":J7Q#2]8SJ@-'Z3P%D<<-J:@2F2Y0#CF#0K6JNV7;E"=
MW9ZFZ$;4'=8]1+?G:<M6WMXOZ$[1YEJ,UV*D5VX*=0TR?&TTMXYD-)/,R..,
MIK,?-AFU$/UGK9X5A_\ T?1L5Y:(Z>T6Y]+-A=GW[8?R/AG4?<]4:C8,2L2(
M$:UIK5-JOB=KLOQ929C;-)6D%)6K)0'+C,&XFZ<)C[Y=$6F\3YT>%8?HE]&Q
M65H]H]M8A6ALQLN[MK]@7I<&XZ3K;$O.ZJVNKNUZ Q;TVLBD3:?XI("0Y'4T
MA96H\SG+CL[K$7L<&WQS1CIZ5(PK#LL)?0DTAVG;>;SM39+2;OMN%53*J^Z=
MQRVZG7*BB'J)5;.<G_)"S$J7,#$53RV$(#;82\1P)./-5HQ83R99FB!&2]'S
MJ/"L/.:7]'8J':5MEINI6H>L5ZZU[+=.=*D6A$LVB0M,?B.K5&N5B/4+FF4N
M/=E"MIV8J5'3(@M=G(EJR9S:YR/"SQV>*<6QIF!4DVEF3V33Z1:YP)@1E@5I
MD87AIRMEPYF[$S=)I'8&A>VGSL.G.EM"CVS9\?6O0.?2J!&=4B'">G49A<N+
M#<?=<4MED\2I'!)Q43Z^?C5 :@/>'$1B"000(QBLE;AU!+8X-$L D:,R^<A
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M2\^0*=20 <?F;'\!Q/O]3,;,F.(F$Y7$P)) R9-"^M4E50MII0>R63<$8@:
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M.XKM!0FH0T#),U ![BV/A,3+D4<IQ?+<T./-M2WR<1=U23="8)D '/QQ&?\
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MW7$B[J"ULEO=",5P3J^ONJ>I-?TBU*N_6^VJ]0ZM2]2]:H&CUO1H(;L"AVM
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MV%^@!*G4[);+PCK*B2E/'CF<N'3W^_EB9<R>)D)T+G,%$NG:YL;=:9FK/IR
M)SX9\,4JA5WQW6&[S]4%+;*A-#+8DV*H/*<N7VV1Z#GQR^EC0Z^R27.A? T+
MH"0T>E'6K.>NN N?*H\6JTQZL0FFUR:.F8PJKH[10 6N#S]H&2#GF!C!1XI2
M%CWU5WJ G18.8)$Q]*V:)1C D"$3D)@O;8?4I+?:+3FH))"4J#B2<N!0KJQ2
MH;B%5)%=ATV6*0MO 7 21SI[Z"E$7-#KH_2*T$\X8I"K&T?Y,QEKSI^#GF<O
MW>@?2QU.%\5I<7G3*=D-\QACDRBTV07,G4@: 1&$=*Z(1VD #@?:CZH^Y3W\
M29CG98:EJ%/+&G654=DCN'U3BL>;4CN\OEUE'9([GKGV<$>9,W;>5'9([GKG
MV<$>9&[;RH[)'<]<^S@CS(W;>5'9([GKGV<$>9&[;RI>S1W/7."/,H,IAM,=
M::66STCUS[."\>34HW,OEUE+V2!U>N?9Q-X\BC<2]!UE,6T@E&8Z^'$YCHZ#
MU8B\>1&XE\NLK66>VGRP;5''+R>[_P#JC^,/34=.>>&WCNH6>EH2.[2N\7[;
MUR&4Y(K.]!\.D0L_Z#"^'="\_4SQC/HCF5*#+K4]6DO18ZU-ADA:%.R%OK+;
M;:6ASJ4WT\Q"!T#%%OG>@5SPLBX=H^Y[5O4NNL6+1ZMJ1HI4&*74+LKU,;IC
M\F%&4XI^JQUOJ;;J-*I4EEUCM7$J',T2#C>UCW,;#)!<7O,MKBS."LR3=6-M
M.F5@Z@753[JLBEVA;,>5=>HIMFHP)S3,>0?%6YDZ$TZ[X506LH4$CE )PYM%
M,<;L#$K=+JY4(\BU1G75LQTQLRJ:BV=H1;MPV!7-/JO>\^OV?#H\UBI4FH38
MSDREJC27_&%K\:DAU24E*$DJ&&]TF2Q=M@%BJZB48Q@L&U?2RFWGIAJ)?=MZ
MVL7DK46Y+&;U%HEH46B-UZC:4QY,1-N:44RFKEM1*&B&Q/ DO<Z^?CPPMSWL
MMT+%3-E3)@ R%=&WJ7MT35HEBW6UI[\M;KLNEVE*MVKR:9(N:KVO3XS;T2AR
M4*S=,9I/%U(X!7M"1A1;,FF_;:NK,ERF'F"P';VIVS#XJN6W=(K'M>Z5Z57B
MC3NY[4M:#'9GVG+N5P0*LMAF>$NNP"7$AQ0)#@Z.C$;J9RK.ZHE2[!!9OE:?
M;5[FU%H%'DT#3&HZB6A1&:?2*(B3 %P4FG1$MOQ(CT:,XI:D1G/LB&3F$KX]
M>&79@DGG_(IE3),Z;$YED74V?HK$5:]+U*F6>TY&J$>N6]3+ODQ8CBZM#"V&
MIE-:F)0HR0X\4GDR01PX8P-$TS/.NJ\R]W;D@K<;INWQJLVI9<B!8*+DH$VH
M759]M/R*6FI4N;5([@JU5I40J(SFQ'U< ,E))XXWS9<YP#FFR'*L=.^0TN!A
M&*M^J6IM'O6TTQI5#TGK%BZ>U&6A3K)HC-.LR7,5)$U#T]*VW::MR6\OM6BX
M IU8.1RPHR:F,-/.M.]IN3H5#<-I[1[CI5JZESZ9IA/MBRVX%*M"]A)I;M-I
M28_V>%%:J7C'BZ8L1UK+E6KF*TXG<S_GQ2*A].X"$#!>-$\FFI7Y><CY"V4[
M2*Q1:/?UQZHOJHGR1N*= <3XBY,DH6N::G32@*9?2E*4I'MB<L1NIG*LT9)L
ML@O#NN[-B^F=7MK72X'M**?<FH=PQ+8@7NR*?)1-K#Y[-F.[)'.$OOL-E*7B
ME*R<LSGB'4TV:(",1:B,G*5=MS:?;:+BH?S/T6I63:]7J\>XJG:\2C2*?%N:
MASKT8DOUBM6ZVUF['J-1CSU.=LKPRI?-A'=ZGT(_*ENJ); <D J&W]8-&-O#
M&CFWV@3F:]4'*K#TYC0J'.I[U2AU!J(7WIMQ0F7"ZJ0XI/.ZL)!4ZHJ.'S,,
MFR9!JI@-T$#6D&ME3OL1E)6][*R5]F> \!(4H<I6>515RIXY<I2,<9UCBN]2
M_NUH#O\ >%L: I'1\_MD'U)*S]''6D?NCS!+J?2'/^1=!HOA)YCT@E(]#).*
MG*FL_(E?64I.1 *LP.CZ9 ]7%AE":1&6XZ&E:(R-[D&5K9=FC=I:2:@WJFPI
M'B=Y7I0OBI%'H$TT]R8S$EPITJ/47ER5I"$+90M&9XG+&D2SI%JY.]B+"O M
MWSA>F]TQ[<9HENW/4*Y5:)>]>N.DQ8["UV#$L<2C-8N[G<2Y"E3U12VQD"A;
MBAQRQ(E.)NV(WW*O,TR\X[I=JK8>C=^V];UUQ6=8+Z3I_!MVH06&:Y;M5<4X
M$2;F84Z##:6RRIUH-<_:HZ,3,H'C*%0U7*5FW7G=#"T*9MN"Y:=?U!O&]ZL[
M2+,LJS_%55VM.18Y=DO$376HC"$D=!7PQR9TF8PE1WJRPE:XN^<JMNHVE;LZ
MT](=2[UU$JU4N2DUS2FAQ8"+BLV39*5KNU-=<D/MM-IIK*"M*AP</!..P* 7
M XPR!3WJ.<JY[W\XQI-:.@]D:\4F@W5=5,OR?'@T6T:7"SNEM+<QN!77ZE&6
M0W#%!D*(=S/*HIX'$=PZQ; 1A%3WD0B2M[[2N5-S4FDU41WX3=6I<*J,QI:$
MHE--38Z)"&9*4*4E#[:%Y* ) (QSZQEP7#F3J.>7/()SJY)!/)S <!W>KAEW
ML9*;]XNA.9>9:N5>X[4.VM-/.#[8[RO"K1J-0!H3K-16YCZ>9+]6EU>WWHL!
M S^WJ::40.O&;'.(L-PFD<RHK9$E[;2QSX')E(BO,3J_N<XRYAA#Y%M&-Y^@
M8\!Z[VT*'MFS!DJ4@GCD5);4D]/5CY*?BWP](J2TXG26'V@VI[>*J"2.N[I&
MU.3O-V\D?]<NOZF!*R_V+#YGQJ^'$IUS$L4I15PM G,:(9K+VA'O?0NM#A#S
M;4_RR]O9Z+Q41_2,GX/"OQO^%/\ JM-_F&?61[VT>9S>C:HG-Z&W]L@)NUQ0
MRSS$&3ETGA]K&%/^/?PSIS<DU4NH:;;S9LMP!T1+LJ1,XII7NB'#)R;4@WJ:
M!#HNMWTJ?*/^UG%?Z@OAQVV^O*^LJCB:F[8Z-J:K>KH'_&QT>C39?O!B[/Y@
M_AT,CV^O*^LCWGIA\X:QM2#>KH(/^UCA]&F2S_G,7_J#^'?;;Z\KZR/>BF[0
MUC:E\M?00<?E8OTJ7*]YBKOY@_ASG>/7E?61[STW:'1M3O+;T '_ &K=!Z_Z
MFR_@\4_J!^')_M&^O*^LK#B2E/SV]&U1*WK: ',B\RQW77Z=*#:!ETGP!GQQ
M=GQZ^&$]URJJI<B7EO&;*;'DC>5F\34K#$O:?.-JTOV^;@]-[,W';K;RN*O)
MC6OJ#<M F6E44092A,8@TUMN2KEY/"!</3U8[ ^-OPH,ENYQ:FO6QC42X'FM
M3/>NB]$N:0.4;5NNK>GM["3_ &Y+5F>@4V43T]0Y,<J?\=?A=(?O)6(2)\X?
M-;/EF.DPO9E=G%= 7B\X0YQM47EJ;>AQ^5[WWLE>]PC^H/X=]MO]Y*^LM!XI
MPV'I#6W:@[U]O67_ %P='?\ BR4?\[@_J#^'?;;_ 'DKZRJ.*,,[0UMVIHWK
M[>B0/EDX>/1\5RN/ZW$_U!_#KMM_O)7UE/O1AG:&MNU2>6KM[_C>[][)7O<
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ML14Q'U>*U"!28[$J.HA/MFW4G/!5?S ?#AD"7_9DF'7E?65O>:FAZ0CYMJS
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M&77!;Z<S_H>)'\L_%4KJRI6$AO,[[I,;P;7-$ Z;K/U4YO2:Y0#RN:CI&?7
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MP^)*</0A,'URC/&>9)KW.BVMG0_7"GOC>R-11\C;7/'XDIW\$:3ZP1EBFXQ
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M=_+ U;]*-3/IHQ'?*25U9C!>YRDS!-O=4V02IVCZNC_*_P!6S_O>E^]Q'B%
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M(]Z\.\KNU'E1:$?C,M_^$J][@_$# _\ B' /7&U'O9AWE=VIOE1Z#_C-M_\
MA1][@_$' _\ B' ?7&U1[V8?Y7=J?Y4&A/XS+>/^^OTL'X@X'_Q#@'KA3[UX
M=Y7=J4;H-#NO4F@I_DI)^D, ^(&!?\08#ZX5?>FAT?)M3O*@T+_&70?X0?>X
MG\0,!_XAP'UPI]ZL/Y?H[532-SNB+T64AC46WG%F.^TA(E#-:@RI.0SX]>+T
MWQ!P NA[PX%&/;_.L55Q9A[08"/J[5ICL8UHTZL33>^*?==Y4>ERZAJYJ!6X
M;#SJDJ=ITVJ+5%>2,N*7&D<P/1D1AU5\0L"AUN(<!A^N$FBXLH7$WH!OFVK=
ME6YO0U)/-J/0@?Z85[&,H^(.!$1]X<!]<+JGBO#1GCZNU,.YW0P<3J301_OD
M^Q@_$# _^(<!]<*IXMP[3_R5#Y4>A!44G4>BYCK\8.7I9#&EGQ(X:8T-?Q!@
M5[_K!M4>]E&?1R?L[5.-T&A 2,]2*+^WK[O\CB_XE<+9^(,$_O!M5_>BA(B8
M1_9VI1N=T)7Q&I%#'5QDD<?0(SP?B3PM_P 08'_>#:H]ZJ(&'U=JD&YO0D#(
MZEV^D]Q4T)/J'!^)7"W_ !!@G]X-J@\54(RVZDOE-Z%?4ZD4)8[J)16/0S2,
ML\'XE<+?\08)_>#:I'%- ;<GJ[4U6YS0L=.HM$]-]P_0&(/Q*X7S<08)_>#:
MK>\]"<A U;5"=T6A0("=1:)Q'2'W.[WQA,SXE<-1%WB# X?]8-J4[BR@:0'6
M^KM6$=RVOVD=T[>==+>H%[TFJ5RMZ1Z@4^E4UA]7C$Z;)MN>S'BL\P"5.O/+
M2E(ZR</E?$KAUG7'$&!69.N.FU5=QA0M$6P/J[54[<=?-);?T$T:HU8OFD4Z
MJ4S36U*?48#\C)Z'.B4MAJ3'= &0<:<!21WL%1\1< FVLX@P(&,3%XZ%9O%M
M <L,D;+NU9J5N8T/0,UZD4% / %4K($]SHQD_$# _P#B' /7"O[V8=I_Y.U,
M\IO0H].I=OY?TYEZY&);\2.%J8WZ['<#F2C8 U[8QTVJKN+:!HBTB/+=VI#N
M:T)_&503WDS H^H,7'Q5X /_ *MA'KL51Q?1DPBSH1Y3FAB 5)U'H!*03]DF
M)0G(=)*G,DC&#%?BUP)(HS,E8GATQ]YHNRIC+YB869//R(=Q32S!<#F1/-M6
M6J%==&NRDL5RWJI#J-*EMEV/46"EV(M"5K0XH/#-&2"V<>\PS$^&:S#F8DR<
MPR'")-\&'.5OE3I53+OQCS%8YA[A-*9]:8M>->5)E5R3/=I;,!E2 \Y.9<[,
MLI.8!5S#J[F//UO&W"?6E4$^6ZOR-:'M)CS94H8A)[PRC#A%YA!7_>-Z6Y9E
M%76;KJK%+I3;G8JDO$I;#A(2&RH#@I1..][R4=!A'B-7!K@TFV ^535NW0M(
M 7S&[F=S^I-F[YKLK>BVH\Z%1JW0Z3\41''9+UK3G8303*I[T!P>+EZ1T%2
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M-I-5&^::Y6;?O:=+AQ:G6:$^XW;3:&43X);BR$#D01FEWAW>&&U?\N>-!O\
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M<GE9::6EOM'XP41GQ&6/PY2_#K&L#KYC,><R:V82/LRYUA/Z30OE=7)J750
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MF_K0K170:P:QIAI=?UXV';=T6_HQ:3-!HK:)DMH^*TNG3:;)4A;KR5-,#MT
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M/^U8ELNC<([N7J_.F=WE(^:+3[^*U)_@;'P>+;FC]G+U?G1N)7E!)\T6GO\
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M3[25A);/#E204DY8WNIY4QMQPL*U5,IE0VT+BGNM\VE;-_ZM5[6,*<F/52'
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MRIQ6XDRG0IE3<9@([('F#3K+*5 $9Y'"9[=XPL9:5.[FM$7Y%OZX"%LJRX>
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M+I:?D3>Z2YG6S+HO$4M3*.T24GE3[89?4C&5553@0C A&!","$8$(P(1@0C
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M5*9Y2'4CCEB_X]_$$V@X/#GF?>++[Q5CC$1MY]JRLGSC&KRV^<7U"24$)/\
M:?.R4>@Y9L<<4=\?^/V9\'CSS/O$QG$%;>R/Z=J0><8U@S']O,-7>^2$X9^G
MV'#%/Z@_B!_[-KF?>)WO!7:'ZCM3E><7U?((-ZQ .Z+2FJ/I)6R$GT\2W^8/
MX@7O_1_]Y]XI'$%9&T/AY]JB_.*:N_QYC_@8[[S#OZ@^/_\ V;_>?>)OO!4Z
M'^7G2_G%-7?X\,?@8][S$'^8/X@0L\&C_P!I]XCW@JM#]7YTGYQ+5_\ CNS^
M!CX]<()&*?U _$+_ -G_ -Y]XI]X*G0_4=J0^<4UA_CNS^"=0/K%G+%?Z@?B
M#_[/_O/O$>/U6A^H[5'^<4UE_CFC\"7_ (+#?Z@^/M.#:YGWBK[P56A^H[4G
MYQO6/^-[?X#R?@\']0O'^G!M<S[Q3[P56A_EYU3K\X_JR&%EZZFY +)YVQ:5
M0;[13RNS<9 [#BI*3F0.C&2A^/OQ!,PDG!XQ.>9]XD'B*=R].U8[TMWA7=HS
M1*A;MHW&6*=7KDKMZ27Y%HU)1^,Z])6J6VT3'XH2\O(9=['2G_'[C]K+78+K
MF?>(]XIV2WIVK)?YR+5YP#DNID*(&:ODG4$@GK.789#/%Y?QNX_F,$S_ .SV
MB.69]=.'$DZ&?IVH'G%]9!X2KL"DJX@)M%Y0RX=!4V%'T^.+?C9Q_P#^S_[S
MZZ/>2=R^7G3_ ,XUJ_U72!Z-JRT'ZU+! QPJKXB_$>MJ'53*NCEM>8W63)H:
M,U@O6*?>*J-K0^',=J7\XUK!EG\J1E_[+S/N?&?W[^)/\=3?WLWZR/>*KT/U
M':HW/..ZO)3S"YRH\?:VK./H=$?&R3\4^,*-G=ZYLRHGBTOEB8]A!R .+LHS
MC,FMXBG@=8D.Y?\ :H$^<CUAR.=PJ/$\?DK/'#T/%\,_%WB3^'JO4F?75O>.
M;VCK_.E/G(]8_J*\X1UE-I2E\?16TDC$_C7QI3=2E;1RY9M(JA,:^.D"_P"C
M^6*/>.;IZ?SI1YR36,(455US,=&=H/YY9=7@9XG\<^/NU@NN9]='O%-T^6M4
MR?.5ZT!1":R^I.?2+0<_SS>9Q(^./Q!<>H<'(Y#,^ND3N(I]ER\>:.U6W?._
MG4G4"SKJLFXILB50KNMVJVU56$VFXEY<:O1E4EUQOE;"BAIN6HJ/0!TXUR?C
M9\0O_:/]Y]=<Z;Q%5_I1\^U+9F_K4S3VU+:L>V*E,:H=H4&G6Y!C.6>Z76FZ
M6PF.,UK;S4 $Y=[$U?QQ^(+6-O'!P(Z9GUU-%Q#5ESHAYLY=JN1SSEVM"0.:
MI2SF>&5GK/\ M>,(^.7'_:P;7,^NNCX_4Z'ZCM3$^<OUG4<DU&:#EGPLUS/J
M_P!#. _';X@2^L'8-KF?729W$-4&Q <#'0=J?^<MUK_Y1GD]P6>L'UVL1^/G
MQ!TX/KF?>++[QUG+T[5&]YRS6WD/)4:B#F.BT>__ *7BS/CI\0JAVZ:["(GE
MF9OVT>\=;I=T[51GSEFN7_*-3/>^21&?I]GAOXQ_$?MX3KF?74>\=9^ET[4#
MSENN.8_=527^H^2I\+O<6\L5F?&SX@TC#4U P^9)9:6R=XZ:1H8+]I5Y7%=7
M23!4W7/N&-V!,?-&U02O.2:YOCD:<J;06DATHM1*E<N1SY4K0$*.74>&*_C+
MQ/CC8&FJ6\\N8/\ XRKU/&M=7Y)3V<[2/RKFUK7>LR_-:VM6Z\%J5<,&*W78
MU<IPI"'8S+"H[M2[!L9N18RN"EI&0/#/'A<8K,7JWNJYSIC81,"7#H*\O5&L
MFO-7O#>;UH!QMA;DSKSK)W=TG16O-U#1/7U^UGDRB%T>/\:U*U:E(;6%2H<J
M"\EQ2P>4IS;'#/ACUG!W&N,T<D2J=LYQ,+&AQ^0K=AF/XBYPOMF 1T.VKH?4
M?.&N[FK7T@T_O>TJA3KC@ZUZ?/QKLI$92K;K2O'$K#CHJ*&C%4O+/(D$8_8O
MPSQ2MQ*27U['RS<)ZX(C9RE?1:#&)[V@.!Z=J^F2G2S)82I.2P$I',GPDCP>
MC,$CJQ[!>G7J8$(P(1@0C A&!","$8$(P(1@0M9)Y'EA6IQ&7D\:@?\ U"TS
MQ?\ L_.J_.\RSE;G]:*7_2?^V8RG)YEBEYE<)!SZ#ZF(6YN3SKQJF5(#9RR^
MV<4<5#,9=70<-8(6E9'RR7&(&5?/EN#.L+E_[@]0Z%K'JC;4ZT=<=)K!M"D4
MUZ0;;IUO7/R,5A:8"&U"2>19&8!Y#TY8Z$N<P6YPJ[HY(!>TK4R_- ;R-K7%
MJ7?,O3.P=Q]JQ;AO:OO3)LJ';5RT)4N='JJVF5A=NHFOJZ#]CS .6-;6L>V^
M,ZPS9#C,)6/K0ORHZ\:ETF<W6Z_6;;D;B-=J!9=QO1JDU5V;9780$%JW''V4
M&+!D/O<\1U607SY))Q;=R]*5N"O&VR5+Y&[=]M]/M2_KGJ%TQ[TU3BWQ3KE<
ME3*W:M=@4RMN1Z0[XXVMZF9=F'"5\B5*XC%FR ;1D*L'[H7%X.F&IM2N2W;6
MF6?K%?\ JO<%Z:7ZLTW7JU+C$VJ4NWXE/BU 6_+-*[)+3!>EA+;3R3S.H'#/
M+$BG$<T%;O!7DWSJ+KPB]=,]/K>U%H&D-#H&D.E%2TC-WUNLVO1ZO<$U]"+E
M3 ;@QW17)@J#;<=,-T^ DJ)R&> R&QS*0-Z+RZ0[^J]>MKZ$Z93D:N1]/:P[
M7J=4+Q:$B50E:HQ(E/1.JUJT:KQ$.*IM2?E .0D*"0\I0!/'+%1(!<1H5MU9
M"U:YV]K/3]0-<:-\]6I.J6C]$IUMV'5=#-/5/SH<F]'JDPV)?QDEB.4UBH"4
MG*3S$I"5 G#-R ,@)S*1)C'*M8;ROG6.WJ+8]E6[>,#3O3&YKYUFN*K7/7JM
M6+(HXO*'5EHM^#4JY#B*6TXHK4IQ@A*7R4Y9X9NI?)%3N#RP6TEK?/Q>5VTR
M;5]3KEKESZ=;6U7S1*#94R8BU[^O*/\ &J:9.FN26FG*HL=@VE#*\EO@<1D1
MB#*E"&A5=&0(VVK&FF>J5U394%.F&X^^*W<M\:(W8_K]7[M@3YE(T+OMQ!,"
M4N$['0W0S1:FI31C(!*&AV@)RRQ7<,-KK+=85.\.S14NAVJEQ5]&BM#I=S75
M-EVUJ1>%"N74R1*E73;=S3&K!FEN\K3K4MA3TF%.EA<GQ?P4L.-<F R95VRS
M.@/=--TYEMUYM2]ZA<-P:MVG<EVU?5.YK>G(ES-36JS+K5D5B/)GRO%HU.CS
MFFEV_<T5'@3HJ 4#E&6,,YP8(M.1:Y4LC(NNK,'E6IWM>#I!+8&2>]QX=&.:
M^I,WJ+I2&EICR+TPD)Y4#H[HRZAT'JQ@=Z2LZV$%SX\X >6V]OR>[K]9 /H=
MNYCMTGH._5"S?/;SE=!6".Q5F<L^<=_BE X=_&9V5/SJQ[PL.WKZHLRW+NIK
M->H4[Q42J1)0%QWUP7!(86H*S'M@,\8GCK#]9#K1!6\WH_I\FJ5RN,6C3U5*
MY:&S;5Q/.)S-3H,9CQ9NF/9Y%QEN/FD)/#+&JU)W?(%:+6V_1'XBK%LLZ?4-
M-#K% A6C5Z>J(4-3[?@NF3'ICG'(L-+RR'0,L$86H,M>O4-!]+:N*JY5;)HM
M0<JUHQK#JGC,9"O'+0A@-1J4H<F0134@!EP>'PX8OW\YB4C<'0%BIO9%MN-B
M(TZ=TUB/6DU5TUT09%0J[CJJFVKL$NR9ZI1DK0$'[2#V>75@\0.DHW!T*Z)V
MUK12HU"W)TK3>B-JM"VYMH6[)9;[!F!;TY!;DT+Q%L=G+I,A"O!YP2A9YNG$
M^(NTE6[@S.!%>AI%MJT;T/FU&7III_2[6E51F/#E/1&WW9[D".\J1&C/U!]Q
MQSQ=J6M1"4GE ZL5.(.(@24=Q8,UBV*3&"DI4H(22D$@9Y GJ!X<..,C3><7
M:7+6UMUH;H3'(RT J2H9<<@#ZF6-TLYE!7*[<W9S6HN^G0"P:@W D0:QM]UB
MJC/C,9N0NGUJ!6J S"J;0<24AUIMY0!'$8Y&-8!0XZQTB?",.3\JX]5@HJY[
MIYRN*\=6Q.Z'9+RF+G;0PXHK93XG&;\!?A)S26N!RZ<?/OP:PFEG&JEW"8_H
M[%G]W!G2'8'=[AYDW2G(]QF,!_L.)F_#O@*8^]B^'RJBNA O,D/) R=;/ )K
M>%J*8+TZ%_S*)6P&\P?!N=LCNJCQB?5['"OPX^%_^DR?\N%;W3P[]'4$].P2
M\TC(W2VD].0C1LLOVG!^''PO_P!)D_Y<*[>':"2+HAIS)3L#O!7$W2DY=QB,
MG_:A@_#?X7_Z3)_RP5O Z#/#4$#8%> Z+I;'\DQ%/J?8C@_#?X8?Z3)_RX1X
M%09H:@E\@.\/XU,_P:)\#@_#?X8?Z3)_RX1X%0\FH*-S8#>*LO[:6SE[EB*G
MZ#0PV7\./A>(QPF1'_Z<*1P[A\VQT+.0*!6P"\DY%-SHZ?JV(RAZ7V(\<*F?
M#GX7G+A,G_+!6]U\-Y-04YV#7BVV5+N=G(9*/)'B9@(\,<"SED>7"I'PS^%T
MV=#P>1"!_P##!9*SAK#FRQ=[6@+6+1O:SJ!?.OFY.S7[X:=ING-8MF!1H:XL
M/)A$Z$9$G(I:/+X2QCT,OX7?"P2@3A,B'_T[5FE<.T RPLYELWY!-[!DH^4S
M)';+) CQ0>\0>QQSYOPN^%AF?_B:?_+M6]O#] !>LZ$Q&PB\^89W*V@<?"[&
M*<N!_P!!Z\4_"WX6_P"DR/\ +M5O Z#DU!3*V#WB01\K&CGU>+QO@<5=\+_A
M:QI<,)D1'_EV[$>!4/)J"B\@*\CP3=;85U$1HF>?>S9RSPG\-_AA_I,G_+!'
M@5#R="7R ;X'%5VD@=(\6A<1UC@SG@_#?X8?Z1)_RP1X%0<G0D\@6\/XT?ZQ
M&^!P?AO\,/\ 29/^7"CP.@Y-04_D"WA_&@?M,7X+!^&_PO-GA,C_ "X1X%0\
MFH)/(#O;^,Z?VF+\'C1^%OPL_P!*D?Y=NQ3X%A_)J"7R!;Q_C1_K,;X+!^%W
MPL_TF1_EVJ/ J#DU!0N[![P2EU:KM: CIDR1G'C>V2T2D?:LL^&"D^%WPL#X
M>$R,O\.U8O=W#XY!ET!:R[4MJFH6JM@7%5JI>XDR:)JI?-L,%QF,H(A4>JA;
M" >R.20G(##JOX7?"T6'")$?_I@CW=P_0-06SXV$7B1F+O:'>["+P[WVK&%O
MPE^&Y +:9C&]G=,$.2'(M+>%</<T& M&AJ/($O8\1=[.1Z/W/%Z/VG%OPE^'
M'L&_W3%;W4P_0-34GD"WP.'RN:_@\7X'"S\%^%IIOTK6"G/HBZP=$-*L.'L/
MEBY99S*-S8)>Y&?RJ0<^DAF, >YP#.(_!7A[0S4S8I\"P_DU!-;V#WPA 2+M
M;1Q/@EB,3T]]GKPQOPFPNF&ZDAN['(W/S*AX8P^:;]GT4*V"WNLYFZT+X99A
MJ*!Z&79#%OPOH=#=3=BCW5PX:-03D; KTR\*ZF <_JVX^?I<K1X8J[X:<$RS
M#'*&74U69QE-?!NB//$PY5'NIAQT="?Y %YJXBZV?Y1N,1Z?,UTX@?#?X8?Z
M1)_RX4'A3#L\.A'YO^]!Q^5:.'^AQ?@L0?A9\-:DQE4$J1=T26MCKRP5APUA
M\MIA#4%BW6[9E?=BZ/:L7K%N],>7:.FE\7#%E%J,>PD4FW9\]@Y!K,GQAA!'
MH8UROA)\.8_N&0_ZIBS3>'J#+9T*;1G9;?E^:1:6WK(O)F5,NK3ZUJ]/DK1'
M;[6H5*F,R)BN7L@05.KS.?3B:KX6?#2F:USZ&7.#C8#):Z'+9I44?#U$U[H0
MR#0LF>0%>X_[4Q%]X]AP[_VK&/\ #?X8?Z3)_P L%T/ */DZ$Y.P6]QG_;1$
M1P/%(8.?>/V+H. ?#?X7G_TF3_E@J/X<H9HNNA#S*#R!KZYR?E9'Z_J6/@L3
M^&_PO_TB3_EPE^Z>'\G0GG8-?)_[6QSZ"&/@L,E?#+X8SG[MF&R93C\X2&B'
MG.E X4H.3H2>0+? XJNM@CK'(Q\'W<:?PF^''\/+_NV*WNI0?H]"#L&O10*3
M=4<9]?8QU?K0V,\!^$?P_>+E+)8VH/HG=L$#SJDSA2C#"9<+^;(D3YOZ\LTG
MY6-D @E+4)CGRSX\N8RSPFJ^%>&TL@]SNQA^CL7.F<,60A;YEP+WN;?=8W]P
M-\:<4V35ZA3J93Z91U76B$Y%IU(I\G*9+C1"AM+#SBD@A7*3QZ<?#N(/ASB\
MW$&R6-)DNF 'F)YESIO#,#$#)Y:%<^VSS=<JJ+@&+;+U3?DE"94^='YV8ZT*
M 5):2I&25/\ 7EW<>SX=^'3L*G N;DYMBM(P4L(L\M2Z1:K;,J?HO8^C=:J!
M#%0EZ_:<,MQHOV-+:1*3P4D99#/'Z&P*@$F1<T-BO0R,-#(:(KZ&Z9%3 C(8
M3D0 GH/ZD9<1PZ,/7:7I<Q]R?T>E@0CF/N3Z_L8$(YC[D^O[&!".8^Y/K^Q@
M0CF/N3Z_L8$(YC[D^O[&!"3G_4^O^E@0CM.]Z_Z6!"<D\Q)Z.CZ>!"UAG_XX
M%J__ &\7_P#_ %#TTQ;YGG5/[3]G\JSM0'/ZDTSJ/B8)_;",O1QE)6.6;0K@
M[;+,=/I?IX,JW-R*GDI+R,B.SX9\V8](]>-'5#(QM@H@V-JME=O4=8>;DTBD
MRO&9+<]V2_3H*B]*8_>\Q]I:%%^3 '0ZKP\8)LYP/(%,&JCG6A0:M"<AS:%0
M9$2>Z954;F46FU1BK <.SEQGVE)EK6 %<ZP2,\NK%V5[F,NZ%!E2R8D!43%C
M6U >;53Z/1(3+!;^+VH5)@4Y5/G)&0<A!EI/)(1&3R)X ) R&+>(.*C<R\P"
M\R;I?9<JGW%346U0(2;A9J*I<N)1*?!J$F75(;].D3G9[327)%6+3Y/:*XY]
M>-DFO=<C%*?2L<8JVM+-"[$T>LZE6=95#I+"(4-N"]5'*32_CNJ0FBI3L:L2
M^Q$FI!*E*R2M1 SX88:TN,257NDO(KTJ6G5G5R12WJC:%IU9NB.>,4E-6MRG
M2U4MT9Y*@>,1'GJ6ZAS,@M%(S.(%:Z!@>L<ZMN6R^KF5;7+*MNXX28%ST.DW
M%%;6VN'!K-&C5R!#DMD*9EQV)T1P-.M9 )=3D4@9# *T@Q!M1<;#(GRK'M:H
M3*+4JG0*!4:G06'&*'4YE(ITV324J0$=G2GY$)3\%?@C(-%( &%OK2VR-A6B
M4QD#&"II>G]K5>!\55ZU;<JU'=>3.=I4^APJG3'J@ISG,]Z%-AN,)FE8!+B0
M% C%!B!C>SI]R5DB%ZJ+;I;8:,*!2X,EA"&6'XL..V6([!RCQ67V([2V&4]
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MINT.G:L_>':#K4OEZ4W\GC<7^!#?W;BW@DCM#4=JGO,SEZ-B/+UIWY/6XO\
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M5;(H-6OO=-9=LZ96::)2JC;<BAUERO5*9)KSB4P+6F06D\[E:?2M);2C,I/
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M0S-Q5/:T\I ^5<ZIJ6AT"ZV*V5H-PT2O4V/5J+5X-<IL]M+T6I4^9'F1G&U
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M7'1;KH5+>F6II$U9<9^.ZBD+NO2GQ4M1ZZ(O(4TJJ/-+01D4DK!/1A<RI$\
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M(E.Q$0F(Q$0A&"(0C!$(1@B$(P1"$F6?6?2Q,5*:K,%/$\3W?0Q8*(K62?\
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MS'<[OHX8J*;M4=WZ'LX$*E=<3S=0[X]'+'(K[)FI0<BYZ><,4?D)H[Q_\>;
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MB.^70#16@V_H6]1],;.IRIVNME1)OBM%BM"3'6\XE3;P2CPP0<;),PNED')
M*CJ5DQMQWHG*M[D;9-OJ_#5I#8W,KP5$4.(DN#)))<\#PU$]>*1*)>&4K>;G
M*<=L&WL<!H]8WWCB>]P![F]<&T6K0,/IX9.DI/)@V^?B?L;[R0_@\'B=1Y *
MOAU/Y13?)>V]?B>L;[RQ/@\'B=1Y (\.I_(E'DN[>?Q/6-]Y(OO,)\3G^4%'
MATCEUE+Y+6WK\4%C_>6+\'B?%*CR@CN$A/\ )>V]_B?L7[R1?@\1XG/T?(H\
M/D<NM)Y+>WK\3UB_>2+[S!XG/T?(CP^1RZT#:YMZ_$]8_P!Y(F7\QAG>'.%X
MD1-J#AU,1GUE0.;8=O:>8?-%9(]"BQ?6\#ABXJ!"UP629A=+G/25H'J+H1HQ
M#\XKMRMF-IK:C% JVW?6-^I4MNDQTPYKL6O6^MEQ]H(Y7%I(XD\3AHFDRXQM
MBJ-PJDB"#;YUOXG:]MY<65'1^QR5*4KC0XG E6?#P. &? =6,LV=RK6S"Z8#
MDYRIE;7MO1.?S/6-]XX@_P YA0<"$SPVDT'64WR7=O7XGK&^\D3WF)O!'AM)
MH.LIPVO;>QT:/V-]Y(GO,%X(\,I-!UE(=KVWL].C]C?>2)[S!>"/#:30=92>
M2[MZ_$]8WWDB>\P7@CPVDT'64>2[MZ_$]8WWDB>\P7@CPVDT'64>2[MZ_$]8
MWWDB>\P7@CPVDT'64HVN[>>O1ZQO2HD3WF"\$>&4N8'65"=KNWA:N56C]C@#
MCE\21./@G@1R\1QQ1\P 1Y5$S"J6['\I6@^VW0/1BK;G]Y-.J&FEI3X5&NRV
MV*7"D4F,XQ!:=IB.U3';*,FPKE'1CIMFN,L'(L_A5+Y$K?E.V+;^M*$'1VQP
ME(/+_4.*"/3[//JQSYLV,V!RA-DX?(DOOL],<ZD1M<V^!0/S06/U]-$BY=!_
MT(8K?6O=\JE5M=V^*!'S06*,^Y0XN?\ ,8D/&A5=*O-(BHO)8V]_BBL?[R1?
M>8G>C04CNI2C:SM[!!^:*Q^!S_K)%]Y@W@Y4=UC8<BD\EW;Y^*"Q_O+$]YB+
MXY5/<*?1\J@<VN[?![71^QA_T'$/^<P"8 8J1AM.X?G*B3M@V]@^'I#8I]"A
MQ!E^L&-KZ\.$+P2C@5-FCK*<G;!MW5T:16/]Y(GO,8YDW>Y,B#@5.,L51S-M
M&WQJ-)<&D-D-J1#>Y2BAQ$C(1W!QR1D21C6VIA9>"S5>%4D+3TE:0>;\T&T6
MN;2V_7*QIG:-37#UIU$A13*I$5U3$2-51XNPV5-^"AH  #N#+%G53?FD I%%
MA=+?,3$^=;X+VP;?NK1VQ<_["1.GZSKPL.B8DY5UAAM-I^5(-L&W_(9Z.V+G
M_82)[S!'E4^&TVGY4X;7=O9&9T>L4'K_ *B1/>8J7&*J<-I(VQUE+Y+NWK\3
MUB_>2)[W!>*CPVDT'64AVN;>S_X/V+]Y(GO,2'*1AU,,@,.<I/);V]_B?L;[
MR1/>8+RGP^GT=)3AM?V]IX?-!8W=_K'$]Y@B2H\-I76D'64>3!M[_%!8WWCB
M^\P1*/#*70=:4;8-O>1RT@L;[QQ#]%&(B4M^$TKB+#K*P#NDVY:%TC;5N#J%
M+TKLVGSXNC&I$B/+BT>*T^R['M:I/-*0XE&:<G$#/NX8,RKX+3:>DJ;;%MUT
M+K>W;1*JU;2JS)]2J&F%G2YDV118BY$A]^C1EN+<<Y 5 JZ!U85,= >=,EX1
M2L)S^<K.ODO[>E</F?L?TZ)$][A-\<JN<,I=!UE*-KFWH\/F?L8>A1(GO,79
M4OD&_+]+(K,HI$DWY?I)?):V\_BALC[R1?>8;XI5:/D3;B/):V]#C\T-D'O&
MBQ<OYC$.Q2I(M%GF5'R&S&W'9$':WMZ_$_8H]"BQ?>85XG/T?(D]PD<J3R6M
MO7XH+'^\L7X/$^*5'E!'<)"/):V]?B@L?[RQ?@\'BE1Y01W"0CR6MO0X_-!8
M_#_F6+\'BS,3J+PAECR*102(IIVP[?!D!I!8XX]=$B'N?J,<[%,3JP\1M\P3
M#AU,ZT_*5HAOOT%T5MVRM*7:1IG9\!<_7.P(TDL4>*@.-*FI0I&7)D 4G+':
MP?%*G=F(^;R+(_"Z8G+\JWP&UW;SD?\ N@LCPTIYOZBQ0>@=Q&,GBD_R@G^'
M2()?):V]?B@L?[RQ?@\'BE1Y04=PD(\ES;W^)^QOO)$]YC0)[R(QZ%/A]-H.
MLH\ES;W^)^Q?O)$]YB=^_3T(\/IM!UE)Y+>WO\3]C?>2)[S%"\DQ*/#Z?0=9
M1Y+>WO\ $_8WWDB>\Q%Y3X?3Z.DH\EO;W^)^QOO)$]Y@O(\/I]'24>2WM[_$
M_8WWDB>\P7D>'T^CI*>-K6WH@?\ =!8P_P"A(GP9Q4O(*8R2R4+C/12G:[M^
M0/ T?L4_]"1.[W.SP;P^96NK7>;MUT11NKMJC)TJLT4V1H'>]1=@?$T7Q9<V
M)?NGT6/++?9\O;-L3G$ ]Q6&;SJ<D53=]>/(MWZ'X5*IV?U41*CZ/:9_1QSZ
MA@E-ZD5GEN-A5QH/-GGA4D7R;RW DA2XVBP00C A)EA9EM)B8Q4Q5'*=4VDI
M;RYU(6I)4,TYHY>D9CNX-RSE27S'-R06@>H?G"=*M-=6+CTON6V-1&XEG56V
M*1>&H\&W_&;!MF9>#3;M 9J=4"PI*Y:G0E60\%1PQN&[X7Q>@42ZGJ]:$8K:
M9W5.T15F:$U=UM2*[(99F(HC-8@_&34%YL/,R7(JWDNF.ZPH+4K+-'<P#"2<
M@?TIHJ@,X6/[QW5Z$Z<QJ7+O?56S:1&K=QQ+5I;RZS'*EUR:I;;,":VA2A#<
M+H 23P4,NO!X:]E@#E(K)8]*"RNJ]Z Y!D5"+<E&?@Q$1%R*@S4H3D1"Y7(E
MF(I9>2&I,A3B2@*RS2H=W!W";H*GOTC/#H7E.ZE6D9\NC-WQ:K=<I;*9-7I#
ME8AJJ-+AI4#)F3XS3RE,-,MD<?:C/B<1W";H*GOU/R="L2X==J#"J.G\>VBJ
M_P"E7M6JA0G+GM:; E4BWGZ;'<F2Y55>$CLA'2RD<$DE.1SP=PFG,4=^D<G0
MLK63?ELWI%D/6]<=$N 4]SQ6I.42HL5!B',S*A'=<:4KD>[+(D=&(-,^3Z48
M%+?42YG[N$0LA)&0S'7@#!RJH<4\8D- 5@8I<2I35>U/I?1&)&5 $;"J<J/.
M!^CI/L8P3R=Y!26-$(+GQYP$96]H VG@#K[8^6?'CVZ\;Z4G=GE62=Z,,Q70
M2,V.3,GB%<!GUY)X##'..;(B5*;Z1)CSI7'TM'E41QZSU=_TL%V+8A;1+;=R
MG6@/,<I5VN?*"2 3GP&9]$X3%_)J2-TW,7:U&U*8>&:5K'H@^S@B[DU(W3-+
MM:FYD<_+S#+NYGT<6ZN@:D;IFEVM*I:$^V.7HG]/!U= 4[MG+K40D-<I5F>&
M?#NY8B(T!*NCEUI$2&UYGF3RC//E45'KZ@.'1@B- 1=&DZTPR!FK/[&D9E)4
M3FM/40 .&8PFY%T<T59P:&6$Q4/:AT'LSQ!R5X1(S];#A+EFPQ7,G..:*YWZ
MFC__ *8[80,O\7G6M!)[GQW;JLL4=7TDF-*YKS/!L,1"'RHDM#IP8\G)F*Z+
M)("E G(@D9] ''K]+"YA=-9>DM=%=<TS&B]++B>>*J&U$ISY@>)Z,\L9MW/%
MCW,:[05+ X-ZV5/S/=]8X+DSVC%9&9[OK'!<F>T8A&9[OK'!<F>T8A&9[OK'
M!<F>T8A&9[OK'!<F>T8A)S$=)]0'!<F>TEJ0(I"OAUGT<3NYGM)?2K!D53*(
M4K($@_2R^GB1)F@QWDOI6:H9!@B3".E<[MJZ0-UN]M7'/Y8VL.'1E\5I[V-$
M:EC("=)(//$+,R4PDDDZUT72K+PN/JD].$ELUYMF2_-%;)<EC;6DQY2GAW,Y
M?2.#<S.VSI3KO,G<WH^I@W,SMM1!&??5ZF)W4SML4ZDTJX'(JSR.7#%)DN<U
MA<QS2\"P<J@B((3$G-&95DK+HX_0Q:47"FWM0UP>!;F26R;>M&"A4X3P"@,C
MQS"NCK]+',9C>'3GF2&O#\F494\4\H6F]K5@:D:DVEI9;<V\KZK$:WK4IHBJ
MGUR<.6#&2^^&B'%CB#D>GJQKE2Z.12=XJG$/ [4.96<]@;$F"FMB^K8NNC1;
MBM6O4RNT6HLQWZ?4*=):FQ)#;WU2%LJ4[[4_5 8Y6#X[1UE4Z1->T,A9: LD
MVK8VT&Q7/*4V_$EMJ4%+5">(Y"0 51W">&/0TSJ:H= .C;F.9(FTTJ:+2ZWE
M6@OFXDE&E>I 3TIUUU,3U\<JMEC?6TM-(;>D7LF<Q6*73&2Z,N]ESVKHR$9I
M3F5 Y#/(Y8SL<;HYETVRP6@F,4[LQ[I7JCV,6O%3NF\NM. R&69P15@V @(H
MR[YQ"F'.D*0>L^KB8JI8"8F*.0=_U<%XJ-TWEUH"0,$2K!MVP$I<A@BIMTE(
MI(R/H8(E06QRDK6S=L2-JVXMT>V^9/4[T/\ JE5.K%KY27MN@P)UJ?:6,]LN
M@Q__ (HLD?\ X)%QFJG&#><HE$EQM.0+8A(\++O?3PJ6T.RIX'*5)RCOXTM8
MUIB%(2Y=\^KBUF@*8I.4'K/JX+- 4.%X0*3D'?\ 5P6: E[MO+K1R#O^K@LT
M!&[;RZT<@[_JX+- 1NV\NM'(._ZN#S!2)8!C;K5,OBLCJ'TL<RNF$/A 0'(I
M+ XQ)*YW><);2Y8VCI45?W>=/SP.7^[T8[.#SWF620WT3F2332R8Q='G71="
M 4CIZ$]?ZD839H&I7W0TNUI_(._ZN"S0%.[;RZT<@[I]4XB"-VWEUHY!W3ZI
MP01NV\NM+R#O^KBT2C=MY=:.0=_U<%XHW3>76CD'?]7!>*-TWEUHY!W_ %<%
MXHW3>76E RX8C*K@!H@$N!2M9)Y/EA6H,S_B[:@#OY?.'IH?HC%X?9^=4C]I
M#-!9SH/]:J9_22?YO&>L]%8I60*XV^O"*;*5O;D5/)F)C(<4O(E !'*.DJ.0
M3R\V:B.O+&Q2F-2G"E?:!',EM+J5 %*5)4,^0I*LPL=>!"B\==+[;*@VV7.9
M202I2E(0,UC($<BB.C/&=\R#B+5*BE*4^#V!"E#LLBKARI<6D.@_J@V.CJ.*
M[SG62:%R&A[/JKJKNQW*7-J=(OBB:4S[@TTJU)MR/+9%IW\[;].0V9E18=;<
M#R*54$)S">4DC'<HJR7+I6M(&\B[+Y9UA,N8YT1&ZM,[7VPZP,;C[@IU]6]J
MM(JT6^;HO*UKSMVGTLVK+M9;$EF@P)=:D2_&TMMQT)1XKP;1D.!SQT17TL,O
MR*FZG<JO^Y]HKM&VAZ6OJT"F7WJ9;VNU%U&ORVT/,5:Y*_08=\37Y4E2ZC)D
M-!2:=*2I#3:TE/)P&66$/K9!>8$0AR),V1/)$(]*EU'L_7R)6-P6E5J[?KVJ
M%,U\O?2[4&S+CA5*!!M^R;:@LT0UBF5D/S&WZ55(!B+:+#0*5)'-S9G+%.^2
M(B#A#/D2N[SX9X^=,9TAOI.M^NE%@:(:J/Z:W)IE<9NZ\Y*:3%O"F7+)2PS2
M:1IK5C4@W7*345,J4M+J24Y!/'//%C62/FD1YPI%/49[T/.O5TBTVUBDV[H%
M'K&C=W6O:-EWCJ4Y*H[+4>B7)5[5D:>SZ=%E7)36JI\7IKLBIIYFUJ4A#R^H
M98COE-'TAT([O4Z#TK9/S9]H:@6+3-2[<K>E]R6'946LLJL^LWY'BQ+\NIAQ
MY]Q^57FZ7,F4M]#"5@-/-%!4G(%/7C'6SI4UK1+,2"MM#+FRW.WD;0%UH0_X
M+8SS4I7*D<I43D,R#ED$\!TG&$%=(%#TH,IYU+:0V,DJ5F5\JE*"$A7+ED.=
M0P15VF)48G**R.4!()01DK,+;XN>'GEDH*'+PP*ZK%. H2H Y+(RS'1QZ^/#
M%FB)5F")4:AQ2KK.7KYG'.J/WA4N7/C?^%.4#0#EX*^?ZQ0,N_(4#Z@.-])^
M[61XB6@Z5O%6ZHW1X-5J3@?7$H].F5.0EALO2%MPH2Y;J&6AD775(9(2D=)P
M\9+5+G!@B%S1L[?GJ+?MB:E:P4#0_P"-M++3B2Y] F4^Y($JZ:E$I4]<2N)K
MMO)4)M"FTZ.TMT,K05. <,78+S@W25F=6701&Q6_J3YS6C6YISJ7JOICIO.U
M0L;3ZEZ=&+6*=.1$1<UQWY48,=5!IR'$*Y9E*AS>T=0<U)6"D\<;12]H"*1W
MHY02MDM.]X=NZF:C678-K4QZ8S>&E!U+;KZ2E+$)YJ4F)+H#T0Y."3!D\S3J
MBH<JD9Y=6*.I@T$D  *14G259&X+>G<FEU[5.R]-M*Y&J53L>T&]1=4Y#%41
M2HMK64CF+KU/,AOM:Q6)#:%%MA"01EQSQF$N(C *#5$& )6-[U\Y(YVT6X--
M-(ZY?&F5O6M:5XZHW<)D:&NU:3>91\6Q8L9:RJ;68(43*C^V: XX-T>1'>SI
M*]BS=]-ZZB;C:UHS:EB6!'MBWY=$CS*Q<.H<2F7E4(];I[549FTRTG8R9#S*
M(KP]JI6:L&Z@,RMO3I6P5TZT7?'O_5:P**W1:<BR=+*5?5&J\QP!=0JD]Z>A
MZ _#4XAQ<=MN"HCE(5QSSP;KF1O3I$%@S4#=YJ9I'M-3KI)MV%J5=KS$:7\F
M;:9<*68TQUV.T$(4\MXN(>1FKG+:<N@G$NDB[9E4"?F6S6V[6:KZS:46=?U8
MM\6O4KLCN/2*)+4^W.IKW9!QM,IEYAOD))X\2.X<<R=,N&&=.$L31%:&;R]>
M;7V[;Y=L^IMYL2GZ-"T3U9HTE,#LU.JDU2M6\U$ [12&TE3X]T>&.%CO%.&8
M%0;^HE%\X1)(:#TQ!6"I=W6;O'>BLRGSB]GGF<1IU=KJ"AMT+2[3N5:7FTK2
M0!+5TA0Z\?!:S^9C"Z&>:;NTTW3"R6/O%G'%%#+ZDQQO#E&U'YQZSD ).FEX
M@Y9\':=EQX_T0<2S^8[A*H:)M:VHEU!RMNL;#189D4.XGHB8M)AYMJ</./V:
M1G\V]XCT7:;]T#%OZAN"--1_N_O%7WFI-/R;4\><=LL].G-X _Z93/NG$?U#
M\$::C_=_>(]YZ/.?DVI#YR"QTG)6GEX ]/MZ:?\ TG$_U#\$::C_ '?WB/>>
MCT](VH'G(;$Z]/KO]-ZCH_V6<C/TL0?YA^"!GG_[O[Q0>)Z3,1K&U(?.0V/]
M1IY=ZN[E(HZLOVN:YEZ>6#^H?@C34?[O[Q XGI,YZ1M2I\X_9)SSTZN\>B[3
M#_Z3@_J'X(TU'^[^\5V\3T<;#\FU(?.0V-GE\WMV)[ZG:8!Z64C$'^8?@C,Z
MHC_V?WBL>)J6%CK>?\ZA5YQVQ\P4V!=@RS*BARG.*"0"3RM"2E3BB<AEGUX!
M_,/P4#&,_P#W?WBRU/$D@RQ=(C'RSK6#1_=;1].M:-P&H\ZTZS,I&KU6H]9H
M,&-)IOQC#:I,),>9\9H,K)A2EGP$GCW\!_F(X*B8&? _]7]XL\O'Y5XF/5.3
MRBMFD^<JT_4D)%AW67,^+?;TT='3X7C&7##&?S#\$Q$#/O?]G]XN@.(:=@!C
M;Y<J!YRBPT^$K3ZZD@=)5,I*1Z:ERDI'JX=_4-P7IJ/]W]XI]YZ;.1#S;4I\
MY?IXD9JL.Y0D=)^,*&<O2\?P?U#<%Z:C_=_>*?>>DT](VIA\YKIJ 3\A[FX=
MV=1 /3/C_#$_U#\%::C_ '?WB/>:DTC6-JB_.<Z:#B;*N$#K/QG0N [O[_Q5
MW\Q'!S 7RM^9@M A+,3F'[Q6E\34A> 382,XVJ ^<[TR'VNS;A4<NNH44Y]/
M#A/XXM_4;@<Z1UY$P$V6L;#_ /L5ZKB6E:^ZTV>;:L_;>MVEJ[AZE<5,MRCS
M*3(MF'$FU(3W8ZU!J4YR)[/Q=;HYO1Z\>\X#XXX>XE+GLE0FG)U6"WUBNGAU
M;WP1:20 M./.G:V07M*[_P!O3%->^5%PVM3ZQ"J$R3#;B%D3!P4PZ5)SR20<
M@,>8^+7%[N'6]U8ZZ3RZ?.%Q\<Q3NDN -OERKB)MWU<UBTFID:YM)[SJ%#DT
MQ3-)K5K5*:J9;]10T?;1(4IP)8*E=;9 Q\!P[CRLE/[PQY YS]9>);Q"^887
MK(Z?SKL?H3YU>SZC*B6AKQ1U6!6Y\4P6KK84)5K2YZXZT([=U+KKE,0I7%16
M5 8^^<&\9OJYK ]YM SZ?VEZZEQN6]P:XDV>6=;)^;5J+50T?O>K0W&9-,JN
MLVH$ZERF' ZU4V9%7_?<-T9!V&MK)2#EQ2<\??J>>*NF!-MF5>HI9TN>,V1=
M+4D%*2.((!!'H8F%VS0G'*G8%","$8$(P(1@0C A&!"0]!] _0P(6M.[?_%2
MW&?_  3U._\ VE4\ 2)N0^6A5.TO_%ET%_\ A39/_P"21<(JLC?.JR?2/,/R
MK8E'MO2^GBDG-SK2,BEQJ0C A&!","$8$(P(1@0J-?VQ7IXY%?\ O-2 N>_G
M!T 6)HZ>/]WBP.YU3T=['6P;]T>9&9=$6_:CT$_S*<2A/P(1@0C A&!","$8
M$(P(1@0C A:R3_\ '#M7_P"W>_\ _P"H6FF&?V?G5/[3]G\JSE0?ZTTP_P#D
M:?\ 9,99IWHML6.5F"N5(RQ1C1+-BW-%BQMJQ<(L[3N^+T66TN6E9]RUMI;F
M?*A<"FR)32^5.05R=CGAS'%SH%6=8TD:%S6TPWL_-9I)19>L$*Z;INJKZ55K
M7=B=!9;4BXH,26\GY)V\SR]K(J(: Y!QS Z,=670MFB+79N1<J;73)1A='2L
M>:U><8FU732S+HTKMRZ*;6+C>TXO:9%+,=Z5%HUUU/Q5BTW!RGLJV[R<CJ#P
M3GT87,PF3O"2]T?,AE=.<T.+1'SK/#?G$J0FD7%3Z[I'>U'U1HEZ4>Q(^ECJ
MH;E7KM9N&()M'DPJDRH1?%)40<R_!S:/MNC"SA4J(@]T/,JNJ7NRA4Z]^M+1
M17J'/TJO'Y\OEFFP6]"$RHDBXW+C\31.89%5[,TY%-?AK$@22.SY>!XXD8,7
M"\QYW4,J;+J+K($"\O#A><6MZ;"I-/I&D5[5W5"MW9<&G-5TNI\R-&JEMW9:
M\-<ZIPZE-<:\5:8>CI!;?3]B7EPQ88)--H<8$:0F=Z&@+PI&_&VZY<.GMYM,
M712J"SIMJ;<%X:9*APWJDU5["F-P:E%ER%-AP3(,AOP WD%IR5T$8AV!L ^U
MF.$R-@LR;4F9BLJ0;CFM)@KDMCSBUGRH=ZS;ZTMN_3^HVQIS3]5;?AUQ<-3U
MY6/7IBZ9"J4%38*XCJ9Z0VXVZ,D)(5F!B'X'*RRICSJ69V/RVVEC>G:LM[9]
MVD?7^+J*BI:>3[ IFE[D!51DSJ[3;BIT]F;3S5!4(,^G)+&45A:5%CG6M*\P
M<L)FX0R5 %[XG)D3:7&#5-<YDMD&D1RJQ1OOH#]%O:_9FF%\4;2:T6IJ*+JD
M^_$4S?=6@S13&:-;\!91)+U6F24(:23F05'JQ+,(E/$-X^]YE=^*36F.[9TI
MD+S@-.MRDW,_J-I#=UBW;16K,FQ[2GU.#.=GVS>539IE,K<69''8=HPZ]SOL
M9!QM) ))QI9A,N4_J/<YIRQ@ID8DR<2*EK60R7<_/%7KJ1OMM'3YR_:6;3K,
M^LVC7K>H%.C.2V*3$N&?<T-,R*E%4EI$6FL-1U**W'CRYCAAS<.81$N(/F6C
MO=!VW1Y@M4'/.+:E776=+[AM/1JYU4:MU34&@3=-(-5I-2FUF79C7;+J2:TR
MA4-4!00M8<!Y3R<.)PQF&27&%]W0D5&(4\IH=(-YT86Z%F&!NQDZ@7UM;U)M
M2H3Z=IOJ]4+BL2MVA/2@3:?=T#(21*6WD#)I,F,MKW"LSPQFG4;)0/6)/F5J
M>MWSH$""ZCM]H"X5K!S6D!L_4@>UY>^<LSCEF8YKK %U67">J3D53[9(/<Y?
MT>OC#,=?=$J'+GQYP J;M_0 HXDZ^V,>/^GJ/5WL=2G;=DDC,%AG.<R#F"+@
M5O'5TU!5/FJIC,9VHB'(,-J5PC/RDQREIF2<C]A<)R5WL6OF*RS)D]]EUL/.
MN4^C^V36!S=%5M8+CL&T-&[#DVA<]OW-9]H5-]^EZF5FO-O1XE?JU%4M<5EY
M"EYE3:4]/'%Y4V$P$Y 0LADS222+"O(9V0WK1=G,_0^WZ=0Z?<E2U]M_4-V,
MTD^+/TB#J!"N.HQUJ/A) IK*PVD<$)R2!ECIFH9O0Z-@"CN\R$(6I]M;![UH
MVZC5*[&;H=INW>_=+:U1;>IM$G/4ZY;1N.ORT2:]#I$UDI,& X\V5ME/AI42
M1B754MPA81%'=YH5)J9M2URL*Z*XYH#\4W];.IND8TJN>K:CUV>[<MLJY)#+
M5S&I.*3*GO16Y1Y""02D9C" Z4<I@8H[M,&06+&IV1[A;#HUZZ0:<Q+0N/3#
M5JQ]/+-OJY:S4'J;7+9J%K,I8N&ITRF#-$KM6R5MN\5N*]MGB+T@Y3!'=IHB
M(+*5[[1M2]1=2K"AP--=.[-I&G5?L>KQ]P5/F.LZB7%0+/B,1/BJ2ILI6XJK
M-L\CH=! 3[7+$F9(&=/%.5T8N/02R;NNRGW95H2UU:"VVT\^R^MHU6G-L*98
MIM34@@R83/:J4$GK4<4,V7=C;%'=[56T#0.P;=F7/+@TE"F;N8IT*L4F7E+H
MRJ?2VE(APH]-?YXS#3*U%0*4A6>%3ZF+(- L6ME&R ,22LFQJ-$ID=J/#CHC
ML,%IMIE&08;::2$H;;: "4)Y1EPZL>9JZB9&,!:M4N6)8LR+CEOTT(H>XS>=
MMXTLN);YI?S$ZN7'XK&0RDS)E*KE >BLK*TGE:YSQY?"[F*XI@]/BW#P$V3+
M>XQM(MYESZ^G;51E/ZO*%JM5=I-QT:?,IE+TXJDV$P\66'6ZC4$I4A! '(.U
MR '1C\[S_A+ADZM,UU-+<;W9&Q>7F<!T=0\O-3/'(+NQ41VO7BWX)TGK68 ]
MM4IQ/1_IO1B]3\&,"J)N\F8?3E\!_9C-YEEF<"TS'76U-01^SL3#MBN\'^Y)
M6%=_XSJ ]+@YA'X(\/?Z=3_W8V*GN/3_ ,3/^CL3#M?O!1S^:2K#JR-3J&?^
MRC!^"7#P_P#3Z;^[&Q.E\!TCVQ=55 ,?T=BC5M;O%1X:3U9/>%2GGZ+IP?@G
MP]_I]-_=C8FC@&C'_BJCZ.Q,.UB\#[;2BL'N952H)^@YQP?@GP]_I]-_=C8J
M/X"I1Z-54'U=B3R6+OZM**P/1JM05]%SAB?P2X=_T^G_ +MNQ4]PZ?\ B9_T
M=B4;6;OX@Z35568ZZI4!EZ&3N#\$N'?]/I_[MNQ4F<$2I4"RHGF/ZNQ0G:C=
MW,5)TIJR2>D&I3U#TN9W$?@GP]_I]/\ W;=B5[G-]O.^CL0=J-XJ0M"=**NM
MU?)V245&<@J6EU"^4K2[S)"@GB1QPV5\#^')CH.P^G A[-NQ0>$&-$=]..K8
ML;6?HW<ET:@:NV&QH[*[33.J42DOR4U"H>./HJ4;QQQ<Q0>R4XVI?*G(#,#C
MQQ=_P-X; ZN'T_\ =MV*[>%V"W>S>C8LF+VL7&K[$UI#4BE'7X[.YE'N\W:#
M+"!\%>'6NLPZG_NQL4NX8;-;<,V8-6Q1^2G='7I%5$]_XPG'+TB[EAGX,8!_
MIU-_=C8J>YK/;SNC8GC:G<Q_\)JG_+3IF7I_9,!^#. 0_P#QU/\ W8V*1P:S
MV\[HV)?)1N0\#I--(ZP9DP@^B.;CBGX-8#_IM/\ W8V*?<QOMIW1L3#M/N7,
M!&CTE6?#]]2N.?\ +#IP#X-8$3!N'4X=F(EB(Z$-X.:UP<)TZP\FQ3(VH72/
M!.BTA05P(,F3Q!X',A7'ACG8C\(:4.W39#6M&AHV*S^$FS'WW3IW1L6^FPK3
M).C]P:CU*X;3;L85.D4J(@N.O\DDLO\ A^V22I21QQ]0^'W <GA\7I# XY;0
M!\@7J,+D3<,9NY?6!LM_,M>?.IV^I+UT:KT^UXE>IM)LFG0'[A?2^$Q'?&PD
MM#E4EK(*=1W^)QXWXU<#5O$T\3V.F-(A -R9.8KC<38>Z>" 7".A?-2BV-5M
M8JE3X])55J3:L%0;D/4]^13FZ@\3F)#:FRA;C:0>G'S;ACX13:V7W;$)DZ6T
M'* (]+5Y;#.%&371?,F ^;8N@FWW8Y7*Q4J8942XKKD)>1)"ITN5*IN:&%D=
MO'=*F'DI/NNG'W[AGX28?A4QLR75U3B /2#(= 7IL,X:E;PWYTVSF7>CS3%I
MW=;^@U9IU<D-*CTC5._X,*.V$H12V8E30V(S#2? 2@@<I!Z ,AC[+3TLK#Y.
M[:YSFPA;!>UE4,NB'4>YQAG@NN3?!/*  $@  ?H[V()O&.E/4F!","$8$(P(
M1@0C A&!"170?0.!5)@M:MVX_P %/<8/_P"$]3O_ -HU/ E.ZPM55M,&6V30
M7OZ4V5_^21<9JDQ#>=3+:&F/(/RK8='3GWOIX:R6&M!"<I >.6(;,+GEN93"
MQ+AJA&!","$8$(P(2$Y GN G $"TJD)S63^CHSQR\19!P(SJY;!<^?.$'^T/
M1WOZ\6#_ ,/1CLX)+ZA:ZSJE(<\@>==#V_:CT$_S*<*3$_ A&!","$8$(P(1
M@0C A&!","%K)/\ \<.U/_MXU ];4+33V<,A]E'E58=>/(LWT!?]2*9P_P!Q
M _ZYC&2L4O*%<J'.8Y99>GZ/>[V!;FF(6/-5;88OO3Z]+(?=#2;LMZLVXE62
M22NHTZ0T@9*(!"BOE/>.', %JDY(+FG9NS*K:IZ0;::3J14YME7?M]N4PJLW
M$/;FYK;@/R$IH)D+*%LTF:VI)5DE6>-\NIW>18IM+O+<ZO"A>;>L^BT2Z:";
MSJ<I5S:STG5:.\I"4*H\"A34S:;:, !:@W1F%HZLB22>7CBKZQI=$E+%.YHN
MKV-0]A%)O.\]1=2*+J56K9OBY;QM*_+4K,.,A42T+CM&"[ ;2EMU*TR8]20X
M0\%$%2>KCB@JV 05MPY>+.V"U5VFMWDYK16_*(5>J;^=U5<@14-N5-<%%,72
MDTA/9LFABG(#:&N<<N6>>*.QTR :=MK!FMS^99YE--+HM6";XV*ZD6G?&A3^
MD]YUAV[I%]7G?.KFK#D=AYLU6OTXQ7),^CJ*6GJ:&<FVF0O-/+GGB/>9[0&@
M9N78E&EGB&DK+\'S<%HI@VHA_4"LS:G3++U$MBOU<I#<FY*EJ5+3+K5PI((,
M=49380RT 4E*<B>&>,\S$Y]=,WS38!!.EX,RK%^;Z8L5B[L-E%QRM.[GN#3"
MH5"Z;S@[?J)H-3[?YF6:G5:%3KA16*E58LEU*PY5W820A*#DCACL4=4&B#LJ
MK-X9ENLO6PY,FM>_YO;3C5:TK0U%M*^[(G6KI1)CP8NGM-N:%!IUXRZJ] 3$
MN-RO1*:GLGHZEE79.J42I/4,4Q2L87RRPVAI^5-HL'91->QN1Q!U#G5R1_-Y
M.U"S[_TEN/6*O531BNS)L^T+.9IS+;]JU61.;J\2J,5(+6]V]'J;:51U )R0
M5)(/-PRRJH1O9U>93$B SKT)?F_7KQM?4).J>KM5N_4:\J/;%%I-[QJ<Q38-
MK1;'?8D6T8U,:'9N/E^.DRN/V8YDXT]YNBR,%D=AO>+(P(6J.YS9#JW!L5^H
M"O7;K]<][ZDVI7M1F+?8@P9C="MR"(,=F@4=]?BKRVFT!3@<4D99X.]M%D5
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MH2X4!OM3DI10.OCP*^_BKI0-L3J5@^&950:*5<' ? Y25$%:CGF%%67#">[
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MHS0I.2O#2>'$<!UXGN#38,ZGO+="E16V>P;+TF,RZA*ER M]K[&DJR;+F2O
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MNYEUX$+W(O[W;^T]7M/;=(Z,"%Z6!","$8$(P(1@0C A&!","$8$(P(1@0C
MA&!","$8$(P(1@0C A&!","$8$(P(1@0C A&!","$8$(P(1@0C A&!","$8$
4(P(1@0C A&!","$8$(P(1@0O_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
